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Chapter One General Introduction
1 General Introduction
The general introduction o f this thesis is intended to introduce the reader to 
important background information that is relevant to the findings presented in 
subsequent chapters. Each individual results chapter contains an introduction and 
discussion that will cover more specific areas and address findings in the literature to 
date.
1.1 Oxygen Delivery
The primary function of the cardiovascular and pulmonary systems is to produce 
a flow o f oxygenated blood in sufficient supply to maintain aerobic metabolism in all 
organs and tissues. The system is required to be energy efficient but also receptive to 
changes in cellular metabolic demand. In order to function both at rest and during 
demand the system must also match oxygen allocation to metabolic requirements at a 
localised level. Once blood enters an area that requires substrates, oxygen should have 
the capacity to efficiently move from the blood, across the vessel wall and into the 
tissue.
Global oxygen delivery (D0 2 , product of cardiac output and arterial oxygen 
content) under normal, resting conditions is more than adequate to meet metabolic 
demands/oxygen consumption (V0 2 ) (Figure 1.1). At a tissue level, oxygen delivery is 
governed by two processes, convective and diffusive oxygen transport. Convective 
transport can be described as the bulk movement o f oxygen in the blood, encompassing 
changes in cardiac output and the mechanisms that regulate flow in the microcirculation. 
Diffusive oxygen transport simply refers to the movement o f oxygen from the blood into 
tissue, down the capillary-intracellular oxygen tension (P0 2 ) gradient and is governed by 
arterial oxygen tension (Pao2) [1].
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Figure 1.1. Diagrammatic representation o f  oxygen transport in the body. Note that oxygen delivery (DO2) 
is dependent upon cardiac output (Qt), the arterial partial pressure o f oxygen (PaCh) and the concentration 
o f haemoglobin (Hb). A reduction in any o f these parameters can lead to tissue hypoxia. Abbreviations: 
V-ventilation; FIC^/FEcvfractional inspired/and mixed expired oxygen concentration; FEco2-fractional 
mixed expired carbon dioxide concentration; Qt-cardiac output; PacVPvCb-partial pressure o f  
arterial/venous oxygen tension; SaQ,, SvCV saturation o f arterial/venous blood; Ca02/Cv02-oxygen content 
o f arterial/mixed venous blood; Hb-haemoglobin concentration; RQ-respiratory quotient; Do2-oxygen 
delivery; p50-the p02 at which haemoglobin is 50% saturated. Adapted from [1].
1.2 Oxygen Sensing in the Body
In order to accurately match oxygen delivery to demand, the body requires 
methods o f sensing the oxygen level in the blood stream and hence the tissue. This 
‘sensing’ is generally believed to be carried out by a structure known as the carotid 
body.
- 2 -
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1.2.1 The Carotid Body
The carotid body represents the primary oxygen sensing site in the vasculature, 
located at the bifurcation of the carotid artery. The carotid body is formed from 
chemoreceptor cells and is sensitive to changes in pC>2 and to a lesser extent carbon 
dioxide/pH and glucose of the blood that continually passes it [2, 3]. Within the carotid 
body there are two key cell types, glial-like sustentacular (type II) cells which represent 
15-20% of cells and have processes that surround the more abundant, neuron-like 
glomus (type I) cells [4]. Glomus cells are thought to be the primary cell type involved 
in oxygen sensing, as they are chemoreceptive and release neurotransmitters such as 
ATP, dopamine and acetylcholine, in a calcium-dependent manner [5]. As pC>2 levels 
fall, the firing o f sensory nerves from the carotid body increases, enhancing the 
ventilatory reflex through the respiratory centre to match ventilation on a second to 
second basis [6 ]. The oxygen sensing and signalling pathways of the carotid body are 
not fully understood, however, a number o f candidate sensors and mechanisms have 
been proposed and will be covered in more detail below.
1.2.1.1 The Mitochondria
Mitochondria normally rely on oxygen to synthesise ATP via oxidative 
phosphorylation, with oxygen acting as the final acceptor o f the electron transport chain. 
In hypoxia, this process cannot occur and so cells switch to anaerobic energy generation 
via glycolysis. Hypoxia also brings about other mitochondrial alterations that include 
changes in reactive oxygen species level (ROS), cytochrome oxidase activity and ion 
channel opening [7]. Inhibitors o f the electron transport chain have been shown to 
change the oxygen sensitivity o f glomus cells, mimicking hypoxia [8 ]. However, long 
term exposure to these inhibitors abolishes the glomus cell hypoxia sensitivity when 
measured by neural discharge [9]. The mechanism by which these mitochondrial 
changes result in increased afferent firing and the level at which other pathways (e.g. 
hypoxia inducible factor (HIF) [10]) contribute is unclear. However, agents that 
uncouple oxidative phosphorylation have been shown to alter calcium levels [1 1 ] which
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is known to control neurotransmitter release from these cells. Although mitochondria are 
clearly sensitive to changes in oxygen, it seems unlikely that cytochrome oxidase is 
responsible for ‘continuous’ monitoring o f oxygen level over a broad range of 
concentrations given that it has a Km for oxygen o f ~0.1 pmol/L [12] and so the oxygen 
level would need to fall significantly before the enzyme would stop binding oxygen and 
have reduced function.
1.2.1.2 The Membrane
The increase in cytosolic calcium that triggers transmitter release is thought to be 
partly mediated by calcium entry through voltage-gated calcium channels in response to 
membrane depolarisation [13]. The membrane potential of glomus cells is largely 
controlled by various, different potassium channels [14]. It was first shown that these 
channels were oxygen sensitive in the late 1980s [15]; under hypoxic conditions the 
channels are inhibited leading to membrane depolarisation, which causes subsequent 
changes in intracellular calcium level via other membrane channels. Given that calcium 
is thought to control transmitter release, this could provide an alternative oxygen 
sensitive mechanism.
1.2.1.3 Non-Mitochondrial Enzymes
NADPH oxidase is a haem containing enzyme expressed in glomus cells and is 
postulated to act as an oxygen sensor [16]. NADPH oxidase is known to generate 
reactive oxygen species such as superoxide which can in turn form hydrogen peroxide 
(H2O2) which can potentially regulate membrane potential via interaction with 
potassium channels. The generation o f these species is governed by oxygen, so in 
hypoxia hydrogen peroxide production is lower and therefore the open probability of the 
potassium channels decreases, resulting in depolarisation. In support of this theory, it 
has also been shown that administration of hydrogen peroxide will inhibit carotid body 
sensory discharge [17].
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It is unlikely that any of these proposed mechanisms are mutually exclusive and 
so varying contributions from each of these distinct pathways is likely. Although there 
are a number o f different suggested ‘oxygen sensor’ pathways in the carotid body, many 
of them demonstrate a role for haem-containing enzymes. The carotid body is 
representative o f acute oxygen sensing in the body but there are also chronic 
physiological responses that are activated by changes in oxygen level.
1.2.1.4 Hypoxia Inducible Factor
The identification o f the transcription factor, hypoxia inducible factor 1 (HIF-1) 
was brought about by the discovery o f a genetic response element that controlled 
erythropoietin [18]. HIF-1 has now been shown to regulate over seventy distinct genes 
that mediate many adaptive physiological responses to hypoxia including angiogenesis, 
altered glycolysis and erythropoiesis [19].
HIF-1 is a heterodimeric protein comprised of a constitutively expressed p 
subunit and an oxygen regulated a  subunit [20]. HIF-1 a  is hydroxylated by prolyl 
hydroxylases, with oxygen representing a rate-limiting substrate in the process, under 
physiological conditions [21]. Hydroxylation is required for HIF-1 a  to interact with the 
VHL protein forming the recognition component for E3 ubiquitin-ligase [22], binding of 
VHL results in ubiquitination and degradation by a 26S proteasome [23, 24]. When cells 
become hypoxic, the hydroxylation process is limited and HIF-1 a  accumulates before 
translocation to the nucleus where it dimerises with HIF-1 p and binds to DNA in genes 
with specific nucleotide sequences (Figure 1.2). The hydroxylation process also requires 
co-factors such as reduced iron, ascorbate and 2-oxoglutarate. The requirement for these 
co-factors closely links the process with both the redox state of the cell and energy 
homeostasis.
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Figure 1.2. The inhibition and activation pathway of HIF-1 in normoxia and hypoxia respectively. Based 
on original schematic from [7]
HIF-1 a  is also hydroxylated by factor inhibiting HIF-1 (FIH-1), which prevents 
interaction with co-activators CBP and P300 [25, 26]. The co-activators control 
interactions with RNA polymerase II and other transcription factors. In hypoxia, FIH-1 
is limited and hydroxylation is decreased, which allows the co-activators to interact and 
alter target gene expression [27, 28]. FIH-1 also interacts with VHL, linking 
transcriptional activity with protein stability [29]. These interactions allow control that is 
both rapid and graded, depending on the period and extent of hypoxic exposure.
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1.3 Factors Governing Oxygen Delivery
Oxygen delivery in the body is governed by, the oxygen carrying capacity o f 
blood, blood flow, the efficiency o f the lung/pulmonary gas exchange system and 
changes in tissue extraction. This thesis will concentrate on the oxygen carrying 
capacity o f blood and the mechanisms involved in controlling blood flow.
1.4 The Blood
The blood is a convective transport medium composed of plasma (-55%), 
erythrocytes (—44%, this % is also known as the haematocrit level) and Buffy Coat 
(-1% , containing thrombocytes (platelets) and leukocytes (white blood cells)). Plasma is 
composed o f -80%  water and contains numerous circulating proteins, lipids, 
lipoproteins, electrolytes and organic nutrients/waste. Erythrocytes, or red blood cells, 
represent the most abundant cell type in blood and are essential for the delivery o f 
oxygen to respiring tissues.
1.4.1 The Red Blood Ceil
The pool o f erythrocytes that circulate throughout the body represent an essential 
and complex tissue for homeostatic control. In addition to carrying both a substrate and 
the metabolic waste products of respiration, erythrocytes interact with other tissues to a 
considerable extent. In a healthy human with -5L  blood, erythrocytes number 
approximately 2.5 xlO 13 cells, a quantity sufficient to meet the requirements of aerobic 
respiration. The lifespan o f an erythrocyte is approximately 100 to 120 days, with a 
daily loss o f -0.8%  to 1.0% of the total circulating mass. To compensate for this loss, 
the body has a normal production capacity of -2.5x10 11 cells per day in the bone 
marrow [30].
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1.4.1.1 Erythrocyte Development
The total erythrocyte mass requires precise regulation, the mass must be 
sufficient for adequate oxygen delivery without levels being excessively elevated as to 
impede blood flow. Levels of circulating erythrocytes are governed by an oxygen 
sensitive feedback loop which utilises erythropoietin as a signalling messenger. 
Erythropoietin (EPO) is a glycoprotein, largely produced in the kidney by interstitial 
fibroblasts [31]. Once systemic, erythropoietin acts upon haemopoietic stem cells found 
in the bone marrow via specific cell surface receptors [32].
Early haematopoietic progenitors differentiate into burst-forming unit-erythroid 
cells. These burst-forming unit-erythroid cells then further differentiate into colony- 
forming unit-erythroid cells and are dependent on EPO for survival [33]. With 
continued EPO stimulation, the differentiation pathway moves to erythroblasts, which in 
turn enucleate to form reticulocytes and after a few days reticulocytes show loss of 
reticulin, resulting in mature erythrocytes. Once the maturation process enters the later 
phases, both reticulocytes and erythrocytes cease to express the EPO receptor and so are 
unresponsive to further changes in EPO levels [34].
EPO has a terminal half-life o f approximately 5 hours [35]. A number of factors 
can affect EPO levels including iron availability, nutritional status, disease, 
environmental conditions, and genetic factors (congenital polycythemias). A directly 
proportional relationship between erythrocyte production and plasma EPO level does 
exist. However, a significant change in EPO plasma levels only results in a modest 
increase in the rate o f erythropoiesis, therefore it is time of elevated exposure which is 
important, not maximum plasma level achieved. Despite this modest increase in rate, the 
downstream effects tend to be prolonged due to the difference in half-life between EPO 
and erythrocytes (hrs vs. days). It has been demonstrated that only 30 minutes hypoxia is 
required to elevate EPO levels [35], thus a short exposure to elevated EPO levels will 
result in prolonged increases in erythrocyte levels.
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EPO has been demonstrated to directly relax vascular tissue which has been 
shown to be dependent upon both the presence o f endothelium and the operation of NOS 
[36]. Transgenic mice, engineered to over-express EPO show increases in eNOS 
expression, nitric oxide synthesis and nitric oxide inducible relaxation. Despite having 
an increased hematocrit (up to 80%), these mice did not exhibit any o f the 
accompanying effects o f increased hematocrit, e.g. hypertension or myocardial 
infarction [37]. In addition, the effect of EPO upon endothelial upregulation o f eNOS 
and nitric oxide production has been shown to be enhanced at lower oxygen tensions 
[38]. In contrast, nitric oxide has been shown to suppress haematopoiesis in human cells, 
representing a possible ‘feed forward’ mechanism [39]. Haemoglobin mRNA/protein 
levels have also been shown to be altered by nitric oxide through a cGMP dependent 
mechanism in human erythroid progenitor cells [40].
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1.4.1.2 Erythrocyte Geometric and Rheologic Properties
Erythrocytes are biconcave in shape and smaller than most other human cells, 
with a diameter of approx. 6-8 microns (Figure 1.3).
300 mO
■4---------  Diameter 7.82 p ►
217 mO
Diameter 7.59 p
Volume 94 p3
Surface Area 135 p2
Volume 116 p3
Surface Area 135 p2
131 mO
Diameter 6.78 p
Volume 164 p3
Surface Area 145 p2
Figure 1.3. Geometrical data o f the erythrocyte, measured whilst suspended in buffers with differing 
osmolarity values. For reference, normal, isotonic serum tonicity is approximately 270-300 milliosmoles 
(mOsm). Based on original figure from [41].
The study of blood rheology involves two key aspects; firstly, blood flow and 
secondly the deformation of blood cells. Blood rheology is important in the 
cardiovascular system because in addition to vascular tone it is the other key 
determinant of vascular resistance. In large vessels, flow is more likely to be altered by 
the concentration of erythrocytes. It is in the microcirculation that erythrocyte 
deformability, adherence to endothelium and aggregation play a significant role.
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Erythrocyte rheology/deformability can be measured either as a bulk suspension 
o f cells or in individual cells. Deformability can be calculated under shear stress 
(ektacytometry), by erythrocyte fllterability or analysis of individual cells using a 
micropipette [42-44]. The key determinants of erythrocyte deformability are cell 
geometry (e.g. the cells surface area to volume ratio), cytoplasmic viscosity and 
viscoelastic properties of the erythrocyte membrane.
It has been shown that the viscosity of a haemoglobin solution increases 
exponentially when the concentration exceeds 32g/dL [45]. Similarly, when the mean 
corpuscular haemoglobin concentration (MCHC) is increased, intracellular viscosity 
increases and thus deformability of the erythrocyte decreases [46]. Cytoplasmic 
viscosity can also change as a function of temperature and alterations in osmotic balance 
that lead to water loss from the cell [47].
The viscous and elastic properties of the membrane are largely governed by the 
amount and organisation of cytoskeletal proteins. The interactions of these proteins with 
other proteins and the lipid bilayer are o f particular significance [48]. Impairment of 
viscoelasticity has been shown to correlate with levels of glycosylated haemoglobin in 
diabetics, suggesting a role for cytoskeleton-haemoglobin interaction in deformability 
[49]. Erythrocytes which are senescent, abnormally shaped or damaged may be less 
deformable and are selectively removed from the circulation.
Nitric oxide donor drug addition to erythrocytes improves deformability in a 
dose-dependent manner [50]. The exact mechanism controlling this effect remains 
unknown, although it appears to be in part modulated by cGMP. When sGC is blocked, 
erythrocyte deformability is impaired, however, this effect can be reversed in a dose- 
dependent manner by nitric oxide donors, suggesting the participation of alternative 
pathways [50]. It is quite likely that the nitric oxide pathway may involve changes in 
phosphorylation o f the cytoskeleton [51]. In this respect, endothelin-1 has been 
demonstrated to alter erythrocyte deformability though a pathway regulated by protein
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kinase C (PKC) [52]. These findings are of particular interest given that erythrocytes 
may express a functional eNOS [53].
1.4.1.3 The Erythrocyte Membrane
The erythrocyte membrane is composed o f 3 main elements; membrane lipids, 
membrane proteins and cytoskeletal proteins. The structural core o f the erythrocyte 
membrane is formed primarily from cholesterol and phospholipid molecules. There are 
hundreds o f distinct phospholipids within the membrane, differing with respect to the 
polar head group, the carbon back bone and the length and level of unsaturation of the 
acyl groups [54]. This diversity in chain length allows the lipids to be packed into the 
bilayer in a coordinated fashion, dictating protein-lipid interactions. The bilayer that is 
formed is very dynamic, with organised and rapid movement of lipids/embedded 
proteins, which gives rise to domains that are rich in specific lipid or protein species 
[55]. These domains or ‘rafts’ often have specialist functions such as signal 
transduction, with different components working collectively to convey a signal.
A large number o f erythrocyte transmembrane proteins have been characterised. 
Broadly, they fall into groups involved in transport, adhesion and cell-cell interactions, 
signalling receptors and blood group antigens, for a comprehensive analysis of the 
proteome refer to reference [56]. O f specific interest to the current project, are the anion 
exchanger AEl/band 3 protein and the macrocomplex which can be formed with other 
proteins, in particular, the rhesus (Rh) proteins.
AE1 is an integral membrane protein which is found abundantly in the 
erythrocyte membrane (around 106 copies per cell) [57]. AE1 can be separated into its 
membrane-spanning domains and its cytoplasmic domains. The 12 membrane spanning 
sections o f AE1 catalyse the exchange of anions (C f and HCO3 ) in and out of the 
erythrocyte during gas exchange [58]. Carbonic anhydrase II hydrates carbon dioxide to 
HCO3' and Ef1’, HCO3' then leaves the cell via AE1 in exchange for Cf, leaving H+ to 
bind to haemoglobin and promote the release of oxygen [57]. This process not only
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allows the efficient transport o f carbon dioxide (as HCCV in the plasma) but also 
enhances oxygen delivery in the tissue. It has also been recognised that the membrane 
spanning domain o f AE1 may signal for the removal o f senescent erythrocytes from the 
circulating pool [59].
The C-terminal cytoplasmic domain binds to carbonic anhydrase II and forms a 
metabolon to channel HCO3' , facilitating the combined functions of both the enzyme 
and channel [60]. The N-terminus binds to a number of proteins such as haemoglobin 
[61] and glycolytic enzymes [62-64], but its main function is to anchor the erythrocyte 
membrane to the cytoskeleton. Band 3 exists as both dimers and tetramers, in tetrameric 
form the protein binds to ankyrin [65] and protein 4.2 [6 6 ] to secure the membrane to 
the cytoskeleton.
Part o f the AE1 macrocomplex is formed by the Rh proteins, these Rh 
polypetides and Rh associated glycoproteins (RhAG) are thought to act as gas channels, 
involved in the transport o f CO2, O2 and interestingly the solo or co-transport of nitric 
oxide [57]. Despite the highly diffusible nature of these gases, the co-localisation of 
these proteins and their ability to act as channels may aid the efficient transport of gases 
across the membrane within the time course of a transitory, circulatory cycle.
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1.4.2 Haemoglobin
Haemoglobin represents one of the most significant and genetically conserved 
proteins in the human body. Haemoglobin functions to transiently bind/release oxygen 
in the circulation and its ability to perform this function so well is due to its specific 
structure.
1.4.2.1 Haemoglobin Structure
Adult haemoglobin (HbA) represents the most important oxygen carrying 
protein in the human body. HbA is a heterotetrameric metalloprotein (64,500Da), 
consisting o f two a  and two (3-globin subunits each bound to haem. During terminal 
erythropoiesis huge amounts o f HbA are synthesised, constituting around 95% of the 
total mature erythrocyte proteome, a concentration of approximately 35g/dl [67].
The subunits that form HbA adopt a 3-dimensional structure known as the globin 
fold. The fold comprises a number of specially arranged helices that form a pocket, 
which both encloses and binds to a haem prosthetic group (a planar porphyrin structure 
with an iron centre). The haem is linked to the polypeptide subunit via a covalent bond 
formed between a nitrogen atom of the proximal histidine (F8 His) and the haem iron 
(Figure 1.4d) [6 8 ]. The iron found in the haem group is capable of binding diatomic 
gases e.g. molecular oxygen, carbon monoxide and nitric oxide, when it is in the ferrous 
state (2+ oxidation state). Diatomic gases bind to the distal side of the haem plane, 
opposite the proximal histidine, forming a hexa-coordinate iron structure [6 8 ].
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1.4.2.2 Haemoglobin Structure-Function
The intricate conformational changes that occur in the haemoglobin protein 
structure during its binding and releasing o f ligands has given rise to a significant 
amount of research into the protein structure-function relationship.
Haemoglobin exists as two classic quaternary structures which are designated R 
(relaxed) and T (tense) (Figure 1.4a). Perutz and colleagues identified these exact 
structures using X-ray crystallography and their observations generated the concept that 
the molecular structure o f a protein can determine its biological function [69]. In vivo, 
as each successive oxygen binds, haemoglobin conformation moves through a number 
o f states resulting in a transition from T-state to R-state. Within the haemoglobin 
structure there are a number of specific structures that are important to this transition 
that will be covered below.
The a jpi  and (X2P2 interfaces in HbA contain many hydrogen bonds and are 
thought to be relatively fixed regardless of changes in quaternary structure [70]. In 
contrast, the ot2pi and 011P2 interfaces are subject to notable changes during allosteric 
movement between R and T states. Each helix within a subunit is designated a letter, the 
p-chain for example has eight helices, A through to H. Regions in the a ip 2 interface in 
proximity to the pivot point (FG comer of the a  chain and the C helix of the p chain) 
stay in contact and are known as the ‘hinge’ [6 8 ]. The point most distant from the pivot 
undergoes the largest shift during a conformational change and is known as the ‘switch 
region’. During a ‘switch’, P2 9 7 His is displaced to the greatest extent by the turning of 
the C helix (oti) from a position between aiPro44 and ajThr41 to a groove between 
aiThr38 and ctiThr41 (Figure 1.4C) [6 8 ]. All o f these movements result in a physical 
change in haemoglobin conformation that also has different biochemical properties 
compared to its non-ligand state.
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a87His
’ v A ,
a ,44Pro '  “ ^ j Thr
Figure 1.4. Illustrations of Hb A structure. (A) Deoxy-Hb A, viewed along the 2-fold symmetry axis, 
showing the water-filled central cavity. (B) Illustration of the reorientation of a(3 dimers in the T-to-R 
transition. The ai|3i dimers of the two conformations, shown in violet toward the rear of the figure, have 
been superimposed at the di{3] interface, whilst the a2 and fk subunits of deoxy and carbonmonoxy-Hb are 
shown in blue and red, respectively. (C) Switch region of the dj|32 interface of Hb A in the T, R, and R2 
conformations, shown in blue, red, and green, respectively. Here, the backbone atoms of residues 38-44 
in the dj subunit have been superimposed, to illustrate the relative motion of p297His. (D) The d-subunit 
hemes, proximal histidines, and F helices of deoxy-Hb (blue) and carbonmonoxy-Hb (red), with hemes 
superimposed. Reproduced from [68].
In addition to the obvious physical differences between the R and T 
conformational states, it has been long postulated that the sequence of changes in 
quaternary structure when moving from one state to another are responsible for the 
varied oxygen affinities of the states. It was always presumed that T state had low 
affinity and R state high. Haemoglobin’s relationship with oxygen is altered by both 
conformational changes in its protein structure due to substrate (oxygen) binding
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(homotropic allostery) and by effectors that interact with other sites on the protein 
(heterotropic allostery).
1.4.2.3 Homotropic Allostery
The proposal o f co-operative oxygen binding by haemoglobin is attributed to a 
Danish Physician, the late Christian Bohr. It was the sigmoidal nature of the 
haemoglobin oxygen binding curve that stimulated Bohr to generate this concept [71].
At that time it was generally believed that haemoglobin only contained one 
haem, it was not until 1925 that Adair showed that there were four haem groups present 
in haemoglobin [72]. Once this discovery had been made it became accepted that the 
binding of the first oxygen must enhance that of the second and successive oxygen 
binding events. Despite these findings, it was still unknown if the mechanism 
responsible was via electronic interaction between haem groups or changes in the carrier 
protein. A key breakthrough came when Haurowitz demonstrated a change in crystal 
structure upon oxygenation [73], suggesting that a change in conformation was 
responsible. As more detailed structural information became available, it was clear that, 
given the relatively large distance between oxygen binding sites, co-operativity must be 
conveyed through the protein structure. In 1970, Perutz, armed with detailed structural 
information, proposed novel stereochemical mechanisms to explain the phenomenon 
[69]. Perutz noted that specific inter-subunit salt bridges and out-of-plane haem iron 
position was present in the T, but not R state [69]. He speculated that when the haem 
iron shifts from out-of-plane (with respect to the pyrol nitrogen atoms o f haem) to in­
plane this induces displacement o f the proximal F-helix and subsequent helix 
rearrangements. These concerted structural changes take place during the T to R 
transition in addition to changes in porphyrin sterochemistry, globin structure and at the 
subunit interfaces [74]. Given that R state haemoglobin oxygen affinity resembles that 
o f free haem subunits, it can be said that it is the structural constraints that stabilise the 
T-state and alter affinity to govern co-operativity [74].
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Recently, a new hypothesis has been proposed in which variations in HbA 
affinity for oxygen are more likely to be governed by tertiary structural dynamics than 
overall quaternary structure changes [75]. This area of research has received an 
inordinate amount o f attention and there are many variations in models to explain the 
co-operativity phenomenon. As yet a consensus on the different states of haemoglobin 
and how they are changed by allosteric effectors is yet to be reached, for a current 
review of the topic see [75].
1.4.2.4 Heterotropic Allostery
In addition to the substrate affinity relationship seen in haemoglobin, there are 
also sites (other than the oxygen binding pocket) located on haemoglobin where 
alternative allosteric regulators can bind and influence oxygen affinity. Principally, these 
regulators are respiratory metabolites which aid in the matching of substrate supply to 
metabolic demand. It should be noted that binding characteristics can also be regulated 
by non-chemical entities, including temperature which can alter oxygen offloading.
1.4.2.4.1 Carbon Dioxide
The efficient transport o f carbon dioxide (CO2) is often said to be of equal 
importance to that of oxygen. CO2 is transported in three main forms; dissolved as CO2 , 
as bicarbonate or bound as carbamate (to the amino termini of the globin chains, also 
known as carbaminohaemoglobin).
CO2 diffuses out o f respiring tissues into the blood stream, where it enters the 
erythrocyte (Figure 1.5). Erythrocytes are significantly more permeable to CO2 than 
other cells [76], largely due to specific gaseous exchange channels e.g. AE1 and Rhesus 
proteins (previously discussed in section 1.4.1.3, page 12). Once inside the erythrocyte, 
CO2 is converted to bicarbonate (HCO3 ) and a proton (H+) by the enzyme, carbonic 
anhydrase (CA). Since the initial discovery of CA by Meldrum and Roughton in 1933 
[77], a number of CA isoezymes have been found, CA II being particularly abundant in
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erythrocytes with high specific activity (10 times that of CA I) [78]. Once formed 
bicarbonate is then free to leave the erythrocyte in exchange for chloride ions, in what is 
commonly referred to as the ‘Chloride shift’. As erythrocytes enter the lung the reverse 
process occurs, bicarbonate is converted to carbonic acid (H2CO3) which rapidly 
dehydrates to water and CO2 , at the same time haemoglobin is re-oxygenated and CO2 
stored as carbamate is released. The liberated CO2 then diffuses freely into the lung for 
excretion, summarised in figure 1.5. This system is not only key to transport 
homeostasis but also plays a notable role in the buffering of blood pH.
r  ■'n
Alveolus
Blood CapillaryT issue Blood Capillary
Figure 1.5. Carbon dioxide transport in the blood stream.
1.4.2.4.2 The Bohr Effect
In addition to demonstrating the sigmoidal curve generated by the interaction of 
haemoglobin with oxygen, Bohr, with colleagues Hasselbalch and Krogh demonstrated 
that the binding curve was sensitive to changes in both CO2 and pH (H+) [79]. Although 
carbon dioxide can alter haemoglobin oxygen affinity independently of pH (during 
formation of carboxy-haemoglobin), it is the changes in CO2 and concomitant changes 
in pH that occur during CO2 transport that produce the ‘Bohr effect’. An increase in CO2 
and subsequent reduction in pH shifts the binding curve to the right, increasing the p50
- 19-
Chapter One General Introduction
(oxygen tension required to achieve 50% saturation)(Figure 1.6 ). At a molecular level, 
this can be explained in terms of haemoglobin conformational state. As haemoglobin 
shifts from the R-state to the T-state the pKa of specific amino acids change (detailed in 
Figure 1.7), this change makes them more likely to interact with Bohr protons. When 
these protons bind (forming haemoglobinic acid) they stabilise the T-state and delay 
transition back to the R-state [80]. The physiological relevance of this shift becomes 
apparent in respiring tissues, where CO2 levels are high. Haemoglobin encounters an 
area o f low 0 2 /high CO2 and is more likely to offload oxygen and less likely to re-bind, 
aiding adequate oxygen delivery. The converse is also true with respect to the effects of 
oxygen on C 0 2/H+, known as the ‘Haldane effect’ [81].
100 -1
2 0 -
0 25 50 75 100 125 ISO
O2 tension (mmHg)
Figure 1.6. Influence o f C 0 2 on 0 2 equilibrium curves of blood at 38 °C. Numerical values above each 
curve represent the C 0 2 tension in mmHg. Reproduced from [80].
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a-chain
c\  1 /Cls ils 
Val -  -  SerAmino Acid Residue — Arg
Residue number 1 131 141
ft-chain o p o * D2 H* d2 h cl d2 h* H
\  I / \  / \  I /  \  / I
Amino Acid Residue Val His — Lys — His - His
Residue number 1 2 82 143 146
Figure 1.7. Schematic representation o f the major amino acid residues o f the a and p chains o f human Hb 
considered to be involved in binding C 0 2 (C), protons (H), chloride ion (Cl) and DPG (D). D,-binding to 
one P chain; D2-binding to both P chains; & #-Shared chloride binding sites on a and P chains, respectively; 
H*-proton binding in the presence o f DPG. Based on original table from [82].
1.4.2.4.3 2,3-DPG
2,3-Diphosphoglycerate (2,3-DPG or 2,3-BPG) is an organic phosphate 
intermediate formed during glycolysis. The intraerythrocytic 2,3-DPG concentration is 
approximately equal to the molar concentration o f tetrameric haemoglobin (5mM)[83], 
although the amount of free 2,3-DPG is dependent on haemoglobin saturation and can 
fall as low as 0.5mM in deoxygenated erythrocytes [84]. It was simultaneously shown 
by Chanutin & Cumish [85] and Benesch & Benesch [8 6 ] that organic phosphates could 
act as allosteric modulators of haemoglobin. 2,3-DPG binds to histidine, valine or lysine 
residues in the p-chains of HbA, forming electrostatic cross-links with residues situated 
in the central cavity between the two subunits (Figure 1.7) [87]. In R-state 
oxyhaemoglobin this cavity is too small for 2,3-DPG to enter, however, in T-state 
binding is very favourable. Through binding to T-state, 2,3-DPG shifts the T-R 
equilibrium toward T, shifting the binding curve to the right, which indicates an 
enhancement of oxygen offloading with reduced re-capture. Exposure to high altitude 
has been demonstrated to increase intraerythrocytic 2,3-DPG levels which may be 
necessary for sufficient oxygen delivery, particularly at a capillary level [8 8 ].
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1.4.2.5 Other Allosteric Modulators
O f interest to the current thesis, nitric oxide bound to the 93 position cysteine 
residue o f the p chain of haemoglobin (HbSNO) has been shown to produce a rightward 
shift in the binding curve, enhancing offloading [89, 90]. Glycosylation o f haemoglobin 
has also been shown to cause a slight rightward shift in the oxygen binding curve [91]. 
Haemoglobin glycosylation in healthy individuals is -5%  while in diabetic patients can 
range up to 15-20% in some cases. Given these relatively high percentages, the effects 
of glycosylation on haemoglobin functionality could potentially be quite dramatic.
It is also well documented that the oxygen binding curve o f foetal haemoglobin 
(HbF) is leftward shifted [92]. These altered binding characteristics aid in the transport 
of oxygen from the maternal bloodstream across the placenta. In most species the 
characteristics o f HbF disappear during the postnatal period. Interestingly, HbF does not 
polymerise like sickle haemoglobin (HbS) and so augmentation of HbF levels is now 
being considered as a therapeutic option in sickle cell disease [93].
- 2 2 -
Chapter One General Introduction
1.5 Blood Flow
Blood flow at a local level is governed by cardiac output/perfusion pressure and 
vascular resistance or tone.
Mathematically, laminar flow in a tube can be described by Darcy’s law, where 
flow (F) is dependent upon the pressure gradient (AP) and resistance (R) [94].
F = =  ^ rR (i)
To apply this simple equation to the biological setting the components governing 
resistance must be taken into account, in particular viscosity. The Hagen-Poisseuille 
equation describes this relationship, resistance (R), (v) Viscosity, (L) length of tube and 
(r) radius.
R =  ( ^ ) ( - )
r4 7T (2)
Combining equations 1 and 2 gives equation 3. The important thing to note is 
that the relationship between flow and radius is to the fourth power, therefore a 2 -fold 
change in radius will give a 16-fold change in flow for example.
P  A P . r *
™ ^  v . L  (3)
In reality, this is only an approximation, as blood does not behave as a 
Newtonian fluid i.e. viscosity varies with respect to flow and shear rate, the reader is 
directed to an interesting paper regarding the complexities o f the topic by Sirs [95].
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1.6 Cardiac Output
Cardiac output is the product of heart rate and stroke volume. A key factor in the 
control of heart rate is the autonomic nervous system; an increase in sympathetic 
stimulation to the heart releases noradrenaline which acts via p-adrenoceptors and 
results in an increase in heart rate [96]. Stroke volume is governed by myocardial 
contractility (also influenced by the autonomic nervous system), pre-load and after-load 
[97]. Pre-load is essentially the pressure stretching o f the ventricle after passive filling 
and atrial systole. Pre-load is often equated to end-diastolic volume of the left ventricle 
and is largely dependent upon venous return and ventricular distensibility [97]. After­
load is in essence the pressure that the ventricle must generate in order to contract, i.e. 
the force required to overcome aortic pressure, open the aortic valve and eject blood and 
is often referred to as end-systolic pressure. After-load is heavily influenced by 
peripheral resistance as this tends to be a major factor in determining blood pressure
[97].
1.7 Vascular Resistance
Vascular resistance represents the resistive forces that must be overcome to 
produce flow within a vessel. The basic anatomy and biological factors that govern 
vascular resistance are covered below.
1.7.1 Vessel Structure and the Vascular Tree
The vascular tree comprises a number of vessels which are distinct at many 
levels. In physical terms, arteries are more muscular whereas veins tend to be more 
compliant and contain valves to prevent retrograde flow (Figure 1.8). The response of 
these different vessels to environment, local and systemic mediators also varies hugely
[98]. It is important to note that despite the various physical differences, all vessels are 
lined with endothelial cells that are essential in controlling tone and maintaining the 
health of the vessel. Veins generally don’t receive the same research attention as arteries
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have in the past, but the fact that approximately 70% of the total blood volume is found 
within the venous circuit, with the majority contained in the small veins and venules
[99], highlight their importance. Given that these vessels represent the primary 
capacitance region of the body, minor changes in venous tone can impact significantly 
on venous return and thus cardiac output [1 0 0 ], stressing the significance of active 
vascular tone control in veins.
Artery
Endothelium
Smooth muscle
artery artery Capillaries
(C)
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Large Smal Artenotes Capllanes Venules Veins
arteries artenes
Figure 1.8. The structure (A), arrangement (B) and characteristics (C) of arteries and veins. Adapted from 
[101].
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1.7.2 Control of Vascular Tone
The regulated control of vascular tone is so implicit that it occurs via many 
different pathways at both a local and whole body level (figure 1.9). The fact that so 
many different physiological agents and systems influence blood vessel tone could 
suggest significant redundancy. However, because blood vessels play such an important 
role in maintaining flow, the presence of multiple pathways allows for compensatory 
upregulation in the event of a problem. The origins, control and mechanism of some of 
these influences are described below.
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Figure 1.9. Schematic drawing of an arteriole and the various influences that determine vasomotor tone. 
Abbreviations: P 0 2_oxygen tension; TxA2-thromboxane A2 (receptor); 5HT-5-hydroxytryptamine 
(receptor); P2X and P2Y, purinergic receptor subtypes 2X and 2Y that mediate ATP-induced 
vasoconstriction and vasodilation, respectively; ACh-acetylcholine; M-muscarinic receptor; H] and H2, 
histamine receptors type 1 and 2; B2-bradykinin receptor subtype 2; ANG I and ANG II, angiotensin I and 
II; AT]-angiotensin II receptor subtype 1; ET-endothelin; ETA and ETB, endothelin receptor subtypes A 
and B; A2-adenosine receptor subtype 2; B2-B2-adrenergic receptor; ot] and a 2, a-adrenergic receptors; 
NO-nitric oxide; eNOS-endothelial nitric oxide synthase; PGI2-prostacyclin; IP-prostacyclin receptor; 
COX-l-cyclooxygenase-1; EDHF-endothelium-derived hyperpolarizing factor; CYP450-cytochrome 
Kca- calcium-sensitive K+ channel; KATP-ATP-sensitive K+ channel; Kv-voltage-sensitive K+ channel; 
AA-arachidonic acid; L-Arg-L-arginine; 0 2 -, superoxide. Receptors and enzymes are indicated by an oval 
or rectangle, respectively. Adapted from [102].
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1.7.2.1 Neuronal Input and Output
The autonomic nervous system (ANS) comprises both afferent and efferent 
neurons which connect the central nervous system with visceral effectors. The ANS has 
two branches, the sympathetic and parasympathetic (Figure 1.10).
1.7.2.1.1 Afferent Signals
The nucleus tractus solitarius (NTS), found in the dorsomedial region of the 
medulla oblongata, receives thousands of afferent input signals each second [103]. 
Ascending information from baroreceptors represents one of the most significant inputs, 
providing tonic and phasic information that can modulate sympathetic outflow to 
splanchnic and muscle vasculature to produce adjustment on a second-to-second basis 
[104, 105].
A number of functionally different arterial baroreceptors have been found in the 
aorta and carotid sinus, they are pressure sensitive and relay information to the 
vasomotor centre via the vagus and glossopharyngeal nerves respectively [106]. 
Additional inputs are also received from cardiopulmonary mechanoreceptors [107], 
chemoreceptors that are sensitive to changes in blood/cerebral spinal fluid (CSF) 
metabolic metabolites e.g. pCC>2 [108] and pulmonary stretch receptors that respond to 
changes in lung volume [109].
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Figure 1.10. A schematic of the autonomic nervous system. Peripheral vascular function is regulated by 
the afferent input, central integration, and efferent outflow of the sympathetic nervous system. Afferent 
pathways from baroreceptors, pulmonary stretch receptors, cardiac and respiratory mechanoreceptors, and 
gastrointestinal and visceral are primarily vagal fibers that receptors feed information to the CNS. The 
central integration of the vagal afferent input into the NTS (nucleus tractus solitaruis) is responsible for 
initiating the reflex control of the circulation via complex patterns of sympathetic outflow that are 
modulated by other neural inputs, peptides and amino acids collectively termed "neuromodulators." 
Efferent pathways alter cardiovascular parameters through; initiating hormone release, modulating the 
heart and innervating vessels directly. Diagram based on original from [103].
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1.7.2.1.2 Efferent Signals
Efferent signals that control the circulation come from both the sympathetic and 
parasympathetic branches of the ANS. Parasympathetic innervation plays a more minor 
role, working in opposition to sympathetic drive in the control of the heart and to a 
lesser extent in vessels [110]. The sympathetic efferent neurons can be separated into 
three groups; barosensitive, thermosensitive and glucosensitive. The thermosensitive 
efferents are activated in response to temperature change or emotional stimuli [1 1 1 ], 
while glucosensitive efferents are activated by hypoglycaemia or exercise [1 1 2 ]; neither, 
however, play a considerable role in cardiovascular control. It is the baroreceptor 
efferents that appear to have the most significant role. Found in numerous tissues and 
organs, these efferents are highly active (sympathetic tone) even under basal conditions 
[113]. Baroreceptor efferents are thought to have roles in both the long and short term 
regulation of vascular tone and blood pressure [114]. Interestingly, it has been 
demonstrated that nitric oxide and thiol-bound nitric oxide compounds (SNOs) can 
modulate the activity of these baroreceptors in vivo [115]. In the majority o f cases, ANS 
vessel innervation is mediated by noradrenaline and acetylcholine [116]. Activation of 
p-adrenergic receptors on vascular smooth muscle results in vasodilatation, whereas oti 
and to a lesser extent tX2 activation produces vasoconstriction [117]. The 
parasympathetic stimulation of vascular smooth muscle muscarinic receptors can also 
produce vasoconstriction [118]. Endothelial cells have both a  and p adrenoceptors; 
stimulation of p receptors produces vasodilatation through the release of nitric oxide 
[117]. Endothelial cells also produce vasodilatation when stimulated by the primary 
parasympathetic neurotransmitter, acetylcholine [118].
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1.7.2.2 Metabolic Messengers
Vessel tone is perhaps unsurprisingly affected by metabolic factors in the blood 
stream or within the tissues themselves. The existence of this relationship gives rise to 
matching of supply (through alterations o f flow) to demand at a very localised level.
1.7.2.2.1 Carbon Dioxide
Carbon dioxide, or hypercapnic acidosis is know to cause vasodilatation [119]. 
However, the mechanism of action is incompletely understood and it is unclear whether 
carbon dioxide itself or the accompanying change in pH (or both, via alternative 
mechanisms) is responsible. Although it is generally perceived that the pH change is 
most likely the key mediator [120], there is evidence to suggest that differing 
mechanisms involving both carbon dioxide and H+ could be involved [121]. Carbon 
dioxide has also been demonstrated to potentiate the effects of nitric oxide in cerebral 
arteries [122].
1.7.2.2.2 Adenosine
Adenosine is a by-product o f normal metabolism generated via two distinct 
pathways that use either AMP (adenosine monophosphate) or S-adenosylhomocysteine 
[123]. Due to this metabolic link, adenosine release increases during cell stress, as seen 
with hypoxia, for example [124]. Once released, adenosine acts as a vasorelaxant and 
aids to increase flow to areas of oxygen demand. A number of adenosine receptors have 
been cloned and have been shown to be G-protein coupled, operating via phospholipases 
and/or adenylate cyclase [125, 126]. In addition to its direct vascular effects, adenosine 
can also influence the cardiovascular system via platelets, mast cells and the autonomic 
nervous system. Interestingly, adenosine has also been shown to promote nitric oxide 
release in vascular tissue [127].
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1.7.2.2.3 Oxygen
The effects of pC>2 on vascular contractility have been a point of discussion for 
many years [128, 129]. It is clear that most vascular tissue relaxes under hypoxic 
conditions; conversely the same is true of constriction in hyperoxic conditions, however 
the mechanism still remains unclear. As with most rules, there is an exception; the 
pulmonary vasculature behaves in reverse, constricting during hypoxic exposure [130]. 
Although the mechanism of hypoxic vasodilatation has not been truly defined, there are 
several mechanistic theories that have been broadly separated into two groups: those that 
involve energy limitation and those associated with a disruption in excitation- 
contraction coupling/relaxation mechanism [131]. Our laboratory has previously 
published a finding that could explain this phenomenon [132]. At moderately low 
oxygen conditions (~5%) a condition arises where NAD(P)H oxidase generation of 
superoxide is limited, but nitric oxide synthase production is not (eNOS Km for oxygen 
~6-9pM). This produces a situation over a narrow oxygen concentration range where, 
despite the same level of production, the relative abundance of nitric oxide is increased 
due to decreased superoxide scavenging.
1.7.2.3 Endocrine and Paracrine
As previously mentioned, the control o f vessel tone occurs at both local and 
systemic/global levels. Those substances which are known to alter vessel tone are also 
released and act in this way i.e. some act in an endocrine or paracrine fashion whilst 
others may do both.
1.7.2.3.1 Peptides
A vast number of signalling peptides exist in the circulation and carry out a 
number of vascular effects. Primarily, there are those that produce vasoconstriction 
(Angiotensin II (AT-II), antidiuretic hormone (ADH), Neuropeptide Y (NPY) and 
endothelin (ET)) and those that produce vasodilatation (atrial natriuretic peptide (ANP), 
vasoactive intestinal peptide (VIP), substance P (SP), Neurotesin, cacitonin gene-related
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peptide (CGRP) and the kinins). This field is represented by a huge body o f research 
that cannot be covered in detail here, therefore detail on some specific signalling 
peptides that are o f importance in vascular regulation will be expanded upon.
1.7.2.3.1.1 Bradykinin
Bradykinin is a product of the kallikrein-kinin system (Figure 1.11) and is 
generated in blood by converting enzymes found in or on the surface of vascular cells. 
The kinins have broad effects that are mediated through two distinct G-protein coupled 
receptors (Bj and B2), these include roles in; cardiovascular and renal control, 
inflammation and pain [133]. Both receptors are principally linked to phospholipase C 
activation, which in turn causes an increase in intracellular calcium from inositol 1,4,5- 
trisphosphate (IP3)-mobilised stores [133]. Circulatory actions o f the kinins generally 
arise from enzymatic processes which are calcium dependent, in endothelial cells both 
nitric oxide and prostacyclin production are stimulated [134]. Bradykinin has also been 
shown to initiate endothelium derived hyperpo lari sing factor (EDHF) in the human 
forearm [135]. In addition to potent vasodilator effects, bradykinin has actions upon the 
heart, altering both heart rate and myocardial contractility [136].
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Figure 1.11. The kallikrein-kinin system. Abbreviations: ACE-angiotensin-converting enzyme, Bl-rec- 
bradykinin 1 receptor, B2-rec-bradykinin 2 receptor, FXII-factor XII, FXIIa-factor Xlla, HK-high- 
molecular-weight kininogen, LK-low-molecular-weight kininogen, NEP-neural endopeptidase. Based on 
original schematic from [137].
1.7.2.3.1.2 Endothelins
Endothelin is a 21 amino acid residue protein that is released by endothelial cells 
and was discovered in the late 1980s [138, 139]. Endothelin is usually cleaved from a 
precursor protein and exists as three different isoforms, Endothelin 1, 2 and 3, each 
having more or less potency at different receptor subtypes [140]. In mammalian cells, 
the endothelins have two cell surface receptor subtypes, ETA and E T b, both operate 
through multiple G-protein coupled pathways (Figure 1.12) [141]. Key signalling 
mechanisms appear to be through phospholipases, IP3 and changes in intracellular 
calcium levels [142]. Different receptor subtypes are found in varying quantities in a 
number of different cell types, suggesting that endothelins may participate in a variety of 
control mechanisms [143]. In vascular tissue, E T b is found on the endothelium where it 
produces vasorelaxation through stimulation of both nitric oxide and prostacyclin 
production. Conversely, ETA is found in significant quantities in vascular smooth
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muscle where upon stimulation it produces vasoconstriction (Figure 1.12). Endothelin-1 
is released by the endothelium in response to humoral factors and shear stress and is 
preferentially released at the basal surface of the cell directly onto the smooth muscle 
beneath, the subsequent effect on vascular tone is dependent on both local concentration 
and receptor density/subtype distribution [144]. The relative contribution of endothelin 
in the control o f vascular tone is known to be different, depending on the circulatory 
system studied [145]. Sustained exposure to shear stress reduces endothelin-1 
production and is likely to be mediated by increased nitric oxide production and 
increased levels o f cyclic guanosine monophosphate (cGMP) [146].
G-Protein Coupled Receptors
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Actions of ET r  
Bronchoconstriction, 
Aldosterone Secretion
ETB
Non-selective actions + 
Autocrine effect on Nitric 
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Figure 1.12. Several G-protein coupled endothelin receptors have been identified but they are generally 
grouped into ETA and ETB according to their main functions (top section o f diagram). The autocrine 
(vasodilatator, via nitric oxide, PGI2) and paracrine (vasoconstrictor) effects of ET-1 on vascular smooth 
muscle cells (bottom of diagram). In addition, ET-1 is also thought to play a role in the activation 
angiotensin converting enzyme (ACE). Based on original schematic from [147].
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1.7.2.3.2 The Renin-Angiotensin System
When the body detects a loss of blood volume or a drop in blood pressure, the 
kidneys are stimulated to release renin. Renin is an aspartyl protease that cleaves 
angiotensin to angiotensin I. Angiotensin I is then further cleaved by angiotensin 
converting enzyme (ACE, found on the endothelial cell surface) to active angiotensin II 
(AT-II), summarised in figure 1.13 [148]. In addition to the well-know chronic effects of 
AT-II on fluid homeostasis (modulating sodium/water reabsorption in the kidneys, the 
thirst centre in the central nervous system and adrenal gland aldosterone release), it also 
has both direct and indirect effects upon blood vessel tone. AT-II directly stimulates 
angiotensin II type I receptor (AT-IR) present in the vasculature to cause 
vasoconstriction and produces changes indirectly by increasing sympathetic tone and 
antidiuretic hormone (ADH, also produces vasoconstriction) release [148]. Angiotensin 
II type II receptors (AT-IIR) are also known to exist and thought to mediate 
vasodilatation [149], however it is AT-I that is highly expressed in adult cardiovascular 
tissue [150].
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Figure 1.13. Schematic illustration of the renin-angiotensin system including tissue sites, enzymes, and 
intermediates, as well as functional impacts on blood vessels. Based on original schematic from [151].
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1.7.2.4 Endothelium Derived Mediators of Relaxation
The endothelium, adjacent to the smooth muscle and blood flow is perfectly 
placed to sense changes in smooth muscle or blood and make a corresponding alteration 
to address said change. Although the endothelium does produce vasoconstrictors e.g. 
endothelin and thromboxane A2, it is the vasodilators that it produces that are essential 
for normal vessel health and control, particularly in respect to the altered patency 
observed in cardiovascular disease states.
1.7.2.4.1 Eicosanoids
The eicosanoid family encompasses a number of different lipid signalling 
molecules that include prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) 
and hydroxyeicosatetraenoic acids (HETEs). All members of this family are 
biosynthetically derived from the same primary pathway. A change in intracellular 
calcium (Ca2+) brought about by physical stimuli, chemical stimuli (e.g. hormones, 
autacoids) or receptor operated pathways (e.g. cytokines) leads to activation of 
phospholipases, predominantly C or A2 [152]. These phospholipases cleave 
phospholipids from the membrane; in humans arachidonic acid is the most abundant 
phospholipid precursor. Subsequently, unesterified arachidonic acid (AA) is rapidly 
converted to unstable intermediates by either lipoxygenases (LOXs) or prostaglandin H 
synthases (also known as the cyclooxygenases (COXs)) [153]. Further conversion by 
specific enzymes gives rise to final products that have biological activity (Figure 1.14).
Two isozymes of COX are known to exist: COX-1, which is encoded by a 
constitutively expressed gene and COX-2 which is encoded by an immediate response 
gene [154]. The majority of cells contain COX-1, whereas only a number of nucleated 
cells can increase COX-2 levels upon inflammatory/mitogenic stimuli [155]. Homology 
of key residues in the catalytic domains in the two isoforms gives rise to very similar 
rates of catalytic activity [156]. Both isoforms contain two distinct catalytic domains. 
Firstly, an oxygenase domain that oxygenates and cyclises AA to form an endoperoxide 
known as PGG2, which in turn enters the peroxidase domain (thought to operate through
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the enzyme’s haem centre) that converts PGG2 to PGH2 by reducing an OOH group at 
position 15 [157]. The cyclooxygenase site of COX-1 is more flexible than that of COX- 
2, giving rise to differences in substrate binding [158], this difference is thought to 
contribute in the development of more isoform specific antagonists [159].
The biological roles of the eicosanoids are far reaching, with key functions in 
inflammatory regulation and a number of vascular effects on both vessels and blood 
constituents (e.g. platelets, inflammatory cells) (briefly described in figure 1.14). In the 
vasculature, both isoforms of COX have been shown to be localised close to the luminal 
surface o f endothelial cells [160]. Close to the interface between vessel wall and blood, 
the enzymes are perfectly positioned to generate mediators that effect both platelets and 
vascular smooth muscle. The eicosanoids of particular interest in vascular terms are 
prostacyclin (PGI2) and thromboxane A2 ((TX)A2).
Prostacyclin is converted from PGH2 by prostacyclin synthase (PGIS), which is 
found to be co-localised with COX [161]. Once generated, prostacyclin can exert both 
potent vasodilator and anti-thrombotic activities. In vascular smooth muscle, 
prostacyclin exerts its effect through a specific G-protein linked receptor (IP), which 
upon stimulation results in relaxation that is thought to be mediated through increases in 
cAMP and changes in potassium currents [162-164].
Thromboxane A2 is generated from PGH2 by thromboxane synthase (Figure 
1.14) and is produced by a number o f cell types, principally activated platelets [165]. In 
vascular terms thromboxane A2 is important because it has potent actions in contracting 
smooth muscle [166] and is thought to have underlying involvement in hypertension
[167]. The thromboxane A2 receptor is a G-protein coupled receptor that has signal 
transduction pathways involving cyclic AMP and the IP3 (inositol 1,4,5-trisphosphate)/ 
DAG (diacylglycerol) pathway that operates via modulation of intracellular calcium
[168].
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A growing number of publications have shown nitric oxide (endogenous and 
exogenous) to increase COX activity in a number of tissues, including vascular tissue 
[169-175]. The exact mechanism of the relationship remains to be elucidated, however it 
has been suggested that nitric oxide may interact with the haem found in COX to alter 
function in some way [176]. Other work suggests that when nitric oxide reacts with 
superoxide (O2 ) to from peroxynitrite (ONOO'), it can nitrate a tyrosine residue of 
prostacyclin synthase and produce inhibition through steric hindrance [177]. Ironically, 
the same process (specific tyrosine nitration) is thought to activate COX [178].
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Figure 1.14. Biosynthesis of the eicosanoids. Cell stimulation is followed by activation of phospholipases 
which liberates arachidonic acid from the membrane, which in turn is converted to unstable intermediates 
by distinct oxygenases. (LT)A4 and (PG)H2 are then further metabolised into different bioactive products 
by specific enzymes. Based on original schematic from [179].
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1.7.2.4.2 EDHF
In addition to the classic transmitters released by the endothelium, another 
‘factor’ exists to control vessel tone that is more elusive. Termed ‘endothelium derived 
hyperpolarising factor’ or EDHF this phenomenon is receiving increasing research 
interest. EDHF appears to be triggered by a number of endothelial stimuli and ultimately 
results in smooth muscle hyperpolarisation and subsequently relaxation. The 
mechanisms that commence and propagate EDHF remain unclear, although some 
aspects of the phenomenon are understood. EDHF activity is thought to be reliant on 
either diffusible factors or contact-mediated mechanisms (Figure 1.15). Many diffusible 
factors have been proposed and notably include potassium ions (K+), 
epoxyeicosatrienoic acids (EETs) and hydrogen peroxide (H2O2) [180-182]. The transfer 
o f ‘signal,’ either diffusible or electrical from endothelial cells to smooth muscle cells is 
thought to occur through myo-endothelial gap junctions [183]. It is accepted that, 
regardless of mechanism, an increase in endothelial cell intracellular calcium and 
activation of specific potassium channels is required for EDHF activity, summarised in 
figure 1.15 [184]. It is recognised that the contribution of EDHF to overall control of 
vascular tone varies along the vascular tree, becoming more prominent in smaller 
vessels [185]. The study of EDHF is commonly carried out in the presence o f both 
nitric oxide synthase and cyclooxygenase inhibitors. The use of these agents makes it 
difficult to assess the exact, relative contribution of EDHF to overall relaxation due to 
compensatory upregulation in the vessel.
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Figure 1.15. Schematic description of the main hyperpolarizing mechanisms mediated by EDHF. The 
binding of acetylcholine (Ach), bradykinin (BK) and substance P (SP) to their endothelial receptors and 
the increase in wall shear stress(s) ( t )  promote EDHF. EDHF can then hyperpolarize the smooth muscle 
cells via three principal pathways. 1) EDHF can passively diffuse from the endothelium to activate 
calcium-activated potassium (Kca) channels of large conductance (BKCa) located on the smooth muscle 
cells thereby promoting the release of K+ and membrane hyperpolarization. 2) EDHF can act in an 
autocrine manner to facilitate the activation of the endothelial Kca channels, both small (SKca) and 
intermediate (IKca) conductance channels that release K+ and produce hyperpolarization of the 
endothelial cells, which is in turn transmitted to the underlying smooth muscle via gap junctions. 3) K+ 
released from the endothelial SKq , and IKCa channels into the myoendothelial space activates the Na+/K+ 
ATPase and the inward rectifying potassium channels (KIR) located on the smooth muscle cells 
promoting the release of K+ and subsequent hyperpolarization of these cells. Smooth muscle cell 
hyperpolarization decreases the open-state of voltage-gate Ca2+ channels, lowering cytosolic Ca2+ and 
thereby provoking vasorelaxation. Based on original schematic from [186].
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1.8 Nitric Oxide
Perhaps the most widely studied and understood molecule involved in the control 
of vascular tone is nitric oxide or endothelium derived relaxing factor (EDRF). The aims 
of this thesis focus on both nitric oxide and its metabolites in terms of their biochemistry 
and physiologically relevant bioactivity. Different biological aspects and chemistry of 
nitric oxide and its metabolic products are covered in detail below.
1.8.1 Nitric Oxide Chemical Identity
Nitric oxide (NO), or nitrogen monoxide, is composed of a single nitrogen atom 
and a single oxygen atom. The simple covalent interaction between these atoms gives 
rise to a very chemically active diatomic free radical. It is this chemistry which dictates 
the actions of nitric oxide in both simple chemical and biological systems [50].
At the heart of nitric oxide chemistry is the nitrogen oxidation state (Figure 
1.16). The capacity o f nitrogen to form compounds in a range of oxidation states, from - 
3 to +5, gives rise to a considerable and varied chemistry [187]. Nitric oxide is often 
only considered in its free radical form (NO*), however there are two key redox- 
activated species o f particular interest, the nitroxyl anion (NO ) and the nitrosonium 
cation (NO+), formed by reduction and oxidation of nitric oxide respectively.
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NO
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Figure 1.16. The spectrum of nitrogen redox species, extending from fully oxidised (nitrate) to fully 
reduced (ammonia). The positioning of nitric oxide, nitrosonium, and nitroxyl at the top of the arc 
indicates that these species are relatively easily oxidised or reduced. The presence of the higher oxides on 
the left of the arc indicates that reduction of these species back to free radical nitric oxide is relatively 
difficult and that they are more easily converted to fully oxidized nitrate. Based on original schematic 
from [188].
1.8.2 Normal in vivo Production
The production and release o f nitric oxide by the endothelium can be induced by 
both agonists (such bradykinin or acetylcholine [189]) but also by physical stimuli such 
as shear stress [190]. The mechanisms that control the production and release o f nitric 
oxide traditionally centre on the specialised enzymes that produce it.
1.8.2.1 Nitric Oxide Synthase (NOS)
There are three main iso forms o f nitric oxide synthase, the first to be isolated and 
purified was neuronal NOS (nNOS or NOS I) [191], this was quickly followed by the 
isolation and cloning o f inducible NOS (iNOS or NOS II) [192] and endothelial NOS 
(eNOS or NOS III) [193, 194]. Since this initial classification, a number of additional, 
specific splice-variants have now been identified [195]. nNOS and eNOS are 
constitutively expressed and are activated by interaction with calcium calmodulin.
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Conversely, iNOS is inducible in expression and is activated even at resting cellular 
calcium levels [196]. Structural differences in the different isoforms can be seen in 
figure 1.17 below.
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Figure 1.17. A schematic showing the structural arrangement of the three different isoforms of nitric oxide 
synthase. Note the myristoylation (Myr) and palmitoylation (Palm) sites of eNOS. Based on original 
schematic from [197].
The NOS enzymes are haem-based oxido-reductases that catalyse the conversion 
o f the amino acid L-arginine and molecular oxygen to L-citrulline and nitric oxide. The 
NOS family o f enzymes contain both an oxygenase and a reductase domain and have 
been shown to share close homology with the cytochrome P-450 reductase family of 
enzymes [198].
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Figure 1.18. Schematic of the functional NOS dimer. A functional NOS dimer requires calmodulin (CaM) 
and a number of cofactors and substrates. Note the overall oxo-reductase reaction catalyzed in the 
presence of sufficient (solid lines), or limiting (dashed lines) substrate and/or BH4 (tetrahydrobiopterin). e- 
stands for reducing equivalent. Based on original schematic from [197].
In order to operate, NOS must first form a homodimer through the N-terminal 
interface (Figure 1.18) [199]. This dimerisation is stabilised by the co-factors 6(R)- 
5,6,7,8-tetrahydrobiopterin (BH4) (which works as a stabiliser in addition to having a 
catalytic capacity) and the metallic element, zinc (Zn2+) [200, 201]. The C-terminus 
(reductase domain) o f the enzyme shuttles electrons from NADPH (nicotinamide 
adenine dinucleotide phosphate) to the co-factors, FMN (flavin mononucleotide) and 
FMD (flavin adenine dinucleotide), which are in turn passed to the iron within the N- 
terminus, oxygenase domain protoporphorin IX haem [202]. Acting as an electron 
acceptor, the haem becomes reduced, enabling the binding of molecular oxygen which 
in turn leads to oxidation of the guanido nitrogen of L-arginine to form the stable 
intermediate N -hydroxy-L-arginine [203]. A subsequent molecule o f oxygen is then 
recruited to convert this intermediate into L-citrulline and Nitric oxide [204] (figure 
1.19). Scenarios can arise where substrates/co-factors are limited. This can lead to
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‘uncoupling’ of the enzyme and generation o f oxygen free radicals such as superoxide 
(O2 ), peroxynitrite (ONOO ) and hydrogen peroxide (H2 O2) [205] (figures 1.18 and 
1.19, dotted lines).
N=0- + CitrulNne0 = 0  + L-Arginine + NAD(P)H
L-Arginine Citrulline
NHNH NHNH
HN'HN NH2NH.
0=0 -
OH O-OH
Nitric
oxide
Heme
h 2oNOS 0 = 0  + 0.5 NAD(P)H
Figure 1.19. Schematic depicting the reactions at the N-terminus, NOS oxygenase Catalytic site. 
Simplified reaction mechanism in the presence of sufficient (solid lines), or limiting (dashed lines) 
substrate and/or critical cofactors. Based on original schematic from [197].
1.8.2.1.1 eNOS
eNOS is modified at both co- and post-translational levels by myristoylation and 
palmitoylation respectively, these modifications function to target eNOS to caveolae 
(Figure 1.17) [206, 207]. Caveolae are lipid raft micro-domains that form invaginations 
in the plasma membrane and contain specific functional proteins known as the caveolins 
[208]. eNOS interacts with the scaffolding domain of caveolin-1, blocking the binding 
of calmodulin and inhibiting the enzyme [209]. Upon stimulation (e.g. by shear stress or 
by an agonist) intracellular calcium increases, eNOS is released from caveolin-1 and the 
inhibitory state of eNOS is reversed by interaction with the calcium/calmodulin complex 
or Akt-induced phosphorylation at specific sites [210, 211]. It is also thought that heat
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shock protein 90 (Hsp-90) may also be involved in the allosteric modulation of eNOS 
[212]. By targeting eNOS to the plasma membrane and through its interaction with 
proteins within the caveolae, the enzyme is perfectly placed to adapt quickly to changes 
in shear stress or receptor interaction. Nitric oxide is thought at some level, to control its 
own production, in the short-term by inhibitory interactions with eNOS (possibly 
through haem binding) [213] and in the long-term via inhibition of eNOS transcription 
[214].
1.8.3 Nitric Oxide Signal Transduction.
The solubility of nitric oxide in water is relatively low (~1.9 x KT6 mol cm-3  
atm-1  at 25°C) [215]. Given the highly reactive nature o f the molecule and relatively 
short distances it can diffuse in biological media [216], its low solubility can be 
advantageous. Being hydrophobic in nature allows the molecule to easily pass out of one 
cell i.e. the endothelium, and enter another to exert its actions i.e. into smooth muscle to 
produce vasorelaxation.
1.8.3.1 Smooth Muscle
When nitric oxide diffuses into smooth muscle cells, it activates the soluble form 
of guanylate cyclase (sGC) (Figure 1.20). sGC catalyses the conversion of guanosine 
triphosphate (GTP) to the second messenger, cyclic guanosine 3,5,-monphosphate 
(cGMP) [217]. As levels of intracellular cGMP rise a number of cGMP-dependent 
kinases (e.g. PKGs) become activated [218]. These activated kinases phosphorylate a 
number of key target proteins including potassium channels, IRAG (inositol 
trisphosphate (IP3) receptor associated cGMP kinase substrate) which inhibits IP3 
mediated calcium release and phospholamban, which stimulates SERCA 
(sarco/endoplasmic reticulum Ca2+-ATPase) to sequester cytosolic calcium [219-222] 
(Figure 1.20). All o f these signalling events serve to reduce intracellular calcium, which 
reduces the formation of calcium-calmodulin-myosin light chain kinase complex 
(MLCK) and in turn decreases phosphorylation of serine residues in the myosin
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regulatory light chain (MLC), inhibiting vasoconstriction [223]. PKG directly and 
cGMP (via unknown mechanisms) are also known to activate myosin light chain 
phosphatase (MLCP) which de-phosphorylates MLC, resulting in enhanced 
vasorelaxation [224, 225]. The level of cGMP and hence the level o f kinase activation is 
controlled by phosphodiesterases (PDEs) that break down cGMP. These enzymes have 
received much recent attention with the discovery that novel, pharmaceutical PDE 
inhibitors can be used in the treatment of erectile dysfunction [226].
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Figure 1.20. Schematic showing the production of nitric oxide in endothelial cells and the mechanism of 
action of this mediator on vascular smooth muscle mediated by guanylyl cyclase. The activation of 
endothelial receptors produces an increase in calcium entry via channels, and results in a greater 
concentration of inositol triphosphate (IP3) in these cells. IP3 subsequently releases calcium from the 
endoplasmic reticulum (ER). This increase in intracellular calcium in the endothelium activates 
calmodulin (CaM), which in turn activates nitric oxide synthase (NOS). Nitric oxide (NO) is then 
produced from its precursor, the amino acid L-arginine (L-Arg). The nitric oxide that is synthesised then 
diffuses into the smooth muscle where it activates soluble guanylyl cyclase (GC), forming cyclic 
guanosine monophosphate (cGMP) from the guanosine triphosphate (GTP). cGMP activates various 
protein kinases (eg. PKG), causing a lowering of intercellular Ca2+ levels, inhibits PDEs to increase cAMP 
and can also activate KC channels. All these effects of cGMP produce relaxation of vascular smooth 
musle. Based on an original schematic from [227].
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1.8.3.1.1 Soluble Guanylate Cyclase
Soluble guanylate cyclase was first purified in the 1980s [228] and was 
subsequently shown to contain haem and to be nitric oxide sensitive [229, 230]. The 
enzyme is a large a p  heterodimer: haem binds to the N-terminus of the p-chain, while 
the catalytic domain is comprised o f elements from both the a  and p chains and is 
located in the C-terminal region o f the molecule [231]. The traditional model for 
activation of sGC proposes that nitric oxide must bind to the haem and disunite the bond 
formed between the haem iron and the proximal histidine of the porphyrin structure, 
altering the protein conformation and increasing catalytic activity [232, 233]. However, 
more recent studies suggest that the process has two steps that are both nitric oxide 
dependent [234]. Two theories have been put forward to explain the mechanism of this 
phenomenon. The first suggests that a second nitric oxide molecule could bind to the 
haem iron to give an NO-Fe-NO complex, further altering the protein structure [235]. 
The theory is supported by evidence that shows that even when 80% of sGC haem has 
nitric oxide bound, the enzyme exhibits only 10% full activity [235]. This suggests there 
is a low activity form of sGC that is spectrally indistinguishable from the active NO-Fe 
penta co-ordinate complex. The second theory suggests a non-haem nitric oxide binding 
site to be responsible. The model is based on the observation that the rate that nitric 
oxide dissociates from sGC haem is slower than the rate of deactivation [236]. The 
deactivation of sGC is thought to either occur through simple dissociation of nitric oxide 
that subsequently reacts with intracellular globins e.g. myoglobin [237], or the iron is 
oxidised to Fe (III) with the formation of nitrate [238]. Interestingly, the dissociation of 
nitric oxide from sGC has been shown to be 50 times faster in the presence of substrates 
(GTP and magnesium ions); this dissociation rate (0.04 s’1) is the fastest reported 
dissociation o f nitric oxide from a ferrous haem protein and the finding gives insight 
into the control of this enzyme [239].
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1.8.4 Other Actions of Nitric Oxide
The signalling actions of nitric oxide are not limited to relaxation of smooth 
muscle or functions in vascular health, they involve diverse roles from 
neurotransmission to inhibition o f platelet aggregation. Given the magnitude and 
complexity of the signalling roles in question, the next section of this thesis will 
concentrate on those that have relevance to the vasculature.
1.8.4.1 Platelets
Nitric oxide generated by the endothelium and by platelets [240] has been shown 
to have a number o f effects upon platelet responses. These include inhibition of 
aggregation [241], adhesion [242] and recruitment [243]. Although platelet aggregation 
is a vital process in the prevention o f bleeding, disorders or over-stimulation of this 
process can result in unwanted thrombosis [244]. As in smooth muscle, nitric oxide 
signalling in platelets is via cGMP production, leading to a reduction in intracellular 
calcium [245, 246]. The cGMP-dependent reduction in intracellular calcium is also 
associated with SERCA activation and phosphorylation of phospholamban, as in smooth 
muscle [247]. As calcium levels fall, it is thought that the association between platelets 
and fibrinogen decreases and the formation of active glycoprotein Ilb/IIIa is inhibited 
[248, 249]. cGMP increases cAMP levels by inhibiting its breakdown by PDEs, 
producing enhanced cGMP-like activity [250]. In addition, cGMP also inhibits thrombin 
mediated activation of phosphoinositide 3-kinase (PI3-K) which normally promotes the 
active form of the glycoprotein Ilb/IIIa complex [251].
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1.8.4.2 Cell Proliferation and Angiogenesis
Nitric oxide is intimately involved in the control of angiogenesis via its ability to 
alter both cell death signalling and promote cellular proliferation with angiogenesis 
attenuated in the absence of nitric oxide [252]. Nitric oxide has been shown to inhibit 
the proliferation of vascular smooth muscle [253] and is proposed to operate in this 
capacity through both cGMP dependent and independent mechanisms. Through cGMP 
dependent mechanisms, nitric oxide increases levels of cAMP and activates protein 
kinase A [254]. PKA reduces intracellular calcium levels which counteracts high 
calcium fluctuations that are known to promote proliferation [255]. Independently of 
cGMP, nitric oxide inhibits the production o f polyamines required for DNA synthesis 
through blocking o f critical enzymes, ornithine decarboxylase and arginase [256].
Nitric oxide is also capable o f preventing apoptosis and promoting proliferation of 
endothelial cells [257, 258].
1.8.4.3 Mitochondria
Nitric oxide has been shown to interact with a number of metal-centred enzymes 
of the electron transport chain (ETC), including Complexes I, II, III and cytochrome c 
oxidase (complex IV) [259-261]. The effects o f nitric oxide on the system can be both 
reversible and irreversible and appear to be dependent upon concentration [262]. 
Cytochrome c oxidase is the final enzyme complex of the ETC which catalyses the 
reduction o f oxygen to water. Cytochrome c oxidase is inhibited by nitric oxide due to 
nitric oxide binding to the haem oxygen site of the enzyme at physiological 
concentrations [263]. The inhibition o f cytochrome c oxidase causes a reduction in flux 
through the ETC and a block o f cellular respiration [264]. The sensitivity of this 
mechanism to changes in nitric oxide to oxygen ratio has been proposed to provide a 
potential link between oxygen sensing and respiration [264]. One scenario in which this 
reversible/transient mechanism could beneficially alter physiology is in smooth muscle, 
where a depletion o f oxygen and consequent change in respiration/nitric oxide 
bioavailability could result in vasodilatation [265].
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1.8.4.4 Protein Modification
In addition to classic signalling pathways, nitric oxide is now believed to signal 
through modification o f specific proteins, at specific sites. A biologically relevant 
example of nitric oxide mediated protein modification is S-nitrosylation of cysteine 
residues, which was first shown by Stamler et al in 1992 [266]. Unusually, the covalent 
bond formed between nitric oxide and the sulphur of a thiol group is readily reversible 
(i.e. could infer an ‘on’ and ‘o ff  mechanism) and in light of the fact that nitric oxide can 
easily pass from one thiol group to another (transnitrosation) there is a suggestion that S- 
nitrosothiol complexes could have roles in cellular signalling [267]. Since the original 
observation by Stamler et al [266], hundreds o f target proteins and processes that can be 
modulated by S-nitrosylation have been identified, these include regulation of vascular 
enzymes such as eNOS [268, 269] and modification of mitochondrial proteins to alter 
respiration [270], ion channels [271], plasma proteins (e.g. factor XIII [272]) and 
signalling proteins [273].
1.8.4.5 Inflammation
Nitric oxide also plays a number o f essential and wide ranging roles in the 
inflammatory response. The release o f inflammatory cytokines causes the activation and 
upregulation o f inducible nitric oxide synthase (iNOS) in a wide range of cell types 
[274]. The amount o f nitric oxide generated in this response is often considerable when 
compared to the average turn over in endothelium, however, the role that nitric oxide 
plays is very much dependent upon the site of synthesis, local targets and local 
concentration [274]. Nitric oxide is belived to play key signalling roles via the 
regulation o f the transcription factor NF-kB [275, 276], which can control processes 
such as ECAM (cell surface glycoproteins involved in inflammatory cell adhesion, 
rolling and extravsation) expression on the endothelial cell surface [277]. Nitric oxide is 
also important in first-line defence providing cytotoxicity against invading parasites, 
bacteria and viruses [278, 279].
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Although nitric oxide is clearly essential in the immune response, in scenarios 
where production is high (as in sepsis [280]), the ability of nitric oxide to act at multiple 
targets, act as an oxidant or antioxidant and form other highly reactive species (e.g. 
peroxynitrite) can potentially be detrimental.
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1.9 Nitric Oxide Metabolism in Biological Media
1.9.1 Blood
A proportion of nitric oxide generated by the endothelium inevitably enters the 
lumen of the blood vessel where it interacts with blood. The metabolism of nitric oxide 
in this setting varies depending on whether the molecule interacts with plasma 
constituents or the erythrocytes.
1.9.1.1 Plasma
Nitric oxide metabolism in plasma, as in most aqueous solutions, primarily 
proceeds via the autoxidation route where nitric oxide undergoes reaction with 
molecular oxygen to yield N 0 2[A] [281, 282].
2NO* + 0 2 2N 02* [A]
Once formed, N 0 2 can undergo further reaction with nitric oxide to form the N- 
oxide N20 3[b] [283] or can dimerise to form N20 4 [C1 [284].
N 0 2# + NO’ <-> N20 3 [B]
2N 02* <->N20 4 [C]
In turn, these products may be hydrolysed to yield nitrite (N 02')[D] [285] and 
nitrate (N 0 3 )[E] [283], respectively.
N20 3 + H20  -> 2HN02 -»  2N 02- + 2H+ [D]
N20 4 + H20  —> N 0 3 + N 0 2 + 2H+ [E]
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The autoxidation reaction of nitric oxide is second order with respect to nitric 
oxide concentration and third order overall [286]. Under normal conditions, where the 
oxygen concentration is much higher than the nitric oxide concentration, the half-life is 
inversely dependent upon concentration and so the reaction proceeds slowly. This could 
explain how nitric oxide appears to have sufficient longevity to induce signalling within 
the immediate area of generation. In areas o f high nitric oxide concentration i.e. the 
micro-environment surrounding activated macrophages [287], the converse is also true 
and the half-life decreases dramatically.
Both nitric oxide itself and the higher N-oxides (e.g. N 20 3 [B] and N20 4[C]) that it 
forms are effective nitrosating agents and can interact with nucleophilic centres (-S, -N, 
-O, -C) on plasma proteins (e.g. albumin) to generate a number of species [288]. One of 
the key nucleophilic groups found on proteins are the thiol (R-S) groups, which are 
readily nitrosated via several proposed mechanisms. Nitric oxide itself will react with 
both thiols and thiol radicals[F] to generate nitrosothiols (RSNOs) and nitrosothiol 
radicals respectively [289]. In the case of direct reaction where a RSNO radical is 
formed, the RSNO is stabilised by electron abstraction by another molecule, or by 
protonation to form the RSNOH radical [290]. Generally, the formation of RSNO 
compounds is thought to proceed via formation of the nitrosonium ion (NO*) formed via 
interaction with metals (M) often contained in haem proteins [291][G][H], dinitrosyl iron 
complexes^ [292] or via higher N-oxides that have ‘NO+-like’ activity^ 1 [293]. In 
areas of low pH, it is also possible for nitrite to generate NO+ and thus RSNOs[M] [294].
NO- + RS* -> RSNO [F]
NO* + M —> MNO —» M(reduced) + NO+ [G]
NO+ + RS' -> RSNO [H]
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RS” NO+
\  /
Fe(-I) + R'SH = = >  R’S-NO + decomposition products 
RS ^  NO+ [I]
N20 3 + RSH -> RSNO + H+ + N 0 2' [J]
N20 4 + RSH -> RSNO + H+ + N 0 3‘ [K]
ONOOH' + RS -»  RSNO + HOO' [L]
N 0 2' + H+ + RSH -> RSNO + H20  [M]
Nitric oxide present in plasma also undergoes reactions with oxygen derived free 
radicals such as superoxide (O2 ) [295], hydrogen peroxide (H2O2) [296] and the 
hydroxyl radical (*OH)[297]. In vivo, there are many sources of superoxide, including 
the electron transport chain and enzymes such as xanthine oxidase and NAD(P)H 
oxidase [298]. Nitric oxide reacts extremely rapidly with superoxide (6 - 1 0  x 1 0 9 M'V1, 
near diffusion limited [299]) to form peroxynitrite (ONOO')[n]. Once formed, 
peroxynitrite can be protonated[° ] which leads to rapid decomposition to nitrate^. When 
excess nitric oxide is present, peroxynitrite will undergo further reaction to form 
nitrite[Q1.
0 2‘ + NO- -> ONOO' [N]
ONOO’ + H+ -> ONOOH [O]
ONOOH OH* + N 0 2* N 0 3' + H+ [P]
ONOO' + NO* 2N 02’ [Q]
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Peroxynitrite is a potent oxidant and can have deleterious effects upon many 
biological molecules including lipids, nucleic acids and proteins [300]. To control the 
levels of these oxidative species and thus control nitric oxide bioavailability, the body 
has a number of clearance mechanisms. Superoxide dismutases (SOD), represent a class 
of enzymes that utilise metal cofactors (e.g. copper, zinc, iron, nickel and manganese), 
to help scavenge superoxide and catalyse its conversion to hydrogen peroxide [301]. 
Hydrogen peroxide is then catalysed to water and oxygen by catalase/glutathione 
peroxidase or to hypochlorous acid by myeloperoxidase [302]. Both reactive oxygen 
(e.g. superoxide) and nitrogen species (e.g. peroxynitrite) have been heavily implicated 
in vascular disease states, with over-production of these species closely linked to 
endothelial dysfunction [303].
1.9.1.2 Erythrocytes
Although nitric oxide can react with erythrocyte membrane components, it is the 
reactions with the haemoglobin contained within the erythrocytes that are more likely to 
govern its metabolism. Nitric oxide will react very rapidly with both oxygenated (R- 
state) and deoxygenated (T-state) haemoglobin (~107 M '1s '1)[304], however the 
metabolites formed in each case are different. When nitric oxide reacts with 
oxyhaemoglobin it forms nitrate and met haemoglobin i.e. the oxidation state of the 
haem iron goes from 2+ to 3+ in the reaction[R] [305]. Methaemoglobin levels in healthy 
individuals are around 1-3% [306] and are kept at this level by NADH-cytochrome bs 
reductase and soluble electron carrier cytochrome bs, which converts met haemoglobin 
back to deoxyhaemoglobin within the erythrocyte [307].
Hb(Fe2+)0 2 + NO* -> metHb(Fe3+) + N 0 3‘ [R]
The similarities in diatomic spatial structure between nitric oxide and molecular 
oxygen denote similar bonding patterns. Like molecular oxygen, nitric oxide rapidly
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bonds in the same binding pocket o f T-state haemoglobin to form iron nitrosyl- 
haemoglobin (HbNO)[S] [305].
Hb(Fe2+) + NO* ->• HbNO [S]
The dissociation o f nitric oxide from HbNO is very slow ~10 s [308]. 
However, in vivo, where partial nitrosylation can occur HbNO is subject to different 
metabolism. Stamler and colleagues have demonstrated that partially nitrosylated 
haemoglobin can, upon oxygenation, release nitric oxide through haemoglobin 
conformational changes where it subsequently binds to conserved cysteine residues in 
the 93 position o f P haemoglobin, forming HbSNO[X] [309]. At physiologically relevant 
NO:Hb ratios, they report an 80% yield o f HbSNO upon oxygenation [309]. More 
recently, Stamler and colleagues have reported that a similar reaction can occur upon 
oxygenation o f nitrite/deoxyhaemoglobin mixes [310].
HbNO + 0 2 oxyHbSNO + le + 1H+ [T]
Metabolic products of other nitric oxide reactions e.g. nitrite will also undergo 
reactions with both oxy and deoxyhaemoglobin, although at considerably slower rates 
than that o f native nitric oxide [311].Nitrite reacts with oxyhaemoglobin in a process 
that is thought to be autocatalytic and forms nitratetu] [312].
4Hb(Fe2+)0 2 + 4N 02‘ + 4H+—» 4Hb+ + 0 2 + 2H20  + 4N 03' [U]
The reaction between deoxyhaemoglobin and nitrite is more complex and 
involves several component reactions[V][wraY]. The reaction is though to proceed via 
the formation of nitrous acid (pH dependent) and result in the final products o f HbNO 
and nitrate in a stoichiometric ratio of 1:1 [313]. Nagababu et al also propose that the 
nitric oxide formed in this reaction could exists as an unstable met-haemoglobin adduct 
(Hb(II)NO+<-»Hb(III)NO) which, in the presence of excess nitric oxide, is thought to 
decompose to HbNO and the nitrosonium ion (NO+) [314]. However, spectral and
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reaction rate data suggests that this intermediate is transient and unlikely to accumulate 
[315],
H+ + N 02- -> HONO [V]
Hb + HONO -> met Hb + NO +OH [W]
Hb + NO -> HbNO [X]
Hb + ONO' ->• metHb + ‘N 0 22’’ [Y]
1.9.1.3 Tissue
In tissues, nitric oxide is likely to participate in free radical reactions as 
previously discussed in plasma, but perhaps more importantly will bind to metal-centred 
proteins. The adducts formed with these proteins are usually oxidised to finally form 
nitrate, which will inevitably leach into the bloodstream [238]. Nitric oxide will also 
form nitrated lipids through reaction with lipid molecules such as those found in the 
membrane. Theses molecule have recently started to receive attention after it was 
recognised that they can act as potent signalling molecules, particularly in inflammatory 
processes [316]. A summary o f the reductive and oxidative reactions of nitric oxide can 
be seen in figure 1 .2 1 .
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Figure 1.21. A schematic summary o f the reactions o f nitric oxide. M-metal, RSH-Thiol, RSNO- 
nitrosothiol, N20-dinitrogen oxide, NH2OH-hydroxylamine, ROH-primary amine, RONO-nitrosamine, 
RR’NH-Secondary Amine. Based on original schematic from [317].
1.9.2 Excretion
Nitric oxide and its metabolites are known to leave the body via a number of 
routes. Nitric oxide itself can be exhaled, while its metabolites, namely nitrate, can be 
excreted via the bowel or principally via the urinary tract [318]. Other products are 
thought to be metabolised by the liver, through the urea cycle for excretion as nitrate in 
urine [318].
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1.10 Biological Activity of Nitric Oxide Metabolites.
Haemoglobin has historically only been considered in terms of its ability to 
quench the biological activity o f nitric oxide. In light of the rapid rate of reaction 
between the two and the high concentration o f haemoglobin present in the blood stream, 
it has often been questioned as to how it is possible for nitric oxide to exert its effects in 
vivo given proximity of the reactants in question. Several factors that are thought to 
enhance nitric oxide longevity have been proposed within the vessel setting. Firstly, 
haemoglobin contained within erythrocytes does not react as quickly with nitric oxide as 
free haem [319], this is thought to be due to membrane impedance [320] or an 
‘unstirred’ layer around the erythrocyte that acts to limit diffusion [321, 322]. In 
addition, it has been proposed that erythrocytes subjected to laminar flow in the vessel 
lumen do not travel in a uniform arrangement [323]. Erythrocytes travel in the area of 
fastest flow, down the centre o f the lumen, this creates a ‘red blood cell free zone’ 
adjacent to the vessel wall and allows nitric oxide to accumulate on the luminal side of 
the endothelium (undisturbed by erythrocytes) thereby creating a diffusion gradient 
toward the smooth muscle. However, this phenomenon is unlikely to occur in narrow, 
resistance vessels, other mechanisms of nitric oxide ‘protection’ and other regulators of 
vascular tone (e.g. EDHF) are likely to take precedence in these vessels. Despite these 
protective mechanisms, nitric oxide has always been considered a paracrine regulator 
acting within a short diffusion distance. However, recognition that some of the 
metabolic waste products o f nitric oxide could themselves be bioactive has given rise to 
an entirely new field o f research. The relative stability of these metabolites meant that 
nitric oxide (as its metabolites) could be preserved and be delivered in an endocrine 
fashion to distal sites.
Original proposals for the preservation of bioactive nitric oxide came from the 
Stamler laboratory in 1992 [266]. The group discovered that endogenous nitric oxide 
could form RSNO compounds with thiol containing plasma proteins, principally 
albumin [324]. The proposal underwent further development after the finding that 
specific cysteine residues in the p-chains o f haemoglobin could also be nitrosylated and
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convey biological activity [325]. Since these findings, a number of other candidate 
metabolites that could conserve nitric oxide bioactivity have been proposed including 
HbNO [326], the nitrite anion [327] and nitrated lipids [328]. The majority of suggested 
metabolites/mechanisms are centred around two components, erythrocytes and oxygen. 
Native erythrocytes have been shown to transiently relax vascular tissue, but only upon 
introduction to a hypoxic tissue environment [329]. Collectively, these findings have 
given rise to two main theories regarding the mechanism of conserved nitric oxide 
bioactivity and erythrocytes, which will be covered in detail below.
1.10.1 The Hb-SNO Theory
After the discovery that the highly conserved p93 cysteine residue of 
haemoglobin could be nitrosylated (HbSNO) and produce biological effects [325], 
Stamler and colleagues developed a novel concept in which the vasodilator properties of 
HbSNO could be matched to oxygen demand in the respiratory cycle (Figure 1.22) 
[329]. The theory relies upon the conformational state o f haemoglobin (i.e. oxygen 
saturation) and the manner in which this changes over a respiratory cycle.
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Figure 1.22. Schematic representation o f the ‘SNO theory’ depicting the human respiratory cycle 
involving 3 key gases, NO, C 0 2 and 0 2. The SNO theory suggests that 0 2 and C 02 are the allosteric 
effectors that govern the equilibrium between the R-state and T-state structures of Haemoglobin, which in 
turn dictates whether nitric oxide bioactivity is dispensed to dilate blood vessels or sequestered thus 
constricting them. In theory this process has the ability to couple blood flow to metabolic demand. 
Reproduced from [329].
In the venous circulation, haemoglobin is only partially oxygenated and so the 
haems that are not carrying oxygen can potentially react with nitric oxide to form 
HbNO. When erythrocytes carrying partially nitrosylated haem enter the pulmonary 
circulation it is believed that, through oxygen binding and conformational changes of 
the haemoglobin protein, nitric oxide is displaced from the oxygen binding pocket and 
subsequently reacts with the nearby thiol o f the p chain, generating R-state, HbSNO 
[309].
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The re-oxygenated blood carrying HbSNO then passes through the arterial 
system to tissues where oxygen is in demand. Here, the reverse process occurs. As 
oxygen is offloaded, the haemoglobin conformation changes from R to T-state (HbSNO 
being less stable in the T-state) and so SNO is also offloaded, thereby concomitantly 
delivering both oxygen and SNO to the tissue. The dependency of p93 cysteine 
reactivity upon haemoglobin conformation has been known for sometime [330] and 
applies in this situation. One key question of the SNO theory is, how does nitric oxide 
escape from the erythrocyte avoiding recapture by haemoglobin? The proposed 
mechanism involves transnitrosation, through being transferred from the thiol group of 
one protein to another the nitric oxide is effectively protected. The favoured candidate 
protein, AE1, also known as membrane protein band III was originally proposed by 
Pawloski et al (Figure 1.23) [331]. AE1 is the perfect candidate, positioned close to the 
membrane for subsequent transfer, in addition to the cytosolic N-terminus interacting 
with T-state haemoglobin to lower oxygen affinity, thereby enhancing oxygen/SNO 
offloading. The physiological importance of this interaction can be seen with the use of 
DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, an AE1 channel blocker), 
inhibition by DIDS has been shown to prevent HbSNO vasodilatation of hypoxic aortic 
rings [331]. The SNO theory is also supported by in vivo evidence showing an arterial to 
venous gradient o f HbSNO concentration, suggesting consumption across the tissue bed
[332].
Overall, the principle role o f erythrocytes is to deliver oxygen, which is largely 
governed by blood flow [332]. Therefore the SNO theory suggests that erythrocytes 
could have an intrinsic capacity to enhance their primary function.
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Figure 1.23. How does nitric oxide liberated from HbSNO leave the red cell? The cytoplasmic domain of 
AE1 preferentially binds T-state Hb and thus promotes the R-state to T-state transition of SNO-Hb, which 
effects transfer of nitric oxide groups to the membrane. SNO on AE1 is then exported from this site to 
thiols outside the erythrocyte e.g. plasma proteins. Thus, the transition from high to low p02 would be 
transduced by the interaction of Hb and AE1 into increased export by RBCs of nitric oxide-related 
bioactivity and decreased scavenging of endothelial-derived nitric oxide. Adapted from [331].
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1.10.2 The Nitrite Reduction Theory
The vasoactive properties of the nitrite anion have been known for sometime
[333]. However, until recently the biological activity of nitrite has never been 
considered in terms o f its position as a circulating metabolite of nitric oxide. Early work 
demonstrated that nitrite could be reduced to nitric oxide in a biological setting by 
oxidoreductase enzymes, such as xanthine oxidase [334], disproportionation [335] and 
deoxyhaemoglobin[w] [336]. These observations, coupled with the fact that an artery to 
vein gradient of nitrite had been shown to exist [327], prompted research into the 
activation of circulating nitrite in vivo [337]. Overall, this research propagated a novel 
idea that linked these facts, with deoxyhaemoglobin nitrite reduction at the heart of the 
concept. The next major step in the nitrite field was a proposal by the Gladwin 
laboratory, associating the nitrite reduction properties of deoxyhaemoglobin to allosteric 
control [313, 338]. This allosteric control proposal gave the research applicability to the 
physiological setting and, like the SNO theory, could explain a potential mechanism for 
matching vasodilatation/flow to tissue oxygen demand.
Haemoglobin, through a process termed ‘R-state autocatalysis,’ is suggested to 
operate maximally as a nitrite reductase at approximately 50% oxygen saturation (P50) 
(Figure 1.23a), which is based upon several observations. It is possible for deoxyhaem 
within haemoglobin to have allosteric character of both R-state and T-state depending 
upon the ligand status of the 3 other haem groups. Nitrite has been show to react 
differently with these two conformations, nitrite reductase activity being higher in the so 
called R-state deoxyhaem (6 M'V1 vs. 0 . 1 2  M’V 1, R vs. T) [338]. The mechanism is 
only based upon these two rate constants. However, within a haemoglobin tetramer, a 
global rate constant exists which is dictated by the individual haem groups within it. 
These observations have been confirmed by experiments utilising a gel matrix to lock 
haemoglobin in specific allosteric configurations whilst monitoring reaction kinetics 
[339]. As nitrite reacts with haem in the T-state tetramer, the rate of reaction decreases 
as deoxyhaem is consumed. This is balanced by an increasing rate of reaction with R- 
state deoxyhaem within the tetramer, which results from, and is stabilised by
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metHb/HbNO formation [338]. It is likely that the increasing rate of nitrite reduction in 
the R-state is in some part due to its lower reduction potential i.e. the R-state is more 
likely to donate electrons [340]. As levels o f metHb and HbNO increase in the tetramer 
the haemoglobin molecule shifts from T-state to R-state. Therefore, a balance point 
exists (occurring around 50% saturation/when haemoglobin is in the R2/R3 tetramer 
states), where there is sufficient T-state haemoglobin to bind nitrite but also enough R- 
state haemoglobin to efficiently catalyse nitrite reduction. This work has all been 
performed with high nitrite concentrations using in vitro preparations starting with 
purely T-state haem. In vivo, this scenario is unlikely to occur, so how does the theory 
translate?
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Figure 1.23. R-state or allosteric autocatalysis o f nitrite reduction by haemoglobin. A) The rate at which 
haemoglobin converts nitrite into nitric oxide (NO) is maximal when it is 50% saturated (P50). This effect 
is mechanistically determined by two factors, the availability o f deoxyhaems (reaction substrate) to bind 
nitrite, which is maximal in T-state or deoxygenated haemoglobin, and the amount of R-state or 
oxygenated haemoglobin tetramer, which increases the intrinsic reactivity o f the haem with nitrite. B) In 
the mammalian circulation, the allosteric state of haemoglobin tetramers is modulated primarily by 
oxygen ligation such that the in vivo, intrinsic reactivity is therefore dictated by oxygen binding to other 
haems on the same tetramer. This model therefore predicts that the most effective tetrameric nitrite 
reductase would be the R-state haemoglobin that rapidly deoxygenates during arterial to capillary transit. 
The R3 and R2 tetramers would therefore be the most effective nitrite reductases. A1-A5 reflects the 
arteriolar size, which decreases at bifurcation points along the vascular tree. Reproduced from [311].
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In vivo, it is believed that oxygen ligation, as opposed to metHb/HbNO, acts as 
the R-state stabiliser (Figure 1.23b) [341]. Therefore, in venous deoxygenated blood 
maximum reactant levels (high T-state) exist, while in arterial blood the most effective 
nitrite reductase, (R-state), exists. Again, this gives rise to a balance point, suggesting 
that nitrite reductase activity will be maximal in the rapidly deoxygenating arterial blood 
as it crosses the tissue bed. At this point in the vascular tree, it is assumed that the 
haemoglobin tetramer will pass from R4 to R3 and R2 (maximal nitrite reduction) before 
flipping to the T-states, T2 and Ti [338]. This notion is supported by work demonstrating 
that nitrite has maximal effect upon nitric oxide-mediated signalling, vasoactivty and 
mitochondrial inhibition when haemoglobin is 50% saturated [342]. Questions as to how 
nitric oxide can be formed and leave the erythrocyte to exert an effect, within the time- 
course of one arterial to venous transit, and if a saturation near 50% is regularly 
achieved in the circulation under normal conditions are still points of debate [343]. In 
addition to haemoglobin, other proteins with nitrite reductase activity are under 
investigation, such as the previously mentioned oxidoreductase enzymes and myoglobin 
found in muscle [344].
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1.11 Nitric Oxide Metabolites and Hypoxic Pathologies.
In addition to nitric oxide and haemoglobin, the other key factor involved in the 
mechanism of nitric oxide metabolite actions is a change in oxygen level. In vivo, under 
normal conditions, oxygen levels drop over a respiratory cycle, however, dramatic 
changes in oxygen level only tend to occur under conditions of serious vascular 
pathophysiology. Long term vascular pathology is associated with endothelial 
dysfunction and a resultant reduction in so called ‘nitric oxide b ioavailab ilityT he 
mechanisms of endothelial dysfunction remain unclear, although there is apparent 
evidence for a link with atherosclerosis [345], increases in reactive oxygen species 
leading to nitric oxide scavenging and radical damage [346] and altered eNOS levels 
and functionality [347, 348]. Endothelial dysfunction and the accompanying reduction 
in nitric oxide bioavailabilty are detrimental to the overall health of the vessel and 
inhibit the vessel from fully dilating. The inability to accurately control vessel tone can 
lead to a reduction in blood flow and oxygen supply that can be devastating, particularly 
in high demand organs such as the heart, brain and kidneys. Persistent disease can lead 
to narrowing of arteries, such as the coronary arteries o f the heart, causing tissue 
hypoxia and angina in the case o f the heart. As the health o f the vessel deteriorates, 
atherosclerotic plaques can become unstable and if ruptured they initiate a clotting 
cascade that blocks the vessel, resulting in infarction. If and when a clot is cleared, the 
vessel and the tissue which it supplies is then subjected to further damage by a process 
know as ‘ischaemia-reperfusion injury’[349].
Nitric oxide metabolites have been shown to be beneficial in a number of 
hypoxic/ischaemic environments found in the liver [350], the heart [344], the brain 
[351] and the kidney [352]. It is these potential therapeutic benefits that warrant further 
research into the basic interactions o f nitric oxide and its metabolites and the 
mechanisms by which they convey physiologically relevant, bioactivity.
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1.12 Nitric Oxide/Nitric Oxide Metabolite Detection in Biological 
Samples/Systems
There has long been an interest in the measurement of free nitric oxide, however 
its reactive nature and short half-life are the source of a number of practical limitations 
in terms o f real time detection. A practical solution to this problem is the measurement 
of the more stable metabolites of nitric oxide. The measurement of nitric oxide 
metabolites is now common, although disagreements over methodology and measured 
levels still ensue. As detection methods have developed and sensitivity improved, 
reported blood levels have slowly decreased to a consensus between laboratories of the 
level expected in certain media. A review o f methodologies and their development is 
covered briefly below with an emphasis on those most commonly and currently used 
within the field.
1.12.1 Nitric Oxide
The measurement of free nitric oxide can essentially be split into two different 
forms of methodology, those that monitor generation in real time and those that are 
cumulative. The real time study o f nitric oxide is largely based around the use of 
electrochemical methods, principally electrodes. These electrodes are designed to be 
specific for nitric oxide and allow real time and in situ measurement o f in vivo and in 
vitro nitric oxide generating systems [353]. Although electrodes represent the most 
advanced method o f real time nitric oxide measurement, particularly in situ, they do 
have a number of practical limitations. Electrodes often generate non-specific signals 
and are sensitive to a number of environmental factors, such a temperature and 
movement of the surrounding media, the latter being a major problem for the intra 
vascular measurement of nitric oxide in vivo where blood flow is constantly changing.
Cumulative nitric oxide measurement methods exploit the free radical nature of 
nitric oxide and its ability to form adducts that have paramagnetic properties. In this way 
nitric oxide levels can be assessed via the interaction with specific ‘spin traps’ that bind
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nitric oxide to give altered paramagnetic properties [354]. These paramagnetic species 
have unique signals that can be visualised and quantified with electron paramagnetic 
resonance spectroscopy (EPR). The generation of unique signals makes EPR 
measurement of nitric oxide adducts very specific, however the technique does lack 
sensitivity at lower concentrations and signals represent an accumulation of adduct 
rather than a real time level.
It is also possible to image and measure nitric oxide using fluorescent probes. 
4,5-diaminofluorescein (DAF) is one o f the most widely used probes, however this 
probe like many others suffers from a lack of specificity [355]. For this reason, 
fluorescent probes are generally no longer used for quantification of nitric oxide.
1.12.2 Nitrite and Nitrate
Nitrite and nitrate represent the most commonly measured metabolic products o f 
nitric oxide. Although more stable than free nitric oxide, the measurement of nitric 
oxide metabolites does have its own caveats. Firstly, metabolites are present in complex 
biological media; secondly, many similar metabolites are present in one sample; thirdly, 
levels found in biological samples can be in the low nanomolar range; fourthly, many 
chemicals, solutions and equipment contain contamination and lastly, metabolite species 
can change from one to another, particularly in the presence of oxygen.
Early methodology quantified nitrite and nitrate using light spectroscopy in 
combination with the Griess reagent (N-l-naphthyl-ethylenediamine dihydrochloride, 
sulphanilamide and phosphoric acid) in which nitrite forms a coloured azo dye [356]. 
However, the need for a more precise measurement lead to the development of high 
performance liquid chromatography (HPLC) based methodologies [357]. Despite being 
more sensitive, these methods do have more general issues, principally pertaining to the 
over processing of the sample. Due to the continued risk of contamination and 
metabolite stability, methods that employ minimum sample processing are optimal. The 
current gold-standard for the measurement o f nitric oxide metabolite species, where
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minimum processing can be used, is ozone based chemiluminescence (OBC). OBC 
measures nitric oxide directly, therefore OBC is always linked to a reductive process 
that will cleave or reduce nitric oxide metabolites back to free nitric oxide that can be 
carried away by a flow o f inert gas for measurement [358]. Initial chemical cleavage 
reagents were formed from potassium iodide and acid, however it was recognised that 
the reductive power o f this reagent was variable but could however be stabilised by the 
addition of excess iodide to the reagent [359], giving rise to the most commonly used 
cleavage reagent, tri-iodide. In addition to the measurement o f nitrite, tri-iodide has also 
been validated for the measurement o f nitrosothiol compounds (SNOs) [360]. In order to 
measure nitrate, a cleavage reagent with increased reductive power is required, the most 
commonly used reagent for this purpose is vanadium III chloride in acid at high 
temperature [361], which cleaves nitrate, nitrite and RSNO/RNNO compounds back to 
nitric oxide.
1.12.3 Haemoglobin-Bound Products
The vast majority o f research regarding nitric oxide metabolites centres on 
circulating levels in blood. Nitric oxide metabolites are present in the largest quantity in 
the plasma fraction of whole blood but they also enter erythrocytes and directly interact 
with haemoglobin, forming HbNO and HbSNO as previously discussed (section 1.9.1.2, 
page 59).
HbNO levels can be assessed using light based spectrophotometry [313] and 
EPR (electro-paramagnetic resonance spectroscopy) [362]. However, despite the 
excellent specificity, sensitivity at lower concentrations, such as those found in 
biological samples, is an issue with these methods. OBC linked methodologies are 
widely used to measure erythrocyte nitric oxide metabolites and both chemical and non­
chemical cleavage methods have been developed. Photolysis is the most commonly used 
non-chemical method o f reducing HbNO and RSNO compounds (including HbSNO) 
[325]. Photolysis does represent a simple method in terms of chemistry but the need for 
sample preparation, expense o f equipment, limited number o f species measured, reduced
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ease of use and questions over specificity [359] have prevented photolysis from being 
extensively used in many laboratories for the measurement of metabolites.
Chemical reductive methodologies have also under gone development to make 
them more suitable for erythrocyte nitric oxide metabolite quantification. One key 
problem with tri-iodide reduction was a phenomenon known as auto-capture. When 
nitric oxide is liberated in the reductive mixture it can be re-bound by free haemoglobin 
in the purge vessel and cause signal broadening and error in metabolite concentration 
quantification. To combat, this problem three different ideas have been put into practice. 
The first is an alternative reductive agent containing copper and cysteine that is utilised 
with carbon monoxide used as a purging carrier gas at high pressure to block 
haemoglobin from binding nitric oxide [363]. This method is limited to the 
measurement of RSNO compounds and in addition to its increased health and safety 
risk, our laboratory have not found it to be efficient in preventing auto capture. The 
second method involves the addition of a stabilisation solution to blood samples that 
largely contains hexacyanoferrate, thought to bind haemoglobin and prevent further 
reactions before the cleavage in tri-iodide [364]. Unfortunately, the addition of 
stabilisation solution results in the need to process samples heavily, introducing 
possibility o f contamination and can also cause the inter-conversion of metabolite 
species. The third and final method, based on hexacyanoferrate inhibition, was 
developed in our laboratory [365]. Hexacyanoferrate is added to the tri-iodide cleavage 
reagent and blocks haemoglobin re-capture o f nitric oxide during the cleavage process, 
negating the need for sample processing and improving recovery of all cleavable 
species. This method and its validation are covered in more detail in the general 
methodology of this thesis, in chapter 2 .
Arriving at a consensus point with regard to specific, reproducible methodology 
and standardised protocols is the result o f many years of work by a number of people 
within our laboratory. I was fortunate enough to work with Dr Stephen Rogers and Dr 
Afshin Khlalatbari, when this body o f work was in its infancy, who both dedicated the 
work of their doctorates to establishing these methods. Work by Dr Rogers regarding the
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development of modified tri-iodide [365] and more recent progress in our laboratory 
have formed the basis of a text book chapter that details the practical aspects of 
measuring nitric oxide metabolites in biological media and the reasoning behind the 
developments that have been made. In possession of these developed methodologies, it 
was possible to investigate nitric oxide metabolites in different model systems. These 
investigations formed the primary aims o f this thesis.
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1.13 Thesis Aims
This thesis aims to provide a clearer understanding of the relationship between 
nitric oxide, its metabolites and haemoglobin contained within erythrocytes. In addition, 
the physiological contributions o f these metabolites will be assessed and their 
mechanisms of action both at a simple biochemical level and at a more complex level in 
human subjects will be challenged. Overall, this thesis aims to consider the significant 
role of oxygen in modulating these mechanisms and physiological outcomes. The 
literature to date has two distinct ideas regarding the physiological relevance and 
mechanism of action with regard to nitric oxide metabolites, which has led to 
publications that are misrepresented, misinterpreted and polar in view. The current work 
endeavours to be subjective and critical, taking into account all aspects of published 
work in the field and to carry out studies under physiologically relevant conditions.
1.13.1 Specific Aims
• To investigate the effect of oxygen upon the metabolism of nitric oxide and its 
metabolites in blood. In addition, novel methodologies will be developed to 
consider the movement of these species with respect to blood constituents and 
oxygen.
• To determine the acute mechanisms of action by which nitrite affects vascular 
tissue, assessing sources o f nitrite reduction and the contribution of altered 
oxygen level. The chronic effects of nitrite in the vasculature will be reviewed by 
analysis o f gene activation.
• To examine the erythrocyte-induced hypoxic vasodilatation phenomenon in 
detail and to provide novel evidence regarding the nature of the vasorelaxant 
responsible and the mechanism by which it influences hypoxic vascular tissue.
- 7 8 -
Chapter One General Introduction
• To study the effect o f nitrite supplementation on both physiology and 
biochemistry in a human model o f hypoxia. The metabolism of nitrite and the 
mechanisms by which it exerts its effects in human vasculature will also be 
explored.
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2 General Methods
2.1 Blood Collection and Processing
2.1.1 Phlebotomy
Subjects gave consent for a sample to be drawn, all procedures were carried out 
in line with Cardiff and Vale NHS trust phlebotomy guidance/training and were 
approved by a local ethics committee. Blood samples were collected by venepuncture o f 
the antecubital veins (median cubital and cephalic veins) using a syringe and butterfly 
needle. Samples were then decanted into 4ml K3E EDTA vacutainers (Greiner Bio-One) 
to prevent clotting and maintain current oxygen saturation.
2.1.2 Blood Sample Processing
Blood samples, unless otherwise stated, were centrifuged at 2000g for 5 minutes 
at 4°C. Usually, the plasma and erythrocyte fractions were immediately separated, while 
the Buffy coat was discarded. Fractionated samples for future analysis were then directly 
snap-frozen in liquid nitrogen followed by storage at -80°C. Frozen samples, when 
required for analysis were rapidly thawed in a water bath at 37°C and immediately 
analysed.
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2.2 Altering Blood Oxygen Saturation
To alter the saturation of erythrocytes, centrifuged erythrocyte samples were first 
diluted (usually ~1 in 3, to achieve a final haemoglobin concentration of lOg/dl) in 
phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KC1 and 10 mM phosphate 
buffer solution, pH 7.4 at 25°C). The reconstituted mixture was then loaded into a thin 
film rotating tonometer as in figure 2.1. The tonometer is purged with different gas 
mixes that interact with the thin film of erythrocytes created upon rotation to rapidly 
achieve the desired saturation. The system can be sealed to maintain a specific saturation 
and samples can be taken for blood gas analysis. The tonometer utilised for work in this 
thesis was developed by Dr Doctor of the Department of Paediatrics and Biochemistry 
& Molecular Biophysics, Washington University in St Louis whose laboratory has 
previously published established methodology for use of the tonometer [363].
Figure 2.1. Diagrammatic representation o f the thin film rotating tonometer (approximately 200mm in 
length). As the tonometer rotates a thin film o f suspended erythrocytes is formed around the surface, this 
creates a large surface area for rapid exchange o f gases, mimicking a circulatory scenario. Picture drawn 
with the aid o f Ross Pinder.
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2.3 Ozone Based C hem ilum inescence
Ozone based chemiluminescence (OBC) is a measurement technique that 
exploits the luminescent nature o f specific chemical reactions. The nitric oxide analyser 
(Sievers NOA 270, Boulder, CO, USA) utilises OBC for quantification of nitric oxide 
via its reaction with ozone (O3).
The NOA has a specialised reaction cell where a constant amount o f ozone is 
generated, the nitric oxide sample in a flow o f inert gas is drawn into the reaction cell 
where it reacts with ozone to form ‘excited’ N 0 2*[Z]. This form of N 0 2 is unstable and 
so, as electrons in the excited state move back to ground state, they dissipate energy in 
the form o f a photon (hv, A-Plank’s constant v-ffequency)[AA] (in the red-infrared ~640- 
3000nm, with peak at ~1 lOOnm, [366]).
NO + O3 -»  N 0 2* + 0 2 [Z]
NO2 * —> NO2 + hv [AA]
One face o f the reaction cell is a red cut-off lens, which filters the light energy 
before it enters a photomultiplier tube (PMT), preventing the detection o f light at other 
wavelengths, generated by unwanted reactions. The PMT is formed o f a number of 
sensitive surfaces, as a photon hits the first, photosensitive surface an electron is emitted 
which in turn hits the second, electron-sensitive surface to release several electrons, as 
the process continues down the tube the signal is amplified and can be measured as a 
potential difference across the tube in millivolts (mV). Therefore, the change in potential
difference is directly proportional to the number o f photons entering it and thus the
amount o f nitric oxide entering the reaction cell.
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2.3.1 Cleavage Reagents
The measurement o f nitric oxide (and its metabolites) in the gas phase via OBC 
requires cleavage from its parent compound(s) or conversion to its radical form. A 
number o f chemical cleavage reagents have been developed for the measurement of 
specific metabolites (summarised in table 2 . 1 ) and will be discussed in the following 
sections.
Table 2.1. A summary of cleavage reagents used with ozone based chemiluminescence and the species 
that they are capable of measuring.
Tri-iodide Vanadium chloride
R eag en t te m p e ra tu re 50  (± 1 )° C 85  (± 1 )°C
Species cleaved o r  re d u c e d N O ; ,  R S N O , N O ; ,  N O ; ,  R S N O ,
R N N O , R O N O , f c m n o , 'r o n o ,
R M N O  (w h ere R M N O  (w here  M  is a
M  is a m e ta l) m eta l)
The cleavage reagent used is loaded into a glass purge vessel with injection port 
(custom developed in our laboratory) that is purged with inert gas. The gas carries the 
gas phase products formed in the purge vessel to the NOA and also aids homogenous 
mixing o f the reagents (Figure 2.2). The reagent is also heated (see Table 2.1) to 
increase reaction rate and provide clear sample peaks. 20pl o f anti-foam 204 organic is 
added to the cleavage reagent in the purge vessel to prevent foaming upon injection of 
samples containing protein. It should be noted that all reagents are freshly prepared on 
the day o f use. A sodium hydroxide trap (IN ) and solvent filter is placed between the 
refluxing reagents in the purge vessel and the NOA to prevent hot acidic vapours or 
liquids from entering the NOA.
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Figure 22. A schematic o f the purge vessel apparatus utilised for tri-iodide and modified tri-iodide 
reagent measurements.
2.3.1.1 Tri-Iodide and Modified Tri-Iodide Reagents
Originally studies utilised a simple mixture o f potassium iodide (KI) and glacial 
acetic acid as a cleavage reagent, however the reductive power o f the mix was variable, 
so the yield o f nitric oxide from a given sample was not consistent. The requirement for 
a reagent with long-term stability that could measure a number of biological nitric oxide 
species lead to the development o f ‘tri-iodide’ reagent [359]. The tri-iodide reagent is 
essentially the same as the Kl/acid mix, apart from the addition o f iodine crystals to 
saturate the solution and promote the generation o f large amounts o f the reductive I3 ' 
molecule.
• To make the reagent, lg  o f potassium iodide was first dissolved into 20ml of 
HPLC grade water to give mixture 1. In addition, a second mixture was formed, 
comprising 650mg o f iodine crystals and 70ml o f glacial acetic acid [367]. Once 
fully dissolved mixture 1 is added to mixture 2 in a fume hood and stirred for 30 
minutes prior to use.
- 8 4 -
Chapter Two General Methodology
The measurement o f haemoglobin-bound nitric oxide presents its own 
difficulties. When a sample containing haemoglobin is injected into the reaction vessel, 
a process known as auto-capture occurs where nitric oxide released from one haem is 
immediately scavenged by another. In principle this should only serve to reduce peak 
height and broaden signal but not alter the overall area under curve (AUC). However, 
our laboratory has previously found that AUC is significantly underestimated in the 
presence o f haem, particularly when nitric oxide to haem ratios are low as is the case 
with human erythrocyte samples [365]. This observation led our laboratory to develop a 
novel cleavage reagent for use with samples that contained haem, known as ‘modified 
tri-iodide’ [365]. Modified tri-iodide contains the usual tri-iodide mix but also has 
potassium ferricyanide (K3Feni(CN)6)(250mM added 1 in 10 to tri-iodide) added to the 
purge vessel. Potassium ferricyanide reacts with haem injected into the purge vessel, 
preventing it from undergoing further reactions with free nitric oxide thus preventing 
auto-capture (Figure 2.2). Another solution to this problem proposed by the Doctor 
group involves purging the vessel with high pressure carbon monoxide as a carrier gas 
to also bind and block haem groups. However this method does have a number o f health 
and safety considerations [363].
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Figure 2.2. The measurement o f red blood cell lysate in tri-iodide and modified tri-iodide reagent 
mixtures. Example traces o f raw chemiluminescence signals and the same data smoothed for analysis with 
Origin (version 7.0) are shown. Injection o f haem based sample into the classic tri-iodide mix does not 
give a signal. Addition o f potassium cyanide improves the signal, however, the addition potassium 
ferricyanide (K3FeUI(CN)6) (to form modified tri-iodide) restores the signal in full. Reproduced with the 
kind permission o f Dr. Stephen Rogers.
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2.3.1.2 Vanadium III Chloride Reagent
The vanadium chloride reagent is capable of measuring all o f the species that tri­
iodide can, but due to its increased reductive power can also reduce nitrate back to nitric 
oxide for measurement.
• The vanadium chloride reagent is prepared by creating a saturated solution of 
VCl3 (0.785g VCI3 , 20ml HPLC grade water and 80ml of 1M hydrochloric acid). 
Once the solution is formed it is mixed for 10 minutes before being filtered to 
give the final solution that is blue/turquoise in appearance.
The high temperatures required for the vanadium III chloride assay have led us 
to develop a specific glassware set-up. This set-up employs a Liebig condenser which 
prevents loss o f reagent and acid vapour damage under reflux. This glassware also 
allows for larger reagent volumes and so can cope with multiple sample injections.
Purge Gas 
Outflow
Cold Water 
Outflow Leibig
Condenser
Injection PortCold Water 
Inflow
Large Volume 
Purge Vessel
Purge Gas 
Inflow
Figure 2.3. Schematic diagram o f the glassware developed for refluxing vanadium III chloride reagent.
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2.3.2 Pre-Treatments
Most biological samples contain a number o f nitric oxide species, in order to 
measure these individually it is sometimes necessary to employ a pre-treatment to 
remove species that are not o f interest. Measurement o f nitric oxide species in our 
laboratory involves the use o f two key pre-treatments that will be covered in further 
detail below and are summarised in table 2 .2 .
Table 2.2. Summary of pre-treatments used to establish levels o f specific species in biological samples.
Treatment Concentration Use
Acidified sulphanilamide
Mercuric chloride
290 mAf stock (500 mg in 
l O m L o f l  AfHCl)
Add 1 part acidified
sulfanilamide to 9 parts sample
50 mA/stock (67.9 mg in 
5 mL o f HPLC grade water). 
Add 1 part to 9 parts sample
Renders nitrite undetectable by 
OBC.
Requires minimum 15-min 
incubation in the dark
Cleaves NO from RSNO 
compounds
2.3.2.1 Acidified Sulphanilamide
Acidified sulphanilamide is used to render nitrite undetectable by OBC (Figure 
2.3). Firstly, in an acidic environment nitrite forms the nitrosonium cationIABl  The 
nitrosonium cation then interacts with sulphanilamide[AC] and ultimately forms a 
diazonium salt[AE>1 that is undetectable in tri-iodide/modified tri-iodide or vanadium 
linked OBC. The sample is usually incubated for 15 minutes, in the dark (to preserve 
any RSNO is the sample).
N 0 2 + H* <-* NO+ + OH' <- HONO [AB]
NO+ + Ar-NH2 — Ar-N2+ + H20  [AC]
Ar’ + Ar-N2+ —► Ar-N=N-Ar‘ [AD]
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Figure 2.4. Raw (Black) and smoothed (red) chemiluminescence trace from injection of plasma (80 
seconds) and injection o f plasma incubated with acidified sulphanilamide for 15 minutes (625 seconds). 
The plasma signal is largely composed o f nitrite which is rendered undetectable by acidified 
sulphanilamide, the remaining signal, seen at 625 seconds, is attributable to RSNO/RNNOs which are 
thought to be stable in the acidic environment.
2.3.2.2 Mercury Chloride
Mercury chloride can be used to selectively cleave nitric oxide from RSNO 
compounds to generate the nitrosonium cation^AE]. If  acidified sulphanilamide is also 
present then this will feed into reactions [AC] and [AD], rendering the nitric oxide from 
the RSNO undetectable by OBC. The sample is usually incubated for 15 minutes.
2RSNO + Hg2+ — Hg(RS ) 2  + 2NO+ [AE]
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2.3.3 Validation
2.3.3.1 Calibration
To account for day-to-day variation within the assay, a standard curve was 
performed daily (Figure 2.5A). The standards that were used encompass the range o f 
concentrations observed in biological samples which is o f particular importance at the 
lower end. All standards were prepared fresh daily, nitrite standards ranged from 
62.5nM to lOOOnM (200pl injections) (Figure 2.5B), while nitrate standards ranged 
from 6.25p.M to lOOpM (20pl injections) (Figure 2.5D). The presence o f potassium 
ferricyanide in the tri-iodide mix (modified tri-iodide) did not alter calibration (Figure 
2.5C). The accuracy o f  the calibration is high (see Figures 2.5B, C and D) and the 
relationship between area under curve and concentration was always linear in the tested 
range.
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Figure 2.5. Calibration of OBC. A) Raw trace (black) and smoothed signal (red) of nitrite standards 
(water, 62.5, 125, 250, 500 and lOOOnM) into tri-iodide cleavage reagent. B) Nitrite standard curve in tri­
iodide. C) Nitrite standard curve in modified tri-iodide. D) Nitrate standards (water, 6.25, 12.5, 25, 50, 
100pM) injected into vanadium III chloride reagent. (n=4 in all cases, each one performed on a different 
day).
Our laboratory have previously reported the coefficient of variance to be 7% 
intra-assay and 10% inter-assay [368] for the tri-iodide assay, the inter-assay variance 
largely arising from day to day NOA variability, which is accounted for by daily 
calibration.
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2.3.3.2 OBC/Electron Paramagnetic Resonance Spectroscopy Comparison
To assess the relative merits o f the modified tri-iodide assay for haemoglobin- 
bound nitric oxide (HbNO) measurement, a comparison with electron paramagnetic 
resonance spectroscopy (EPR) was performed.
Blood was collected from volunteers, doped with the nitric oxide donor NOC-9 
(MAHMA-NONOate; 1 - Hydroxy -2- oxo -3- (N-methyl-6 -aminohexyl) -3- methyl -1- 
triazene) at varying final concentrations (1, 10, 50, 500 or lOOOpM) and incubated for 6  
minutes at 37°C. Samples were then snap frozen in liquid nitrogen for further analysis. 
HbNO was first assessed with modified tri-iodide as per section 2.3.4.2 (page 97). The 
same sample was then measured with EPR via the following method.
•  Background
EPR is a technique which exploits the unpaired electron(s) o f molecules like nitric 
oxide. In this study haemoglobin is behaving like a spin trap, i.e. trapping nitric 
oxide from further reaction and influencing the outer valance electron o f nitric oxide. 
By manipulating the environment around HbNO with EPR (increasing energy in the 
sample with microwaves at a fixed frequency and altering the electron’s magnetic 
moment by changing the external magnetic field), an energy absorption spectrum 
can be generated (Figure 2.6). This spectrum is very specific to the species being 
studied and is very clear as most chemicals and matrices that would cause noise in 
other assays do not contain unpaired electrons and are therefore undetectable. The 
HbNO spectrum (Figure 2.6) is composed o f a number o f elements but o f interest to 
measurement are the three peaks in the centre o f the spectrum. These peaks are 
attributable to nitric oxide bound to the a  subunits o f deoxyhaemoglobin and are 
known as ‘a  or alpha, hyperfine’.
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Figure 2.6. Example o f HbNO EPR spectrum generated by the addition of nitric oxide (equimolar to haem 
concentration) to deoxygenated whole blood.
• Method
Samples were loaded into a liquid nitrogen filled insulated EPR Dewar and placed 
into the EPR machine cavity. EPR spectra were recorded using a Varian 104 X-band 
EPR spectrometer. Typical instrument settings were as follows, gain 4 x 102 xlO -  
lOx 103 xlO, time constant 0.25 seconds, Magnetic field strength Gauss 3238, scan 
width 500 Gauss, scan time 240 seconds, power lOdB. Using specific EPR software, 
alpha hyperfine peak height and area under curve (area under total spectrum) were 
measured.
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Figure 2.7. Blood doped with NOC-9 nitric oxide donor (1, 10, 50, 500 or lOOOpM) and incubated for 6 
minutes at 37°C. A) Correlation o f AUC measured by modified tri-iodide method vs. alpha hyperfine 
signal height measured by EPR (P0.0001), n=40. B) Correlation o f AUC measured by modified tri­
iodide method vs. AUC o f signal generated by EPR measurement (P0.0001), n=40.
The two techniques show good agreement for HbNO measurement with both 
aspects o f the EPR measurement (a-hyperfine and AUC) highly significant and linear in 
relationship (Figure 2.7). The Pearson correlation coefficients are 0.96 (P<0.0001) and
0.96 (P<0.0001) for EPR alpha hyperfine and EPR AUC measurements respectively.
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2.3.4 Protocols
At the beginning of each analysis session all reagents and standards are freshly 
prepared. The NOA is given time to achieve operating temperature before calibration is 
commenced, which is completed on a daily basis. The following protocols have been 
previously validated in our laboratory [365, 369] and are summarised in figure 2.8.
Whole Blood
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HbNO
Haemoglobin 
bound nitric 
oxide species
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iodide reagent
S M H H f l l
sample diluted inincubated sample
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Figure 2.8. Summary of nitric oxide metabolite measurement protocols for blood borne species.
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2.3.4.1 Measurement of Plasma/Supernatant Nitric Oxide Species
200pl o f neat plasma was injected into 5ml o f refluxing tri-iodide reagent using a 
gas tight Hamilton syringe to give a total plasma signal. A duplicate plasma sample was 
diluted 9:1 with 5% acidified sulphanilamide (29mM final) to remove nitrite. This 
sample was then incubated for 15 minutes in the dark and then 2 0 0 pl injected to provide 
a measure o f plasma protein bound nitric oxide species (RSNO and RNNO). The 
difference between total injection and RSNO/RNNO injection was taken to represent 
plasma nitrite.
In a separate experiment, a further 20pl o f neat plasma was injected into 30ml o f 
refluxing vanadium III chloride reagent using a gas tight Hamilton syringe to give a total 
plasma NOx measurement. The difference between the total plasma measurement in tri- 
iodide and the total plasma NOx in vanadium III chloride reagent was taken to represent 
plasma nitrate concentration.
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2.3.4.2 Measurement of Erythrocyte Associated Nitric oxide Species
200fil o f neat erythrocytes were injected into 8 ml (7.2ml tri-iodide and 0.8ml 
potassium ferricyanide) o f modified tri-iodide using a gas-tight Hamilton syringe to 
obtain a total erythrocyte measurement. A duplicate red blood cell sample was lysed 1:4 
in an acidified sulphanilamide solution (21 mM final) to remove nitrite. This sample was 
then incubated for 15 minutes in the dark and then 2 0 0 pl injected into a fresh 8 ml of 
modified tri-iodide to provide a measure o f haemoglobin-bound nitric oxide (including 
all sulphanilamide stable species). An aliquot o f this sample was also further diluted 9:1 
with HgCb (5mM final) and incubated in the dark for 15 minutes, selectively cleaving 
nitric oxide from Hb-SNO and injected into modified tri-iodide to provide a measure for 
iron nitrosyl haemoglobin (HbNO).
There is a difference between the total erythrocyte and sulphanilamide signals 
that is often taken to represent ‘erythrocyte associated nitrite’. The precise source o f this 
signal is unknown but is most likely from contaminating plasma, as it is impossible to 
remove all plasma even with high speed centrifugation. This thesis acknowledges the 
presence o f this nitric oxide metabolite derived signal but because o f the questionable 
nature o f this measurement it will not be utilised to form conclusions. Therefore, 
validated methodologies for haemoglobin bound species will be used to assess 
erythrocyte nitric oxide interaction.
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2.3.5 Methodological Considerations
2.3.5.1 NOA Sensitivity
The NOA reaction cell is very sensitive to changes in pressure. Reaction cell 
pressure is governed by vacuum, in flow o f purge gas and ozone generation. The NOA 
maintains the reaction cell under vacuum to evacuate unwanted oxygen and other 
reactive gases that may alter nitric oxide ‘detectability’ and to draw the sample into the 
reaction cell. In addition, the NOA is also constantly purged by an inert gas (e.g. 
nitrogen or argon). This must be kept at a constant flow rate as changes in flow will also 
alter both baseline and sensitivity. To maintain flow, the set-up in our laboratory 
employs sensitive flow meters to regulate in-flow at the optimum rate.
The other variable that alters machine sensitivity is temperature. The PMT has a 
‘dark current’ which is background activity in the tube and is known to be temperature 
dependent. The reaction o f nitric oxide and ozone is also temperature dependent. For 
these reasons, the Sievers NOA used in our laboratory is internally cooled to -20°C to 
reduce background signal and increase sensitivity. The equipment is also set up in a 
temperature controlled room to aid consistency.
2.3.5.2 Contamination
Nitrite represents the single most significant cause o f unwanted OBC signal. 
Despite careful laboratory practice, nitrite can contaminate samples from a number o f 
sources:
1. Buffers and water. Even the purer, high-quality reagents and water contain nitrite 
contamination. HPLC-grade water (Fisher) or water for injection (Braun) were found to 
contain the least contamination in our laboratory’s experience. However, once open, 
these waters also accumulate further nitrite contamination over time. This contamination 
is unavoidable, although it can be minimized by good practices and accounted for by 
inclusion o f a water injection in the standards used for calibration, which are made up 
and tested on a daily basis.
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2. Plastics are, glassware, and apparatus. All disposable and reusable apparatus will 
contain considerable nitrite contamination that can be minimized by repeat washing. 
Plasticware in particular can vary vastly depending on both source and batch. The use of 
filters and columns in this respect should be avoided. Glassware and syringes should be 
cleaned extensively (e.g., overnight in glass cleaner, followed by extensive rinsing with 
water). For blood collection, EDTA vacutainers were shown to contain minimum 
contamination.
3. Hamilton syringes. Syringes that are in regular use should be acid washed followed 
by repeat neutral washes on a regular basis, as residue builds up in both the needle and 
in the barrel o f the syringe.
4. Chemicals. All reagents contain a degree o f nitrite contamination, however the use of 
calibration and careful practice can remove or reduce their impact.
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2.3.5.3 Freezing Time
The effect o f long-term freezing has previously been assessed in our laboratory. 
The results demonstrate that although total nitric oxide moiety does not change the 
apportionment between species can change over time. Some species such as 
RSNO/RNNO in plasma (Figure 2.9) and haemoglobin bound species (Figure 2.10) are 
not stable over time and are oxidised to nitrite (Figures 2.9 and 2.10 upper panels in both 
cases). To prevent this factor from confounding results, all samples in all studies were 
measured within 1 week o f collection.
120n
100 -
c  **■
s  s
« e
§ g o
Fresh 1 day 1 week 1 month 3 month 6 month 
Freezing time
Fresh 1 day 1 week 1 month 3 month 6 month 
Freezing time
Figure 2.9. The effect o f sample freezing on plasma nitrite and protein-bound nitric oxide levels (upper 
panel) and plasma protein-bound nitric oxide (lower panel) measured using tri-iodide in conjunction with 
ozone based chemiluminescence. Fresh represents snap frozen and immediately measured. Values 
presented as mean ± SEM (n = 5). This work was carried out by Dr. Stephen Rogers and is reproduced 
from [370], with his kind permission.
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Figure 2.10. The effect of sample freezing on red blood cell associated nitrite and haemoglobin-bound 
nitric oxide (upper panel) and red blood cell haemoglobin-bound nitric oxide (lower panel) measured 
using modified tri-iodide in conjunction with ozone based chemiluminescence. Fresh represents snap 
frozen and immediately measured. Values presented as mean ± SEM (n = 5). This work was carried out 
by Dr. Stephen Rogers and is reproduced from [370] with his kind permission.
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2.3.5.4 Changing pH/Oxygen
Alterations o f pH can lead to in vitro chemistry between nitric oxide metabolite 
species with the sample. Even a minor decrease in pH below 7 is enough to reduce some 
nitrite back to nitric oxide that can form a number o f species depending on the sample in 
question. Changes in oxygen are also important in the case o f RBC nitric oxide 
metabolite measurements. A switch in the conformational/oxygenation state of 
haemoglobin is believed to alter the location o f nitric oxide within the haemoglobin 
structure (e.g., nitric oxide bound to the oxygen binding site [HbNO] or nitric oxide 
bound to a cysteine residue o f the haemoglobin p chain [HbSNO]). In this respect, a 
policy o f minimum sample processing was always employed.
2.3.6 Analysis
To increase accuracy, signals generated by the NOA are reproduced in the 
graphical program, Origin 7.0 (OriginLab Corp., Northampton, MA, USA), this allows 
150 point adjacent averaging to smooth the signal and analysis o f area under curve (with 
a ‘peak analysis’ add-on). Area under curve is much more sensitive to changes than peak 
height, which can vary dramatically depending upon the presence o f different matrices 
(e.g. haemoglobin) in the reaction cell, see section 2.3.1.1 (page 84).
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2.4 Spectrophotometry
To asses the level o f oxygen saturation in some erythrocyte or haemoglobin 
samples a UV/visible light absorbance spectrum was taken using a spectrophotometer 
(6705 UV/Vis Spectrophotometer, Jenway, UK) (Figure 2.11). Oxygenated 
haemoglobin gives a characteristic doublet in the 500-600nm range while deoxygenated 
haemoglobin only produces a single peak over the same wavelengths (Figure 2.11). A 
sample containing both oxygenated and deoxygenated haemoglobin will give a spectrum 
that is a combination of the two and proportions of each can be determined by 
comparing sample data with reference base-spectra o f pure, individual species using a 
least-squares method [371]. The level o f methaemoglobin can also be monitored with 
this method with characteristic changes at ~630nm [372].
400 450 500 550 600 650 700 750
W ave lenqth (nm)
Figure 2.11. The light absorbance spectra o f fully oxygenated (red) and full deoxygenated (blue) 
haemoglobin in the 450-700nm range.
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2.5 Myography
2.5.1 Test System
Male New Zealand White rabbits (2-2.5 kg) were terminally anaesthetised with 
sodium pentobarbitone (120 mg/kg, intravenously). The rib cage was then opened and 
the aorta was carefully excised and placed in fresh Krebs buffer (NaCl 109.0 mM, KC1 
5.36mM, KH2P 0 4 1.17mM, M gS0 4 .7H20  1.21mM, N aH C 03 24.99mM, C6H 120 6 
10.99mM, CaCl2 .2H20  1.49mM). The aorta was then cleaned o f minor vessels and 
adipose tissue and cut into 8  equally divided 2 mm rings, discarding the tissue most 
distal and proximal to the heart (aortic arch and start o f abdominal aorta). For 
experiments where endothelium-denuded rings were required, a wooden applicator was 
used to gently remove the endothelium. Rings were mounted on matched stainless steel 
hooks for isometric tension recording in 8 ml baths containing 5ml o f Krebs’ buffer, 
37°C. Output transducer (AD instruments) signals were amplified (Powerlab 8 Sp/octal 
bridge (AD Instruments)) and converted for visualisation on ‘Chart for Windows’ 
(Version 4.1.2, AD Instruments). Aortic rings were maintained at 2g resting tension in 
all experiments. For each experiment, eight aortic ring preparations were run in parallel, 
n = 1 represents data averaged from 2  individual aortic ring preparations given identical 
treatment. % relaxation is the induced decrease in gram tension as a percentage of the 
maximum phenylephrine induced contraction.
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2.5.2 Experimental Protocol
After a one hour equilibration period, ring tension was reset (allowing for 
stretch-induced relaxation). All tissue was then exposed to phenylephrine (PE, lpM ) 
(Sigma), once constriction had reached a plateau, acetylcholine (10 pM) (Sigma) was 
added to demonstrate endothelium viability/absence. To accept vascular rings for further 
testing, the tissue was expected to relax a minimum o f 50% to acetylcholine when the 
endothelium was intact, and show no relaxation, or a small constriction, to acetylcholine 
in endothelium denuded vessels. The preconditioning process was then repeated until 
consistent PE induced tensions were achieved. Preconditioning was carried out at 95% 
0 2/5% C 0 2.
Hypoxic experiments were carried out at ~1% 0 2 (gassed with 95% N 2/5% C 0 2) 
as utilised previously in our laboratory [91]. The tissue was kept under hypoxic 
conditions for 10 minutes before exposure to PE (3pM, used to achieve the same gram 
tension observed at 95% 0 2, ensuring a true % relaxation as opposed to a contractile 
artefact). All pharmacological blocking agents were pre-incubated at respective 
concentrations and time periods. Hypoxia always caused a degree o f relaxation in PE 
pre-constricted aortic rings, above that seen in normoxia.
The slow and continuous relaxation o f isolated vessels during hypoxia, as 
observed in the controls o f all our experiments, is an established phenomenon. The 
precise cause o f the background vasodilatation remains unknown. Both energy 
limitation and interruption o f excitation contraction coupling have been suggested as 
possible causes [131]. In our model, hypoxia induced relaxation proceeds to the same 
extent independently o f endothelium/NOS (denudation/L-NMMA data). It is important 
to note that the smooth muscle cells are not simply dying in hypoxia. After a period o f 
hypoxia, tissue can be re-equilibrated in oxygenated buffer and show comparable 
contraction and relaxation to exogenous agents.
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2.6 Chemicals and Specialist Items
Table 2.3. Chemicals and agents utilised and sources.
General Methodology
Product Source
Krebs Buffer
Sodium Chloride (NaCl)
Potassium Chloride (KC1)
Potassium Dihydrogen Orthophosphate (KH2P 04) 
Magnesium Sulphate (MgS04.7H20 )
Sodium Hydrogen Carbonate (NaHC03)
Glucose (C6H)20 6)
Calcium Chloride (CaCl2)
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK
Reagent Chemicals
HPLC Grade Water 
Glacial Acetic Acid 
Hydrochloric Acid ( HCL, 1M)
Sodium Hydroxide (NaOH, ION)
Dimethyl Sulphoxide (DMSO)
Potassium Iodide (KI)
Iodine (I2)
Potassium Hexacyanoferrate (K3Feni(CN)6)
Sulphanilamide
Mercury Chloride (HgCl2)
Phenylephrine (PE)
Acetylcholine (Ach)
Anti-Foam 204 Organic 
Vanadium Chloride (VC13)
Phosphate Buffered saline (PBS) Tablets
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Fisher scientific UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK
Chemical Inhibitors and Agents
2,3-Diphosphoglycerate (2,3-DPG)
Carbon Monoxide (CO) Gas (90%)
95% N2/5% C 02 Speciality Gas Mix 
1H [l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ) 
Carboxy-2-phenyl-4,4,5,5-tetramethyl-imidazoline-1 - 
oxyl-3-oxide (C-PTIO)
U-51605
Indomethacin
Raloxifene
Oxypurinol
L-NG-Monomethyl Arginine (L-NMMA)
Sigma Aldrich UK (Fluka BioChemica) 
BOCUK 
BOCUK 
Alexis Bio-Chemicals UK 
Alexis Bio-Chemicals UK
Cayman Chemicals USA 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK 
Sigma Aldrich UK
NO Donors
Sodium Nitrite (NaN02XLaboratory Grade) 
Sodium Nitrate (NaN03)
Spermine NONOate 
MAHMA NONOate (NOC-9)
Sigma Aldrich UK 
Sigma Aldrich UK 
Alexis Bio-Chemicals UK 
Alexis Bio-Chemicals UK
Clinical Agents
Sodium Nitrite (Infusion Grade) 
Saline (Infusion Grade)
Martin Dale UK 
Baxter Healthcare UK
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3 The Metabolism of Nitric Oxide and its Metabolites in Blood, 
the Influence of Oxygen
3.1 Introduction
3.1.1 Nitric Oxide Metabolism in Blood
Nitric oxide derived from the endothelium ultimately enters the blood-stream 
either directly as free nitric oxide or as one o f a number o f metabolites. The suggestion 
that metabolites o f nitric oxide could behave as stores o f potentially bioactive nitric 
oxide (see section 1.10, page 63) implies that the dynamic relationship between these 
species and blood constituents is a very important one. The metabolic fate o f nitric oxide 
(and its metabolites that are subject to further metabolism) is dependent upon a number 
o f factors, such as the concentration o f nitric oxide and other bio-reactants but also the 
ability o f the surrounding environment (particularly in vivo) to alter the ‘reactivity-state’ 
o f said bio-reactants. Ultimately, the study o f this relationship has resulted in much 
interest in the measured levels o f nitric oxide metabolites and the dynamic changes 
between them. The methods used and information yielded from these measurements has 
come under scrutiny [373]. However, with a conversant approach to interpretation, 
metabolite levels can be very informative. In this respect, it should be noted that nitric 
oxide itself has been demonstrated to have an EC50 o f ~10nM in vascular ring 
preparations [374] therefore, at levels that could often be considered negligible as far as 
methodological limitations are concerned, nitric oxide is particularly potent.
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3.1.2 The Translocation of Nitric Oxide and its Metabolites in Blood
In order for both nitric oxide and its metabolites to have biological function, it is 
essential that they have the ability to progress from the site o f synthesis to the site of 
action. In the vessel, movement is governed by factors such as: reaction with bio­
reactants, rate o f diffusion in diverse media, cellular uptake, trans-cellular transport and 
the flow o f blood within the lumen [323, 375]. One particular area that has emerged, is 
the study o f nitric oxide movement into erythrocytes. Studying the movement o f such a 
reactive molecule is inherently complex and most studies have relied upon ‘stop flow’ 
or competition experiments which present their own difficulties [320, 376].
In contrast, the relative stability o f nitric oxide metabolites reduces the 
complexity o f studying their movement. However, practically completing this is not 
without complication. Proposition o f the nitrite reduction theory (see section 1.10.2, 
page 68) has resulted in increased interest in the movement o f nitrite particularly with 
respect to erythrocytes. One aspect o f the theory that has been debated in the literature 
surrounds the ability o f nitrite to enter an erythrocyte, be reduced to nitric oxide and 
subsequently escape from the erythrocyte to alter biological function during transit 
across a single vascular bed [343].
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3.1.3 Aims
This component o f work was undertaken to:
•  Establish the apportionment o f nitric oxide metabolites at baseline in human 
blood samples.
•  Determine the effect o f oxygen level upon metabolite apportionment.
•  Assess the species formed when exogenous nitric oxide is added to human 
blood.
• Develop specific methodology for real time assessment o f nitric oxide entry into 
erythrocytes and investigate the effect o f haemoglobin oxygen saturation upon 
nitric oxide uptake.
• Consider the interaction o f nitrite in the physiological concentration range with 
erythrocytes and how this interaction is altered by oxygen.
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3.2 Specific Protocols
3.2.1 Baseline Nitric Oxide Metabolite Measurement
Baseline samples were taken from consenting male patients undergoing 
angiography at the University Hospital o f Wales. Patients receiving acute or chronic 
nitrate (i.e. GTN, ISDN) treatment were excluded from the study. Arterial blood 
samples were taken via a catheter inserted into the radial artery and venous samples 
were taken via a catheter inserted into the antecubital vein. Immediately after collection, 
samples underwent blood gas analysis (OSM3, Radiometer, Copenhagen) and were 
centrifuged and processed as per section 2.1.2 (page 80). Plasma and erythrocyte 
fractions were subsequently analysed via ozone based chemiluminescence as per 
sections 2.3.4.1 (page 96) and 2.3.4.2 (page 97) respectively.
3.2.2 Exogenous Nitric Oxide Addition to Erythrocytes
Aliquots o f the arterial and venous samples taken in section 3.2.1 (page 110) 
were also exposed to exogenous nitric oxide addition. The nitric oxide donor MAHMA 
NONOate (NOC-9, ti/2=2.7 minutes, [377]) was added to all samples to achieve a final 
concentration o f 425nM. The NOC-9 molecule is capable o f liberating two moles o f 
nitric oxide for every mole o f parent compound, giving a final nitric oxide concentration 
o f 850nM. Samples were incubated at 37°C for 30 minutes to allow reactions to 
complete before high speed centrifugation (10,000g for 2 minutes). Plasma and 
erythrocyte fractions were immediately separated, snap frozen and stored at -80°C for 
future analysis. Rapidly thawed plasma and erythrocyte fractions were subsequently 
analysed via ozone based chemiluminescence as per sections 2.3.4.1 (page 96) and
2.3.4.2 (page 97) respectively.
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3.2.3 A Real Time Nitric Oxide Reaction Model
This model utilises ozone-based chemiluminescence, however, it is employed 
almost in reverse to usual cleavage reagent methodology (section 2.3, page 82). Instead 
o f a cleavage reagent, the purge vessel (figure 2.2) is filled with 5ml o f PBS, maintained 
at 25°C and purged with nitrogen. The nitric oxide donor, spermine NONOate (capable 
o f liberating two moles o f nitric oxide for every mole o f parent compound) is injected 
into the purge vessel to achieve a final concentration o f 38pM (i.e. 76pM nitric oxide). 
Unlike NOC-9, spermine NONOate has a relatively long half-life (230 minutes at 22°C, 
pH 7.4 in phosphate buffered saline [378]). Upon injection this results in an initial peak 
that is followed by a relatively stable, slowly falling, nitric oxide generation level that 
represents the balance between nitric oxide generation by spermine NONOate in the 
purge vessel and the removal o f nitric oxide by the nitrogen carrier gas (Figure 3.1).
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Figure 3.1 Example trace o f Spermine NONOate (38pM) injection into PBS at 25°C. An initial spike in 
signal is followed by a stable nitric oxide generation baseline that drops slowly over the course o f hours.
Once the baseline is stable, the model can be utilised to study any chemical or 
biological sample that behaves as a nitric oxide ‘sink’. The model therefore lends itself 
nicely to studying the interaction o f haemoglobin/erythrocytes and nitric oxide.
When a nitric oxide scavenging entity is injected into the system, the signal 
drops before returning to baseline upon completion o f the reaction. This process 
generates an area below baseline that can be calculated and taken to represent the total
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amount o f nitric oxide consumed by the entity in relative terms. The gradient o f the 
initial signal decay from baseline can also be utilised to calculate the relative initial rate 
o f reaction between nitric oxide and the molecule o f interest.
3.2.3.1 Nitric Oxide Interaction with Haemoglobin and Erythrocytes
Erythrocyte samples were collected from healthy volunteers and processed as 
previously described (Section 2.1, page 80). Erythrocytes were diluted ~1 in 300 into 
either PBS to study whole cells or HPLC grade water in order to study lysed cells and 
adjusted to give a final concentration o f 0.1 g/L.
To alter oxygenation, samples were gently purged with nitrogen or oxygen gas in 
a sealed cuvette. The degree o f oxygenation was confirmed by light spectroscopy as per 
section 2.4 (page 104). Methaemoglobin levels were monitored at 630nm, but did not 
change significantly between samples.
lOpl o f whole or lysed erythrocyte samples were injected giving a final (in purge
■y
vessel) haemoglobin concentration o f 0.2 x 10' g/L. Samples were left to run in full i.e. 
until the signal had clearly returned to the nitric oxide generation baseline. The nitrogen 
purge flow rate was maintained at 200cm3/min in all experiments using an accurate gas 
flow meter.
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3.2.4 Nitrite Interaction with Erythrocytes
Erythrocyte samples were collected from consenting healthy volunteers within 
the Wales Heart Research Institute as stated in section 2.1 (page 80). Post centrifugation 
(2000g for 5 minutes) separated erythrocytes were reconstituted in phosphate buffered 
saline (PBS) to give a final haemoglobin concentration o f lOg/dL and haematocrit o f 
-35% , the mix was then placed in a thin film rotating tonometer as described in section
2.2 (page 81). A nitrogen or 95% oxygen purge was utilised to alter the haemoglobin 
saturation to either -50%  or -100%  respectively, saturation was confirmed using a 
blood gas analyser (OSM3, Radiometer, Copenhagen). The mix (50 or 100% saturation) 
was then separated into aliquots and nitrite o f varying concentrations (150, 250, 450 and 
850nM final concentrations respectively) was added and incubated at 37°C. For rate 
analysis, samples were taken at 5 min intervals (up to 20 minutes and again at 30 
minutes) and centrifuged at high speed (10,000g for 2 minutes) to quench the reaction, 
the supernatant and erythrocyte fractions were immediately separated, snap frozen and 
stored at -80°C for future analysis. Rapidly thawed supernatant and erythrocyte fractions 
were subsequently analysed via ozone-based chemiluminescence as per sections 2.3.4.1 
(page 96) and 2.3.4.2 (page 97), respectively.
3.3 Statistical Analysis
For group comparisons the student t-test was utilised, either paired or unpaired 
where appropriate. To assess correlations, the Pearson’s correlation coefficient was 
used. Data are presented as means and error bars represent the standard error o f the 
mean (SEM). A P value o f less than 0.05 was taken to be significant, individual 
significance levels are indicated within the figure legends.
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3.4 Results
3.4.1 Apportionment of Nitric Oxide in Blood
To assess the relative amount o f different nitric oxide metabolite species in blood and 
the effect o f haemoglobin oxygen saturation upon apportionment of metabolites both 
matched arterial and venous blood samples were collected and analysed.
3.4.1.1 Sample Characteristics
The haemoglobin concentrations o f arterial and venous blood samples were 
15.4±0.7 g/dL and 16.0±0.6 g/dL respectively, a paired t-test revealed no significant 
difference between the sample groups. Haemoglobin oxygen saturation in arterial blood 
measured 97.410.5 % which was significantly higher (P<0.01) than the venous sample 
that measured 67.2±4.2 %.
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3.4.1.2 Baseline Arterial and Venous samples
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Figure 3.1. Apportionment o f nitric oxide species in; A) Whole blood B) Whole blood with plasma nitrate 
level not shown and C) Erythrocytes bound to haemoglobin. No significant difference in total levels (A) 
between Arterial and Venous samples. n=4 in all cases.
The vast majority o f nitric oxide moiety in the blood circulates as nitrate in both 
arterial and venous vasculature (Figure 3.1 A). If nitrate is excluded, the remaining 
metabolites (nitrite, RSNO and erythrocyte associated signal) account for less than one 
percent o f the total metabolite pool (Figure 3 .IB). Interestingly, the total amount o f 
nitric oxide moiety does not change in arterial vs. venous blood (Figure 3.1 A). 
However, apportionment between different species does change from artery to vein e.g. 
haemoglobin bound species and plasma nitrite (Figures 3.1 and 3.2).
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Figure 3.2. Changes in arterial and venous apportionment of nitric oxide metabolites in each of the 
individuals tested A) Plasma nitrate is significantly lower in venous blood compared to matched arterial 
samples (P<0.001) B) A significant (P<0.05) gradient in plasma nitrite level exists from artery to vein C) 
Plasma RSNO, no significant change from arterial to venous D) Nitric oxide bound to the oxygen binding 
pocket o f haemoglobin increases significantly (PO.OOI) from artery to vein E) HbSNO levels show a 
trend which is higher in arterial samples but is not significantly different from matched venous samples. 
n=4 in all cases.
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The transit from artery to vein and associated change in oxygen level alters the 
apportionment o f nitric oxide metabolites. The clearest trends appear to be in plasma 
nitrite and HbNO, where plasma nitrite levels decrease from artery to vein, in contrast to 
HbNO levels which increase by approximately the same amount across the same 
vascular bed (Figure 3.2B and D).
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3.4.1.3 Exogenous Nitric Oxide Addition to Arterial and Venous Blood
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Figure 3.3. Apportionment o f nitric oxide species post NOC-9 (425nM) addition in; A) Whole blood B) 
Whole blood with plasma nitrate level not shown and C) Erythrocytes bound to haemoglobin. No 
significant difference in total levels (A) between Arterial and Venous samples. n=4 in all cases.
The total increase in nitric oxide moiety was the same in arterial and venous 
blood (Figure 3.3A) with an overall nitric oxide recovery level of 154.4%. This recovery 
level is very acceptable given that 850nM nitric oxide equivalent was added to a ~ 
30,000nM pool of nitric oxide metabolites. However, it should be noted that the aim of 
this study was to asses the apportionment of nitric oxide in relation to blood saturation, 
not the addition of nitric oxide per se. The metabolism of exogenously added nitric 
oxide to specific species appears to be oxygen dependent.
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In arterial blood most species appeared to be slightly elevated, however it is the 
observed increases in plasma nitrite (P<0.05) and nitrate that account for most of the 
exogenously added nitric oxide (Figure 3.4). In venous blood, plasma nitrite levels are 
also elevated (P<0.05) (Figure 3.5B), however, there is also a notable increase in HbNO 
level (Figure 3.5D).
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Figure 3.5. The metabolism of NOC-9 (425nM) in venous blood samples. A) Plasma nitrate levels B) 
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HbNO levels appear to increase in all samples, however levels achieved are not significantly different 
from baseline E) HbSNO levels. n=4 in all cases.
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3.4.2 Real Time Nitric Oxide Reaction Model
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Figure 3.5. Smoothed trace showing injection o f a lysed erythrocyte sample (1) and injection of the same 
but whole erythrocyte sample (2). The whole erythrocyte signal is comprised o f a number of components, 
an initial uptake or decay phase (3), a plateau or steady state phase (4) and a return to baseline phase (5).
The injection of whole and lysed erythrocytes into the model produces visually 
distinct signals (Figure 3.5). Injection of lysed erythrocytes produces a signal with rapid 
decay to a low detected nitric oxide level and completes its reaction within a few 
minutes. Conversely, injection of whole erythrocytes produces a signal with a more 
modest decay to a level that is much closer to the nitric oxide level detected before 
erythrocyte injection, with the reaction completing over a longer period of ~20 minutes.
In order to test the suitability of the model for erythrocyte/haemoglobin testing, a 
number of validation experiments were undertaken to establish the characteristics of the 
model. The nitric oxide baseline level was found to be directly dependent upon the flow 
rate of the purging nitrogen gas, for this reason the nitrogen flow in all experiments was 
kept at a constant rate (Figure 3.6A). The relative amount o f nitric oxide consumed upon 
injection o f haemoglobin was found to be inversely proportional to the % met 
haemoglobin content (Figure 3.6B). All test samples were monitored for changes in 
methaemoglobin, however the manipulations used in this chapter did not alter levels 
significantly. The amount of haemoglobin injected was found to have a linear 
relationship with the relative amount of nitric oxide consumed (Figure 3.6C),
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demonstrating that the model is suitable o f erythrocyte/haemoglobin testing. In addition, 
the relative total amount o f nitric oxide consumed was found to be independent of the 
extracellular nitric oxide concentration (Figure 3.6D).
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Figure 3.6. Real time nitric oxide reaction model characteristics A) The effect o f nitrogen purge flow rate 
on the baseline line of spermine NONOate (R2=0.984, Pearson’s correlation coefficient^ -0.992, 
P 0 .0001 , n=8 ). B) The effect o f met haemoglobin on the relative amount o f nitric oxide consumed by 
lysed red blood cells (0.1 g/L) (R2=0.754, Pearson’s correlation coefficient= -0.868, P 0 .0001 , n=40). 
Methaemoglobin samples were generated over time by incubation of oxyhaemoglobin with high 
concentration nitrite C) The effect of haemoglobin concentration upon the relative amount of nitric oxide 
consumed by lysed red blood cells (R2=0.815, Pearson’s correlation coefficient=0.903, P0 .0001 , n=16). 
D) The effect o f spermine NONOate concentration on the relative amount o f nitric oxide consumed by 
lysed red blood cells (0.1 g/L), no significant difference.
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The starting nitric oxide baseline level was not significantly different between all 
groups used for cross comparison (oxy vs. deoxy and whole vs. lysed). This is important 
as the baseline level is indicative o f the extracellular nitric oxide concentration in the 
purge vessel and although this will not alter total nitric oxide consumption, it could 
impact upon the rate o f  uptake.
The initial rate o f nitric oxide consumption is significantly slower in whole cells 
when compared to their lysed counterparts (Figure 3.7A and B). The initial rate of 
oxygenated whole cells is approximately 20 times slower than its lysed counterpart, 
while in deoxygenated cells it is approximately 10 times. Independent of oxygenation 
level, whole cells consistently consume more nitric oxide than when they are lysed 
(Figure 3.7C and D).
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Figure 3.7. A) Initial rate o f nitric oxide consumption measured as a drop from the spermine NONOate 
generated baseline by both whole and lysed oxygenated cells (P<0.001). B) Initial rate o f nitric oxide 
consumption by both whole and lysed deoxygenated cells (P<0.001). C) The relative amount o f nitric 
oxide consumed by both whole and lysed oxygenated cells (P<0.001). D) The relative amount o f nitric 
oxide consumed by both whole and lysed deoxygenated cells (P<0.001). Haemoglobin was normalised to 
0.1 g/L in all cases. n=8, met haemoglobin remained unchanged between samples.
The initial rate o f nitric oxide uptake in whole deoxygenated erythrocytes is 
more than double that o f oxygenated erythrocytes (Figure 3.8A). Once the same cells are 
lysed the relationship is lost with both deoxygenated and oxygenated lysed cells 
displaying the same initial rate (Figure 3.8B). A similar pattern occurs with respect to 
the relative amount o f nitric oxide consumed. Whole oxygenated erythrocytes consume 
significantly more nitric oxide than the same cells in a deoxygenated state (Figure 3.8C). 
Again, this relationship is not present if  the cells are lysed (Figure 3.8D).
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Figure 3.8. A) Initial rate o f nitric oxide consumption, measured as a drop from the spermine NONOate- 
generated baseline in whole oxygenated and deoxygenated cells (P<0.05). B) Initial rate of nitric oxide 
consumption in lysed oxygenated and deoxygenated cells (i.e. free haemoglobin). C) The relative amount 
of nitric oxide consumed by injection o f whole oxygenated and deoxygenated cells into the test system, 
(P<0.01). D) The relative amount o f nitric oxide consumed by injection o f lysed oxygenated and 
deoxygenated cells into the test system. Haemoglobin was normalised to 0.1 g/L in all cases. n=8 , met 
haemoglobin remained unchanged between samples.
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cells, nitrite uptake generally increased as extracellular nitrite concentration incn 
However, at lower extracellular concentrations (150nM and 250nM) in the s; 
containing fully oxygenated cells, the extracellular nitrite level did not fall signifii 
from the starting value over thirty minutes. The same was also true for the pa 
oxygenated erythrocyte sample but only at the lowest extracellular nitrite concent 
(150nM). Nitrite uptake also increased as haemoglobin oxygen saturation decrease* 
relationship only becomes significant at the higher extracellular nitrite concentrate 
450nM and 850nM (oxygenated vs. partially oxygenated, P<0.05 and P 
respectively), tested after thirty minutes o f incubation.
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Figure 3.9. A) Nitrite consumption by erythrocytes at -100%  (98.45 ± 0.15%) oxygen saturation. No 
significant difference between 0 and 30 time points for 150 and 250nM nitrite, P<0.05 0 vs. 30 time points 
for 450 and 850nM. B) Nitrite consumption by erythrocytes at 50% (51.04 ± 0.83%) oxygen saturation. 
No significant difference between 0 and 30 time points for 150nM nitrite, P<0.05 0 vs. 30 time points for 
250, 450 and 850nM. Change in extracellular nitrite concentration after 30 minutes is significantly 
different at 450 and 850nm starting concentration (P<0.05 and P<0.01 respectively), oxygenated vs. 
partially oxygenated. Starting concentrations were measured at 852.6 ± 33.1nM, 475.2 ± 26.2nM, 244.4 ± 
29.9nM and 177.0 ± 19.0nM respectively. Haemoglobin was normalised to lOg/dL (10.07g/dL ±0.08). 
n=4 for all groups, all measurements were made in duplicate and averaged.
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The overall rate o f nitrite uptake, particularly in the physiological range (~50- 
250nM, see section 3.5.2 (page 133)), in relative terms is not very rapid (Table 3.1). 
This is compounded by high haemoglobin oxygen saturation, where entry to fully 
oxygenated samples at lower concentrations is almost negligible. At all extracellular 
nitrite concentrations the overall rate is approximately three times faster in partially 
oxygenated compared to the corresponding fully oxygenated samples.
Table 3.1. Nitrite consumption rate by erythrocytes ex vivo at 50% (51.04 ± 0.83%) and 100% (98.45 ± 
0.15%) oxygen saturation. Samples were taken every 5 minutes over 30 minutes from different starting 
concentrations. Starting concentrations were measured at 852.6 ± 33.08nM, 475.2 ± 26.23nM, 244.4 ± 
29.9InM and 177.0 ± 18.99nM respectively. Haemoglobin was normalised to lOg/dL (10.07g/dL ±0.08). 
Data are expressed as nitrite consumption, nM per minute. n=4 for all groups, all measurements were 
made in duplicate and averaged.
Nitrite 
Consumption 
Rate over 30 
mins 
(nM min'1) 
±SEM
Approx. 
Starting Nitrite 
Concentration: 
850nM
450nM 250nM 150nM
50 % Saturation 17.76 ±1.93 8.72±1.27 3.03 ±0.86 1.43 ±0.72
100 % Saturation 6.01 ±1.03 2.52 ±0.30 1.03 ±0.48 0.65 ±0.23
- 129-
Chapter Three Nitric Oxide, Its Metabolites and Blood
3.5 Discussion
3.5.1 Nitric Oxide Apportionment in Blood
Understanding the way in which nitric oxide is apportioned in blood as 
individual metabolite species is essential for both the application and interpretation of 
nitric oxide metabolite biology. Many early studies based hypotheses and theories for 
experimental findings upon changes in specific metabolite levels. In these studies, 
species levels (particularly haemoglobin bound species) were reported to be relatively 
high, in the micro-molar range [329]. Over time, reported levels have slowly come down 
and consensus between the majority o f laboratories exists [369, 379]. However 
questions surrounding the niceties of measurement methodology still ensue [373]. 
Nevertheless, it should be remembered, especially given the relative potency of nitric 
oxide, that amount measured does not always infer physiological relevance. The 
observed decrease in reported levels is most likely due to improvements in methodology 
and a greater awareness o f confounding factors such as nitrite contamination. The 
methodologies utilised in this thesis have reported levels (~50-250nM, ~30pM nitrate) 
o f individual metabolite species that are in agreement with the values published in more 
recent, aforementioned publications [379].
The finding that concentration gradients o f specific nitric oxide metabolites exist 
in the circulation when passing from artery to vein (A-V) has been the stimulus o f much 
research [337]. The premise o f this research relies heavily upon the assumption that, 
when a decrease in a specific metabolite (e.g. plasma nitrite) is observed it must have 
been converted back to free, biologically active nitric oxide. In agreement with one 
aspect o f this research, this chapter has also demonstrated a concentration gradient of 
specific species in human arterial and venous blood samples. Specifically, plasma nitrite 
decreases significantly across the vascular bed. However, the results o f this chapter and 
other publications [369] do not support the finding that free nitric oxide is produced. 
The explanation lies in the oxygen dependent re-apportionment o f species. The results 
of this chapter show, regardless o f haemoglobin saturation, that the total amount of
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nitric oxide moiety does not rapidly change, i.e. although levels o f specific metabolites 
change with respect to saturation, the total nitric oxide ‘pool’ remains constant. 
Therefore, studying the change o f just one specific metabolite is not sufficient to 
appreciate the dynamic interplay that occurs within a physiological system. In this 
respect, the results presented in this chapter show a decrease in plasma nitrite A-V that 
is matched by a concomitant increase in HbNO, redressing the balance of the total nitric 
oxide pool. The concept o f re-apportionment is complex in the in vivo setting where, in 
addition to changes in oxygen level, there are both multiple ‘sources’ and ‘sinks’ of 
nitric oxide throughout the vascular tree.
As this chapter reveals, the apportionment of metabolites in blood is ultimately 
dependent upon haemoglobin saturation. However, overall apportionment is also a 
balance between nitric oxide production, consumption and the inter-conversion between 
metabolite species. The measurement of nitric oxide metabolites is therefore reflective 
o f all o f these processes and should be interpreted with this in mind. It is therefore 
unlikely that the measurement o f just one metabolite species will be sufficient to gain 
understanding with regard to an overall physiological process (e.g. endothelial nitric 
oxide synthase activity) as has been used in previous studies [380, 381]. Indeed, our 
own laboratory have demonstrated that inhibition of nitric oxide synthase at baseline in 
human subjects effects vessel tone but does not alter nitric oxide metabolite levels in the 
short term [369].
The addition o f exogenous nitric oxide to arterial and venous whole blood gives 
an insight into the way in which blood metabolises nitric oxide in vivo. In arterial blood, 
small increases were seen in most species, however increases in plasma nitrate and a 
significant increase in plasma nitrite accounted for the majority o f the metabolised nitric 
oxide. The observed increase in plasma nitrate occurred in all samples, but, as a result of 
the study having a low number o f samples, was not found to be statistically significant. 
Metabolism to these oxidised species corresponds to the relative quantity o f oxygen in 
the sample. In the parallel venous samples plasma nitrite again increased significantly, 
in addition, the only other species to increase in all venous samples was HbNO. The
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observed increase in HbNO is to be expected in the venous sample given the increased 
availability o f haemoglobin (that is not carrying oxygen) to participate in a binding 
reaction with nitric oxide. The fact that plasma nitrite also increased significantly in the 
venous sample could possibly reflect an inability o f nitric oxide to rapidly enter the red 
blood cell and so free nitric oxide could be oxidised by dissolved oxygen in the plasma 
before having the opportunity to enter. Interestingly, in both arterial and venous blood, 
exogenously added nitric oxide was metabolised to species that are thought be 
biologically active, thereby ‘preserving’ so called nitric oxide activity within the blood.
As with baseline samples, the apportionment o f exogenously added nitric oxide 
was dependent upon oxygen level. In broad terms, nitric oxide added to oxygenated, 
arterial blood is more likely to undergo oxidation reactions. The same is somewhat true 
for partially oxygenated, venous blood, however, haem groups in the sample that do not 
have oxygen bound can potentially form HbNO. In this chapter, the same amount of 
exogenous nitric oxide was added to both arterial and venous samples i.e. production 
was constant and the species that were formed differed depending on oxygen level, 
highlighting the difficulties in interpreting A-V gradients of specific species from a 
more complex system where production etc can be variable.
The addition o f nitric oxide elevated the total metabolite pool by the same 
amount in both arterial and venous samples. The slightly elevated recovery of 
exogenously added nitric oxide could either reflect nitrite contamination in NOC-9 (as 
occurs with most chemical agents) or systematic error introduced during measurement 
(particularly likely with respect to nitrate measurement given its abundance over other 
species). However, given that the amount o f exogenous nitric oxide added only 
accounted for -2.5%  o f the total metabolite pool, this recovery level is very acceptable.
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3.5.2 Real Time Reaction of Nitric Oxide with Erythrocytes and 
Haemoglobin
The bioavailability o f nitric oxide within a vessel is largely governed by the 
concentration o f and rate of reaction with other bio-reactants. Haemoglobin is thought to 
be one o f the most significant ‘inactivators’ o f nitric oxide, due to its high rate of 
reaction. However, despite this high rate and the fact that the vessel lumen contains a 
considerable amount o f haemoglobin, nitric oxide is still able to carry out its normal 
function.
In the early 1990s there was a focus o f research on the simulation of nitric oxide 
diffusion in the vessel setting, with prominent work from Jack Lancaster [375, 382]. 
Lancaster’s early models suggested that the efficient scavenging of nitric oxide by 
haemoglobin would prevent it from entering vascular smooth muscle, igniting claims 
that EDRF was not in fact nitric oxide. As ideas progressed, the assumptions that had 
been made in early modelling work were disputed and previously described phenomena 
regarding blood flow were now being considered in this context. Notably, publications 
by Butler et al and Vaughn et al described a concept that has come to be known as the 
‘red blood cell free zone’ [322, 383]. This work builds on observations of blood flow in 
a vessel like structure or tube [384], in simple terms, blood flowing in a tube is 
composed o f two elements; an erythrocyte core flowing down the centre of the lumen 
and a peripheral plasma layer adjacent to the periphery or endothelium. It is this 
erythrocyte free plasma layer that has special relevance to nitric oxide diffusion and 
bioactivity. This creates an area where nitric oxide can exist without being scavenged by 
erythrocytes and allows the molecule to accumulate. This accumulation creates a 
concentration gradient that favours diffusion toward vascular smooth muscle where 
nitric oxide acts to produce vasodilatation. The Vaughn group went on to demonstrate 
that intravascular flow reduces nitric oxide scavenging by erythrocytes in an isolated 
vessel model [323]. This theory goes some way to explaining the ability of nitric oxide 
to function in the vessel setting, but other mechanisms are expected play a role. More 
recent research and the work o f this chapter have started to focus on the direct 
interaction o f nitric oxide with erythrocytes.
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The preliminary finding of the model developed in this chapter demonstrates that 
whole and lysed erythrocytes generate visually distinct signals with regard to nitric 
oxide uptake. To further explore this finding, assessments of initial rate of uptake and 
total relative nitric oxide consumption were performed.
The measured initial uptake rate is significantly slower (-10-20 times) in whole 
erythrocytes compared to the corresponding lysed sample. The encapsulation of 
haemoglobin, as in the case o f whole erythrocytes, clearly retards the rate of reaction 
with nitric oxide, suggesting an additional mechanism by which nitric oxide may be 
protected in the vessel setting. This property o f whole erythrocytes has been investigated 
by other research groups, leading to a number o f proposed theories that explain the 
mechanism o f limited nitric oxide entry. The Vaughn and Liao group published on the 
topic, suggesting that erythrocytes possess an intrinsic barrier to nitric oxide 
consumption [320]. The mechanisms involved are thought to stem from a resistance to 
transmembrane diffusion or a limited intracellular diffusion mechanism. A competition 
model was utilised in these experiments, which was thought to create a homogenous 
reaction without extracellular diffusion limitation. The Lancaster group countered this 
work, suggesting that the model was inappropriate (in terms o f extracellular diffusion 
limitation) and that it is in fact the ‘unstirred layer’ thought to surround erythrocytes that 
is the main diffusion barrier, not the membrane [321]. A recent publication utilising 
phospholipid vesicles filled with haemoglobin has also provided an alternative 
mechanism that does not implicate the membrane per se [385]. The work suggests that 
as nitric oxide enters the vesicle and reacts with haemoglobin close to the interior 
membrane surface it forms a diffusion barrier, this is thought to retard the reaction with 
haemoglobin in the core o f the vesicle and decrease overall reaction rate. As with a 
number o f studies o f this type, a ‘stopped-flow’ analysis was utilised. In this method, the 
reactants are rapidly mixed and then the products formed (used as surrogate marker 
instead o f actual nitric oxide level) are continually measured. In contrast to the model 
developed in this chapter, the extracellular nitric oxide level is changing over the course 
of the stopped-flow experiment and could potentially influence the measured rate. In
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this regard, the difference in initial rate between whole and lysed cells was calculated to 
be -10-20 times in this chapter, while some reported values have been as much -500 
times [320], this could reflect differences in methodology and rate assessment, however, 
irrespective o f magnitude, the measured rate is always slower in whole cell preparations.
The results o f this chapter do not fully confirm nor refute any of these diffusion 
limitation mechanisms but do provide novel findings that support certain aspects of 
these mechanisms. The model developed in this chapter utilises a reaction vessel that is 
bubbled to provide a homogenous reaction mixture, theoretically, limitations of 
extracellular diffusion should therefore not play a significant role. In this respect, a 
diffusion limitation in whole erythrocytes is still observed, suggesting that mechanisms 
intrinsic to the cell do play a role. Results obtained in oxygenated and deoxygenated 
cells potentially imply a role for intra-erythrocyte diffusion limitation which will be 
considered in the later part o f this discussion section.
The overall uptake o f nitric oxide was significantly higher in whole cells 
compared to the corresponding lysed samples; the potential reasons for this are two fold: 
In its whole form, the cell is more likely to be able to process the influx of nitric oxide. 
For example, the cell will have the potential to convert methaemoglobin back to 
haemoglobin via methaemoglobin reductase and associated co-factors, allowing further 
nitric oxide consumption, a process that is unlikely to occur in the lysed sample. 
Secondly, and perhaps more probable, the whole erythrocyte, regardless of containing 
haemoglobin could act as a ‘reservoir’ due to the relative partitioning of nitric oxide into 
one media vs. another. Nitric oxide, like oxygen, has previously been shown to be -4  
times more soluble in liposomes relative to water [386].
As is becoming apparent, the biochemistry of nitric oxide is heavily influenced 
by the presence of oxygen in the environment. To this end, the influence of haemoglobin 
saturation upon the nitric oxide uptake model was tested. In whole cell samples, the 
initial uptake rate was significantly faster (-2  times) in deoxygenated cells compared to 
the same cells in an oxygenated state. Given that there is no difference between
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deoxygenated and oxygenated lysed samples, this implies something intrinsic to the cell 
as opposed to a difference in the rate o f reaction between nitric oxide and haemoglobin. 
The increased uptake by deoxygenated cells could be due to haemoglobin membrane 
interaction. Deoxygenated, but not oxygenated, haemoglobin is known to bind to 
proteins (such as AE1) on the interior o f the plasma membrane [387]. This positions the 
haemoglobin perfectly, close to the membrane and channels which are thought to 
facilitate nitric oxide entry [83], where it can rapidly react with nitric oxide entering the 
cell. In support o f this, the uptake o f nitric oxide by erythrocytes has been shown to be 
influenced by altering the degree o f AEl-cytoskeleton interaction [388]. The nitric oxide 
permeability o f the erythrocyte membrane is also thought to be considerably greater in 
deoxygenated cells [389]. These data suggest that differences in diffusion rate 
(transmembrane and intraerythrocytic) may be a significant determinant in the 
difference in whole and lysed initial uptake rates.
The overall amount o f nitric oxide uptake was significantly higher in oxygenated 
whole cells compared to deoxygenated cells. Again, this relationship was absent in the 
equivalent lysed samples. Oxygenated haemoglobin in the whole erythrocyte can 
potentially consume two molecules o f nitric oxide compared to deoxygenated haem that 
has the ability to only bind one. It is possible for the first nitric oxide to react with the 
oxygen bound to the haemoglobin forming nitrate and resultant methaemoglobin, the 
methaemoglobin is then reduced back to haemoglobin (by methaemoglobin reductase in 
the whole cell) which can participate in a second nitric oxide reaction forming HbNO. 
This reaction is unlikely to completely cope with very rapid methaemoglobin formation 
in this model, however it may account for the increased consumption observed by 
oxygenated whole cells.
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3.5.3 The Uptake of Nitrite by Erythrocytes
Gladwin and colleagues propose that nitrite may behave as a biologically active 
source o f nitric oxide that is activated by haemoglobin, maximally around the 50% 
saturation point (see section 1.10.2, page 68). For this process to be biologically active 
in vivo, nitrite must enter erythrocytes in sufficient quantities, react with haemoglobin 
and release free nitric oxide over the course o f a circulatory cycle. The mechanism by 
which free nitric oxide is able to escape re-capture by haemoglobin within the 
erythrocyte continues to be heavily questioned [343], however, the assessment of nitrite 
entry to the erythrocyte has been somewhat neglected.
Wider research to date would suggest that the anion exchanger (AE1) could be a 
likely candidate for nitrite entry into the red blood cell. Early work by Shingles et al 
demonstrated inhibition o f HCO3 /NO2’ exchange across the erythrocyte membrane with 
the AE1 channel blocker DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate) [390]. 
However, more recent publications have been unable to demonstrate an effect o f DIDS 
[391, 392]. To further explore the possible role of carrier-mediated transport, Jensen 
attempted to block transport with phloretin (a general inhibitor of facilitated diffusion), 
but again found no influence [391]. Because o f the charged nature o f the nitrite anion it 
cannot simply diffuse across the membrane like nitric oxide. Other possible routes of 
entry are via diffusion through channels (conductive transport) or diffusion as HNO2 . 
Although HNO2 can simply diffuse across the lipid bilayer it has a pKa of ~3.3 [391] 
and so is unlikely to form to any great extent at normal extracellular pH. In addition, 
intracellular pH is normally lower than extracellular and therefore an outward diffusion 
gradient for HNO2 would exist. However, nitrite would be consumed by haemoglobin 
inside the cell and so could potentially reverse this gradient. In summary, a likely 
candidate is conduction channel diffusion. The results o f this chapter show 
concentration dependency and the generally low uptake rates in the physiological nitrite 
range that implies diffusion to be responsible, rather than an active uptake process. In 
this regard, previous studies have suggested that nitrite entry to erythrocytes is relatively 
rapid. However, the extracellular concentrations o f nitrite utilised are often in the
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millimolar range [391, 392]. The rates observed and mechanistic assumptions derived at 
these nitrite concentrations clearly do not translate to mechanisms occurring at 
physiological levels. The extrapolation o f findings, generated under non-physiological 
conditions, to the physiological setting is a problem that is prominent within the nitric 
oxide field. In order to study a system such as nitric oxide metabolism it is often 
necessary to introduce species to alter baseline equilibrium. There is not a problem with 
this research approach, however it is essential to interpret findings in context.
A number o f publications have previously suggested that nitrite uptake by 
erythrocytes under normal conditions is independent o f oxygenation [391, 393]. The 
results presented here find that partially oxygenated samples have a higher uptake rate 
compared to oxygenated samples, particularly at elevated extracellular nitrite 
concentrations. This observed difference in uptake cannot be explained in terms of the 
rate o f reaction between haemoglobin and nitrite, as oxyhaemoglobin is reported to react 
~10 times faster than deoxy [394], However, the removal o f nitrite by haemoglobin is 
still likely to contribute to the force that drives uptake. As with the interaction seen 
between erythrocytes and nitric oxide, an intrinsic interaction between haemoglobin and 
the cell membrane may have a function. Deoxygenated haemoglobin is known to 
interact with channels and the cytoskeleton on the interior membrane surface [387] and 
so potentially could alter the entry o f nitrite by association. The diffusion o f nitrite 
through membrane channels may also be altered by membrane potential. Changes in 
oxygenation are known to alter the membrane potential through mechanisms such as the 
Haldane effect (see section 1.4.2.4, page 18) [391].
The sluggish rate o f nitrite uptake by erythrocytes (particularly in an oxygenated 
state) at physiologically relevant extracellular nitrite concentrations does not favour a 
mechanism by which nitrite, through an erythrocyte/haemoglobin mechanism, effects 
vessel tone under basal conditions. The overall importance o f the findings in this chapter 
section will be put in context with respect to in vivo data that is presented and discussed 
in chapter 6.
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3.6 Summary and Conclusions
• The apportionment o f nitric oxide and its metabolites in blood is dependent upon 
the degree o f haemoglobin oxygen saturation, creating arterio-venous gradients 
o f specific species. However, the total nitric oxide metabolite pool remains 
relatively constant with decreases in one group of species being compensated for 
by increases in another. Apart from nitrate (which is in the pM range), measured 
values ranging from ~10-250nM are in agreement with recent publications.
• The metabolism or species formed when exogenous nitric oxide is added to 
arterial and venous blood differs. In oxygenated blood, nitric oxide is more likely 
to undergo oxidation reactions to form nitrite and nitrate. In venous blood, the 
increased availability o f haemoglobin (i.e. with no oxygen bound) leads to the 
production o f HbNO. In both cases, some o f the species formed are thought to be 
biologically active and may potentially preserve nitric oxide.
•  The rate o f initial uptake o f nitric oxide by erythrocytes is -10-20 times slower 
than the reaction o f free haemoglobin (lysed cells) with nitric oxide. The exact 
mechanisms o f this retarded uptake remain unknown, but the phenomenon may 
serve to increase nitric oxide longevity in vivo. In whole erythrocytes, the initial 
uptake rate o f nitric oxide is significantly faster (-2  times) in deoxygenated cells, 
most likely resulting from an interaction of deoxyhaemoglobin and the 
erythrocyte membrane/membrane proteins.
•  The uptake o f nitrite by erythrocytes is concentration-dependent and does not 
occur at a rapid rate when extracellular nitrite is in the physiological (i.e. plasma 
concentration) range. The rate o f uptake is also influenced by haemoglobin 
oxygen saturation with partially oxygenated (SaC>2 50%) cells taking up more 
nitrite, particularly at high extracellular nitrite concentrations.
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4 Nitrite Induced Vasorelaxation, the Influence of Oxygen
4.1 Introduction
The nitrite anion (NO2 ) represents an interesting constituent o f the nitrogen 
oxide(s) (NOx) family in pharmacological terms. The real-time study of nitric oxide has 
always posed a problem due to its highly reactive nature: nitrite, although significantly 
less potent than nitric oxide, has been utilised as a more stable and practical solution to 
this experimental problem. However, nitrite has its own caveats, most notably 
contamination in in vitro systems and alternative sources in vivo (e.g. diet) where levels 
can be oxygen dependent. Nitrite itself has been known to be vasoactive for a number of 
years [395]. Although relatively less potent than pharmaceutical nitrovasodilators, 
interest in its mode o f action has recently revived after recognition that it may represent 
a circulating source o f bioavailable ‘NO-like’ activity (see section 1.10.2, page 68) and 
may have an important role clinically [98].
Nitrite was previously thought to be a relatively inert nitric oxide metabolite, 
although current studies now allow us to appreciate the dynamic ‘interplay’ between the 
metabolites o f nitric oxide and their potential as physiological effectors (see chapter 3 
and [369]). The biological effects o f nitrite are thought to be predominantly mediated 
via its reduction back to nitric oxide. Therefore, the mechanisms by which nitrite is 
reduced to nitric oxide has become a principal area o f interest within the nitrite field. To 
date, research has largely focused upon the reduction o f nitrite by haemoglobin, a 
mechanism that is thought to match blood flow and oxygen demand (see section 1.10.2, 
page 68). However, this mechanism has not been demonstrated within the in vivo setting 
and the original ex vivo vessel work demonstrating enhanced nitrite induced 
vasodilatation in hypoxia in the presence o f haemoglobin [337] is yet to be repeated 
[315, 396]. Several issues remain with this concept, including the effective entry o f 
nitrite into erythrocytes at physiological concentrations (see chapters 3 and 6), and 
subsequent escape o f bioavailable nitric oxide from haemoglobin recapture. In addition 
to haemoglobin reduction, an alternative mechanism o f nitrite reduction involving
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oxidoreductase enzymes has also been suggested [397]. The proposed mechanism 
suggests that the principal route o f nitrite reduction occurs in the vascular tissue via 
enzymatic reduction as opposed to in the blood stream via haemoglobin reduction. The 
main enzymes thought to be involved are xanthine oxidase (XO) and aldehyde oxidase 
(AO) [397], however it has been suggested that nitric oxide synthase [398], myoglobin 
[344] and mitochondrial enzymes [399] also have the capacity to reduce nitrite.
Despite the considerable amount o f speculative work surrounding nitrite as both a 
circulating vasoactive moiety and a potential therapeutic, very little work regarding its 
downstream mechanism o f action has been completed, particularly in hypoxic vessels, 
where it is though to be most effectual. Dalsgaard and colleagues have presented some 
interesting mechanistic findings from rat aortic rings in hypoxia [396]. The work finds 
that in the presence o f cyclooxygenase and nitric oxide synthase inhibitors, nitrite 
appears to operate via soluble guanylate cyclase. The authors also fail to show a role for 
haemoglobin, mitochondrial bc\ complex or xanthine oxidase in the reduction o f nitrite 
and suggest that a mechanism involving the formation o f s-nitrosothiols within smooth 
muscle could be involved. More recently, the Zweier group assessed the mechanism of 
nitrite-induced vasodilatation, also in hypoxic rat aortic rings [400]. As with the 
previous publication, this work was unable to demonstrate the involvement o f xanthine 
oxidase or the mitochondrial transport chain, in addition to nitric oxide synthase and 
cytochrome P450, in the reduction o f nitrite. They also found that nitrite induced 
vasorelaxation could be inhibited by ODQ (lH[l,2,4]oxadiazolo[4,3-a]quinoxalin-l- 
one). ODQ is commonly used to inhibit soluble guanylate cyclase, but will bind to a 
number o f haem based proteins. To complement the vessel-based work, the authors also 
completed some nitric oxide generation measurements from aortic tissue using a nitric 
oxide-sensitive electrode to consider the involvement o f haem-based enzymes in nitrite 
reduction. The generation o f nitric oxide from the aortic tissue was inhibited by both 
heating o f the tissue (to denature proteins) and ODQ. The results suggest that haem- 
based tissue enzymes are responsible for nitrite reduction. In the case o f soluble 
guanylate cyclase, the enzyme could potentially be acting as both a nitrite reductase and 
catalyser o f cGMP production to affect vasorelaxation.
levels both directly and indirectly. Within the cell, nitric oxide is capable of modifyin 
proteins via thiol, tyrosine and metal groups, like phosphorylation, these modification 
can have huge influences upon the functionality o f the protein. In the short term thes 
modifications can influence receptor sensitivity and enzyme or channel activity fc 
example. However, if the protein is a transcription factor, then exposure to nitric oxid 
can have long lasting effects via alteration o f gene expression (for a comprehensiv 
review of nitric oxide signalling particularly with regard to gene expression see [401] 
Given these facts, it is important to consider the additional effects of nitrite, not onl 
from a clinical dosing or chronic administration point of view, but also in terms of th 
potential mechanisms that could be activated in vivo by basal nitrite levels, particular! 
during a hypoxic insult. Publications in this area are limited but some studies have bee 
completed. One study that utilised a rodent model has demonstrated that twenty foi 
hours after high dose nitrite infusion, aortic heme oxygenase-1 and heart heat shoe 
protein 70 expression (at a protein level) had been altered, despite plasma nitril 
returning to basal levels at the same time point [402].
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vasodilatation in hypoxia. In addition, the broader effects of nitrite in vascular tissu 
will also be investigated in this chapter in order to gain crucial understanding about t 
acute effects o f nitrite exposure at a cellular level. Specifically this chapter aims to;
• Assess the effect o f vascular tissue oxygenation upon nitrite-dependc 
vasodilatation.
• Investigate the dependency of nitrite-induced vasodilatation upon the formati 
o f nitric oxide and elucidate the primary routes o f nitrite reduction witl 
hypoxic vascular tissue.
• Establish the down-stream mechanisms involved in nitrite-medial 
vasodilatation in hypoxia via the selective blockade of key enzymes/steps witl 
vascular signalling cascades.
• Examine the acute effects o f nitrite exposure upon the expression of speci 
genes in normoxic and hypoxic vascular tissue.
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4.2 Specific Protocols
4.2.1 Myography
Rabbit aortic rings were harvested, mounted and conditioned as per section 2.5 
(page 104). For experiments requiring endothelium-denuded tissue, the lumen of the 
ring was gently rubbed with a wooden applicator and absence o f endothelium was then 
tested during the experimental protocol by acetylcholine challenge. In hypoxic 
experiments, tissue was always exposed to 10 minutes o f hypoxia before phenylephrine 
induced pre-constriction (detailed in section 2.5.2, page 105). The final concentration of 
nitrite utilised in all experiments was 10pM, an effective concentration previously 
established in our laboratory in vitro [98], but also a concentration that is achievable in 
vivo, in plasma with pharmacological nitrite dosing [98, 379, 403].
The slow and continuous relaxation o f isolated vessels during hypoxia, as 
observed in the controls o f all our experiments, is an established phenomenon. The 
precise cause o f vasodilatation remains unknown. Both energy limitation and 
interruption o f excitation contraction coupling have been suggested as possible causes 
[131]. In our model, hypoxia-induced relaxation is independent o f the endothelium or 
NOS (denudation/L-NMMA data). It is important to note that the smooth muscle cells 
are not simply dying in hypoxia. After a period o f hypoxia, tissue can be re-equilibrated 
in oxygenated buffer and show comparable contraction and relaxation to exogenously 
added agents. O f related interest, our laboratory has previously shown that relaxation 
induced in arteries and veins by nitric oxide donors (such as GSNO) and nitrite is 
enhanced under hypoxic compared to normoxic conditions [91, 98].
All pharmacological inhibitors were incubated for thirty minutes under normoxic 
conditions before switching to hypoxic conditions for experimental testing. 
Concentrations o f pharmacological inhibitors used were selected after the completion of 
concentration curves (see results section o f this chapter) or were based upon values used 
in the current literature, CPTIO [404], U-51605 [405], raloxifene and oxypurinol [397],
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L-NMMA [398] (for values see table 4.1). Pharmacological inhibitors were all dissolved 
in dimethyl sulphoxide (DMSO) apart from oxypurinol, which was dissolved in IN 
sodium hydroxide (NaOH) and CPTIO and L-NMMA, which were dissolved in Krebs’ 
buffer. Control experiments to test the effect o f vehicle solutions upon vascular response 
to nitrite were completed and showed no demonstrable effect.
Table 4.1. Concentrations and actions o f pharmacological inhibitors utilised. These represent final in-bath 
concentrations required or established for maximum effect on nitrite-induced vasodilatation.
Agent Action Final
Concentration
ODQ Soluble Guanylate Cyclase (sGC) Inhibitor 10 pM
Indomethacin Cyclooxygenase Inhibitor (COX) 5 pM
CPTIO Nitric Oxide Scavenger 1 mM
U-51605 Prostacyclin Synthase Inhibitor (PGISi) 10 pM
Raloxifene Aldehyde Oxidase Inhibitor 50 nM
Oxypurinol Xanthine Oxidase Inhibitor 100 pM
L-NMMA eNOS Inhibitor 300 pM
Maximum relaxation was measured twenty minutes post nitrite addition and 
expressed as percentage o f the maximum constriction to phenylephrine. The twenty 
minute time point is used to reflect total nitrite-induced relaxation, as vasorelaxation to 
nitrite was observed to reach a sustained plateau and have had its maximum effect 
within this time. When using pharmacological blockers, percentage inhibition is always 
with respect to the appropriate control tissue/agent control as some inhibition agents 
alter basal tone alone.
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4.2.2 Gene Expression Study
4.2.2.1 Sample Generation
To study the effects o f oxygen level and nitrite treatment upon the transcription 
of specific genes, equal sized aortic rings were prepared and mounted in myograph 
tissue baths as per the vascular reactivity studies. The phenylephrine conditioning phase 
o f the vascular reactivity protocol was omitted and all experiments were carried out at 
two grams o f resting tension. Each pair o f aortic rings were designated to one of four 
treatment groups, those incubated in normoxia in the presence o f lOpM nitrite or saline 
(0.9% w/v) and those exposed to hypoxia in the presence o f lOpM nitrite or saline 
(0.9% w/v). All groups were exposed to the specific treatment (nitrite, saline, hypoxia or 
normoxia) for thirty minutes before aortic rings were carefully demounted and rapidly 
snap frozen in liquid nitrogen. Thirty minutes o f hypoxic exposure was chosen as it 
corresponds to the vascular reactivity studies o f this chapter and an exposure o f this 
duration has previously been shown to alter gene transcription in endothelial cells [406].
4.2.2.2 Total RNA Extraction
Samples were homogenised on ice in TRIzol® reagent (Invitrogen) to extract 
and stabilise RNA from the sample. RNA was then purified from the homogenate using 
a Purelink RNA mini kit (Invitrogen) according to the manufacturer’s instructions. Once 
purified, the yield o f RNA was measured using a Nanodrop (Thermo Scientific) 
spectrophotometer reading absorbance at 260nm, with RNA integrity assessed from the 
ratio o f 260/280 nm absorbance ratio.
4.2.2.3 cDNA Generation
A cDNA library was constructed from RNA samples using a high capacity cDNA 
reverse transcription kit (Applied Biosystems), after normalisation for initial sample
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RNA content. The thermocycling conditions utilised were 25°C for 10 mins, 37°C for 
120 mins, 85°C for 5 mins samples were then maintained at 4°C before storage at -80°C.
4.2.2.4 Real Time Polymerase Chain Reaction Assay
COX-2 (cyclooxygenase-2), eNOS (endothelial nitric oxide synthase), GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) and H IF -la  (hypoxia inducible factor-1 
alpha) mRNA expressions were all analysed on an Applied Biosystems 7500 real-time 
polymerase chain reaction (PCR) system using platinum SYBR green qPCR supermix 
UDG (Invitrogen). All rabbit primer sequences (table 4.2) were obtained from literature 
[407-409] and were constructed by Sigma Aldrich. PCR conditions were 50°C for 2 
mins, 95°C for 10 mins, 40 cycles for 15 s at 95°C and 1 min at 60°C, followed by a 
melt curve (95°C for 15 s), ramp to 60°C for 1 min and 95°C for 20 s. Conditions were 
taken from those optimised in the literature [407].
Estimates o f cDNA abundance were assessed from the portion o f the curve for which 
the plot o f the log input amount versus the cycle threshold (Ct) differences resulted in a 
slope o f approximately zero, which indicated that the amplicon efficiencies were 
approximately equal. The relative quantification o f the target genes was calculated using 
the formula 2‘AACT, in which ACt equals the difference between C j values for both target 
gene and GAPDH.
Table 4.2. Specific polymerase chain reaction primer nucleiec acid sequences.
HIF-1 alpha sense GGATATAAATTTGGCAAT GCTT CCAT
HIF-1 alpha anti-sense G AGT GCAGGGT C AG CACT ACTT C
GAPDH sense ACTTT GT GAAGCT CATTT CCTGGTA
GAPDH anti-sense GT GGTTT GAGGGCT CTTACT CCTT
COX-2 sense GAGAT GAT CTACCCGCCT CA
COX-2 anti-sense GATT CATAGGGCTT CAGC
eNOS sense GCT GCGCCAGGCT CT CACCTT C
eNOS anti-sense GGCT GCAGCCCTTT GCT CT CAA
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4.2.3 Statistical Analysis
Data was compared using a one way-ANOVA with a Bonferroni’s multiple 
comparison post hoc test. All analysis was carried out using Graphpad Prism software 
(version 4.0). n=l represents data averaged from a pair o f matched aortic rings in both 
vascular reactivity and genetic studies. Data showing time course profiles were 
compared statistically over the entire profile. The 20 minute time point was chosen for a 
single time point comparison o f total relaxation induced.
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4.3 Results
4.3.1 The Effect of Oxygen
To establish the effect o f oxygen upon vascular constriction in the 
aforementioned aortic ring model, vessels were subjected to a phenylephrine 
concentration response at both 95 and ~1% oxygen. Vessels constricted with 
phenylephrine at 95% oxygen constricted to a maximum o f 8.21 grams, the tension in 
these vessels did significantly decrease thereafter (over 2 0  minutes) by a mean value of 
1.08 grams (Figure 4.1 A). Vessels constricted at ~1% oxygen also lost a significant 
amount o f tension over the 2 0  minute investigation period with the mean loss in tension 
(3.08 grams) considerably more than that observed at 95% oxygen (Figure 4 .IB). The 
phenylephrine EC50 at 95% oxygen was significantly less from that at 1% oxygen 
(P<0.002), indicating that a higher concentration o f phenylephrine is required to achieve 
50% of the maximum effect at 1% oxygen.
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Figure 4.1. Phenylephrine concentration response curves at maximum constriction and 20 minutes post 
maximum constriction. A) Response at 95% oxygen, and EC50 at maximum, 8.21 ±0.10 grams and 
133 ± 6.7 nM respectively, Rmax 20 minutes most maximum constriction 7.10 ± 0.11 grams. R ^   ^
significantly different between maximum and 20 minutes post maximum (**P<0.01) B) Response at -1%  
oxygen, R ^  and EC50 at maximum, 6.38 ± 0 .1 8  grams and 1560 ± 289.9 nM respectively, Rmax 20 
minutes most maximum constriction 3.02 ± 0.19 grams. R ^  * significantly different between maximum 
and 20 minutes post maximum (***P<0.001). EC50 at maximum is significantly different between 95% 
oxygen and 1% oxygen (P=0.0023). (n=4 in all cases).
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Our laboratory has previously found that the responsiveness of vascular tissue in 
this model to S-nitrosoglutathione (GSNO) is increased when the tissue is subjected to 
hypoxic conditions [91]. To establish if the model would react in the same way to nitrite 
exposure, nitrite vasorelaxation experiments were carried out at both 95 and 1% oxygen. 
As is the case with GSNO, the same concentration of nitrite induced significantly more 
vasorelaxation in hypoxic tissue compared to normoxic tissue (P<0.0001) (Figure 4.2).
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Figure 4.2. Raw trace o f nitrite induced vasorelaxation. Aortic rings were pre-constricted with 
phenylephrine (1 xlO^M final at 95% and 3 x lO^M final at 1% oxygen) before addition of nitrite (lOpM 
final). Nitrite induced significantly more relaxation in hypoxia (1% oxygen) versus normoxia (95% 
oxygen) (***P<0.0001) (n=4).
4.3.2 Pharmacological Inhibitors
The two key inhibitors utilised within this chapter, ODQ and indomethacin were 
subjected to concentration-effect testing to establish the appropriate concentration for 
maximum effect (Figure 4.3). ODQ gave maximum effect at a final concentration of 
10pM, incubation with higher concentrations reduced inhibition, possibly due to toxicity 
at these elevated concentrations (Figure 4.3A). Indomethacin in the concentration range 
of 1-1 OpM had a similar inhibitor effect (Figure 4.3B), therefore a concentration of 5pM 
was chosen for experimentation.
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Figure 4.3. % inhibition o f nitrite-induced vascular relaxation, an inhibitor concentration-effect analysis. 
A) Inhibition by ODQ over a concentration range, a concentration of lOfiM ODQ gave maximum effect 
(lpM  versus IOjiM, **P<0.01). A concentration o f lOOfiM was found to have a reduced effect, most 
likely due to toxicity. B) Inhibition by indomethacin over a concentration range. No significant difference 
was found between the effects o f 1, 5 and lOfiM indomethacin, therefore 5pM was chosen for 
experimental testing. (n=4 in all cases).
4.3.3 Downstream Mechanisms in Endothelial Denuded and Intact 
Vessels
To investigate the role of the endothelium in the downstream mechanisms of 
nitrite-induced vasodilatation, both endothelium-intact and -denuded vessels were 
assessed. Nitrite consistently induced significant relaxation in hypoxic blood vessels, 
regardless of the presence or absence of endothelium (Figures 4.4A and 4.6A). It should 
be noted that the time-course of this relaxation is minutes rather than seconds as is seen 
with more potent nitric oxide donors, native nitric oxide or RBC-induced hypoxic 
vasodilatations (see Chapter 5).
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4.3.3.1 Endothelium Denuded Vessels
In vessels that are denuded o f endothelium, ODQ (lOpM) blockade of soluble 
guanylate cyclase completely inhibited the nitrite induced relaxation (PO.OOOl, 
comparison of entire profile versus appropriate control) (Figure 4.4C). This result was 
unaffected by the addition indomethacin (5pM) (PO.OOOl, comparison of entire profile 
versus appropriate control) (Figure 4.4D). Incubation with indomethacin alone had no 
inhibitory effect upon the nitrite-induced vasodilatation (Figure 4.4B).
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Figure 4.4. 20 minute relaxation profiles o f  endothelium denuded aortic rings. A) Nitrite (lOfiM) produces 
a marked relaxation compared to control (***P<0.001). B) No inhibition o f nitrite induced relaxation by 
Indomethacin (5pM). C) Complete inhibition o f nitrite induced relaxation by ODQ (lOpM) (***P<0.001) 
compared to Nitrite alone. D) Complete inhibition o f  nitrite induced relaxation by indomethacin (5pM) 
and ODQ (lOpM) in combination (***P<0.001) compared to Nitrite alone. (n=5 in all cases).
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To simplfy comparisons between groups, the twenty minute time point was chosen, with 
maximum response to nitrite typically occurring within this time. A comparison at the 
twenty minute time point in endothelium denuded vessels (Figure 4.5) confirms the 
findings observed over the entire relaxation profile, with ODQ incubation completely 
inhibiting the response to nitrite.
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Figure 4.5. Maximum relaxation induced by nitrite at the 20 minute time point in endothelium denuded 
aortic rings. Nitrite produces a marked relaxation compared to control (***P<0.001) which is completely 
inhibited ODQ (lOpM) (***P<0.001) compared to Nitrite alone. Indomethacin produced no inhibition in 
denuded vessels. (n=5 in all cases).
- 1 5 4 -
iu mu lit  i^ igu it 11 u it p iu iiita  u i vasuuiicuauuii aic muuicu 111 m u it uciaii, &um<
interesting dynamics can be observed. The inhibition by ODQ appears to be havinj 
maximum effect during the first six minutes, before gradually declining (Figure 4.6C) 
Conversely, inhibition by indomethacin appears to be continual throughout (Figun 
4.6B). Regardless o f these dynamics, when used in combination, the two agents produc< 
complete inhibition throughout (Figure 4.6D).
Interestingly, the use o f COX inhibition in combination with a nitric oxid 
scavenger also completely inhibited the response (Figure 4.8). Utilising a prostacyclii 
synthase inhibitor (PGISi) (that in itself altered baseline tension) we were able t  
demonstrate that prostacyclin was not responsible for the COX-mediated effects (Figur 
4.8).
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Figure 4.6. 20 minute relaxation profiles of endothelium intact aortic rings. A) Nitrite (lOpM) produces a 
marked relaxation compared to control (***P<0.001). B) Partial inhibition o f nitrite induced relaxation by 
Indomethacin (5pM). (***P<0.001) significantly different from nitrite alone over the course of the profile 
C) Substantial inhibition o f nitrite induced relaxation by ODQ (lOpM) (***P<0.001) compared to nitrite 
alone. D) Complete inhibition o f nitrite induced relaxation by indomethacin (5|iM) and ODQ (10p.M) in 
combination (***P<0.001) compared to Nitrite alone. ODQ relaxation is significantly different from 
indomethacin and ODQ in combination (PO.OOl). (n=5 in all cases).
At the twenty minute time point, nitrite-induced relaxation is partially inhibited by 
indomethacin, although the result is not significant (Figure 4.7). ODQ does produce a 
significant inhibition (PO.OOl). However, it does not generate the complete inhibition 
seen in endothelium-denuded vessels (Figure 4.5). When both ODQ and indomethacin 
are used in combination, a complete inhibition of nitrite-induced vasodilatation is 
observed after twenty minutes.
- 1 5 6 -
Chapter Four Nitrite Induced Vasorelaxation
100-
^  ^
? *  „ *  „*/  ^ ,*
o f  f
S
Figure 4.7. Maximum relaxation induced by nitrite (lOfiM) at the 20 minute time point in endothelium 
intact aortic rings. Nitrite produces a marked relaxation compared to control (***P<0.001) which is 
inhibited in part by both indomethacin (5pM) and ODQ (IOjiM) (P<0.01) respectively and completely 
inhibited by indomethacin (5fiM) and ODQ (lOpM) in combination (***P<0.001) compared to Nitrite 
alone. (n=5 in all cases).
4.3.3.3 Nitric Oxide Dependency and Sources of Nitrite Reduction
In light o f previous research, it is likely that nitric oxide could represent a 
significant intermediate in the downstream actions o f nitrite. Utilising a nitric oxide 
specific scavenger, (CPTIO), the relative contribution o f nitric oxide was assessed. In 
endothelium intact vessels, the actions o f nitrite did not appear to be solely dependent 
upon its reduction back to nitric oxide, incubation with CPTIO was capable of 
abolishing the nitrite-induced vascular response in part, but not completely (Figure 4.8). 
Interestingly, inhibition o f soluble guanylate cyclase in combination with a nitric oxide 
specific scavenger was capable o f increased inhibition compared to the individual agents 
alone, but was not able to produce a full inhibition (Figure 4.8).
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Given that nitric oxide clearly plays a significant role in the mechanism of 
nitrite-induced vasorelaxation, sources of nitrite reduction were examined. Three tissue 
based enzymes, xanthine oxidase, aldehyde oxidase and nitric oxide synthase were 
considered, using specific pharmacological inhibitors. Aldehyde oxidase was found to 
be responsible for a significant amount of nitrite reduction, while inhibition of xanthine 
oxidase and nitric oxide synthase fail to have an effect (Figure 4.8). Interestingly, L- 
NMMA did not appear to alter the basal hypoxia induced relaxation in control tissue 
(data not shown).
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Figure 4.8. % inhibition o f nitrite vasorelaxation in endothelial intact vessels. Inhibitor concentrations 
used, ODQ 10(iM, CPTIO ImM, Raloxifene 50nM, Oxypurinol lOOpM, PGI synthase inhibitor lOpM, L- 
NMMA 300pM. (n=4 or 5).
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4.3.4 The Effect of Acute Hypoxia/Nitrite Exposure upon Gene Expression
To investigate the wider actions o f nitrite in the acute exposure setting, the effect o f 
nitrite upon the expression o f specific genes was assessed in normoxia and hypoxia. A 
thirty minute exposure to hypoxia increased relative expression levels of both HIF-1 a  
and COX-2 (P<0.001) (Figure 4.9A and B). The expression of COX-2 was inhibited by 
nitrite in both normoxia and hypoxia, however, the study was not powered to confirm 
this statistically. The acute exposure to nitrite and a change in oxygen level did not alter 
the expression o f endothelial nitric oxide synthase (Figure 4.9C).
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Figure 4.9. The effect o f acute nitrite exposure upon specific gene expression. A) HIF-1 a  expression 
levels, exposure to hypoxia increases expression o f HIF-1 a , however the increase is not statistically 
significant. B) COX-2 expression levels, exposure to hypoxia significantly increased expression of COX- 
2 in the hypoxic control group (PO.OOl versus normoxia nitrite and normoxia control groups) but not in 
the hypoxia nitrite group. C) eNOS expression levels, no significant changes in expression between 
groups. n=4 in all cases.
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4.4 Discussion
Nitrite is capable o f exerting direct vasodilatory effects that are enhanced in the 
hypoxic vessel setting. An enhancement in activity of other nitric oxide donors under 
hypoxic conditions has previously been reported [91], however the mechanism behind 
the observed difference is unknown. It is possible that soluble guanylate cyclase (sGC) 
is more responsive to the same nitric oxide stimulus in hypoxia or that down stream 
signalling is perhaps more sensitive. In this respect, an experiment involving the 
measurement o f cGMP production over a range o f oxygen tensions after stimulation 
with known sGC activators could provide important information. The increased activity 
o f nitrite in hypoxia represents an interesting and potentially exploitable aspect o f its 
pharmacology, consequently, insight into the mechanistic background o f this 
pharmacology is therefore o f great value.
It has long been assumed that the vascular actions o f nitrite in hypoxia were 
reliant upon the formation o f nitric oxide as an intermediate, with stimulation o f the 
classic downstream pathways. This chapter is the first to provide evidence that nitrite 
(under hypoxic conditions at physiological pH) is also capable o f exerting physiological 
effects independently o f a free nitric oxide intermediate and via the operation o f multiple 
signalling pathways.
4.4.1 Component Pathways
The signalling pathways that are stimulated by nitrite in hypoxic vessels appear 
to be dependent upon the cell types present in the vessel. In endothelium denuded 
vessels, the actions o f nitrite are largely, if not completely mediated via a mechanism 
involving sGC. In contrast, despite the same level o f overall vasodilatory response to 
nitrite, the actions of nitrite in endothelium intact vessels are mediated via multiple 
pathways. In these vessels, nitrite at a pharmacological concentration operates via two 
distinct pathways, one controlled by nitric oxide/sGC and the other through COX,
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although the effect appears to be predominantly signalled through the former. Figure 
4.10 depicts a summary o f the potential signalling mechanisms involved.
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Figure 4.10. Potential pathways that control the nitrite mediated relaxation of hypoxic vessels. Upper 
section of diagram depicts denuded tissue where sGC appears to predominantly control relaxation. Lower 
section of diagram attempts to show possible pathways in endothelium intact vessels.
Having found that the COX pathway appears to operate independently o f nitric 
oxide as an intermediate, this interesting aspect o f the signalling was investigated 
further. COX is known to be essential for the generation o f prostacyclin, a key COX 
product responsible for vasodilatation in the control o f vessel tone (see section 1.7.2.4, 
page 38). To explore the relative contribution o f  prostacyclin as opposed other COX- 
derived eicosanoids, prostacyclin synthase, which occurs distally to COX in the 
prostaglandin biosynthetic pathway, was inhibited using a specific agent. Inhibition o f
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prostacyclin synthase did alter the vessel baseline tension, but failed to show an effect 
upon the nitrite-induced hypoxic vasodilatation. This suggests either a possible role for 
other COX-derived eicosanoids such as PGE2, also known to cause vasodilatation [410] 
or an enzymatic function o f COX, possible involving the haem component o f the 
enzyme, which could convert nitrite to an alterative bioactive nitrogen species. In 
relation, endothelial COX has been demonstrated to be capable o f free radical species 
generation under hypoxic conditions [411]. Given that some COX products are 
vasoconstrictors, it is also possible that nitrite may have a negative effect upon COX 
that could cause an inhibition o f constriction, as opposed to an enhancement o f 
relaxation. Previous studies that have investigated nitrite vasodilatation have failed to 
recognize these differential signalling pathways, principally due to the pre-incubation o f 
tissue with indomethacin and nitric oxide synthase inhibitors [396].
Although the nitrite-induced vasodilatation requires twenty minutes to reach 
completion, it is interesting to note the differences in profile between inhibition o f sGC 
and COX over the full time course. The inhibition o f COX by indomethacin appears to 
be uniform throughout the profile, whereas sGC inhibition (with ODQ) is appreciable in 
the first part o f the profile, but appears to tail o ff over the twenty minute period. It is 
possible that a sGC mediated mechanism takes precedence during the initial part o f the 
nitrite response, especially given the longevity o f nitric oxide which is most likely the 
source o f activation. The constant inhibition produced by COX inhibition is more 
suggestive o f nitrite having a negative effect upon constriction as opposed to a positive 
effect upon relaxation. It would seem that these pathways could be mutually exclusive, 
however crosstalk between them cannot be ruled out. It has been demonstrated that 
nitric oxide can regulate COX, both increasing activity via a cGMP independent 
mechanism [170] or inhibiting activity. The effect o f nitric oxide upon COX is also 
thought to be dependent upon the COX isoform in question, i.e. differential effects are 
observed with COX-1 compared to COX-2 [412]. In terms o f these two nitrite 
stimulated pathways, it is important to remember that inhibition o f one may simply 
cause up-regulation o f another, making the relative contribution o f each difficult to 
estimate. This difference in profile also reinforces the idea that nitrite may operate via
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pathways that are separate both physically and with respect to time. However, 
irrespective o f the different inhibition profiles, the combination o f sGC and COX 
inhibition abolished the response to nitrite throughout the entire profile.
4.4.2 Nitric Oxide Dependency
Inhibition o f sGC or nitric oxide scavenging (using CPTIO), individually or in 
combination, was not able to abolish the vascular response to nitrite in hypoxia. 
However, the combination o f the two agents was additive, but the results did display 
more variability when compared to other agents. CPTIO is a competitive nitric oxide 
scavenger, therefore it is possible that some o f the nitric oxide generated may not be 
scavenged. This nitric oxide does not appear to be acting through sGC and would need 
to be generated in very close proximity to the enzyme it activates. This idea could fit a 
model in which an enzyme acts as a source o f nitrite reduction and is simultaneously 
stimulated by the generated nitric oxide. This mechanism could be operational in the 
case o f COX, for example, where the haem group o f the enzyme could both reduce 
nitrite and bind nitric oxide. It has been suggested that nitrite may be capable o f 
generating species such as nitrosylated products without the requirement for free nitric 
oxide as an intermediate [393]. It is possible that these products may be responsible, in 
part, for the actions of nitrite in the ex vivo tissue model o f this chapter, interestingly, the 
data would suggest that these products operate through or are generated by a COX 
mediated mechanism.
4.4.3 Sources of NO2' Reduction
In spite o f the presence o f different mechanistic pathways, nitric oxide is the 
signalling intermediate that appears to be largely responsible for the vascular actions o f 
nitrite. Nitrite must be reduced to produce nitrite oxide and this process can occur via 
several routes in a biological setting, most notably via enzymatic reduction. 
Haemoglobin has been touted as an important nitrite reductase in the in vivo setting (see 
section 1 . 1 0 . 2  (page 6 8 ) and chapter 6 ), however the current chapter is concerned with
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the direct actions o f nitrite in vascular tissue and those mechanisms that are independent 
o f haemoglobin.
The importance o f tissue-based oxidoreductase enzymes in the vascular actions 
o f nitrite has recently become apparent, with both xanthine oxidase and aldehyde 
oxidase being identified as key reductive enzymes [397]. For normal function, these 
oxidoreductase enzymes rely upon the presence o f oxygen. In hypoxia, these enzymes 
are capable of reducing alternative substrates such as nitrite [397]. The results o f this 
chapter confirm the involvement o f aldehyde oxidase in nitrite-induced hypoxic 
vasodilatation, but fail to show a dependence upon xanthine oxidase. This is in 
agreement with published reports, showing a more significant role for aldehyde oxidase 
in nitrite reduction to nitric oxide at a tissue level [397]. However, a reductase role for 
xanthine oxidase cannot be completely discounted because although oxypurinol blocks 
the molybdenum site, the flavin site o f the enzyme remains free and could be 
functionally active [413]. Other studies have suggested that endothelial nitric oxide 
synthase may also function as a reductase [398], however, the results o f this chapter do 
not demonstrate a role for the enzyme in nitrite reduction. As is potentially the case with 
COX, it is possible that sGC may be acting as both a nitrite reductase and be stimulated 
by the subsequently produced nitric oxide. In respect to this point Alzawahra et al have 
shown that ODQ prevents the reduction o f nitrite in vascular tissue, suggesting that sGC 
could behave as a potential reductase [400].
4.4.4 Vascular Gene Expression
In addition to its effects as a vasodilator, the results o f this chapter demonstrate that 
nitrite has additional biological effects at the gene expression level. When aortic tissue 
was acutely exposed to hypoxia, the expected increase in H IF -la  expression level was 
observed (see section 1.2.1.4, page 5). However, the result did not reach statistical 
significance, which, could be attributable to the short hypoxic exposure time and the 
requirement for repeated testing. Interestingly, hypoxic exposure also resulted in a 
significant increase in COX-2 expression, which was blunted by the simultaneous
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exposure to nitrite. However, because the study was under powered the effect o f nitrite 
was not found to be significantly different. Nitrite was also able to cause a degree o f 
inhibition on COX-2 expression under normoxic conditions, supporting the result 
observed in hypoxia.
Hypoxic exposure has previously been demonstrated to increase the expression 
o f COX-2 in arterial smooth muscle cells [414]. Although, the effects o f nitrite upon 
COX-2 expression have not previously been studied, studies with nitric oxide suggest 
that nitric oxide augments, rather than inhibits COX-2 expression [415]. This would 
suggest that the inhibitory effects o f  nitrite upon COX-2 expression observed here do 
not operate via a nitric oxide intermediate or that the aortic tissue utilised in this chapter 
responds differently to those previously studied. The majority o f studies have focussed 
on gene regulation in inflammatory cells, rather than vascular cells, which are stimulated 
with nitric oxide at considerably higher concentrations than those that could be achieved 
with the concentration o f nitrite used here. It is therefore possible that the effects of 
acute, lower nitrite concentrations on certain gene expression, may differ from those 
seen when relatively higher concentration o f nitric oxide donors are utilised.
COX-2 is generally thought to be involved in processes that are pro- 
inflammatory [416]. The results presented here would suggest that nitrite could be 
acting as an anti-inflammatory agent in the hypoxic vasculature. This effect o f nitrite 
would complement its actions as a vasodilator and anti-platelet agent [417], thereby 
enhancing its actions as an anti-inflammatory agent.
The final gene studied was endothelial nitric oxide synthase (eNOS). The thirty 
minute exposure to both hypoxia and/or nitrite did not significantly alter expression 
levels within aortic tissue measured. Previous studies have found that hypoxic exposure 
can increase eNOS mRNA expression in human umbilical vein endothelial cells 
(HUVECs). However, the hypoxic stimulus utilised was more chronic [418] than the 
one used here. It should also be remembered that the tissue sampled in the current model
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was taken from the complete vessel and therefore, contained both smooth muscle and 
endothelial cells, with the former being the most abundant tissue present.
It is possible that nitrite may have the potential to protect hypoxic tissue areas 
via a number o f mechanisms, above and beyond a simple increase in blood flow. 
Although the changes observed in gene expression are unlikely to have significant 
effects at a protein level during this acute exposure, the results o f this study do suggest 
that even a short term exposure to increased nitrite levels, particularly in hypoxia, could 
impact upon the vasculature in the long term.
4.4.5 Implications for in vivo Conditions
The findings o f this chapter are directly applicable to conditions in which plasma 
nitrite is elevated pharmacologically or by diet. A common misconception in the 
literature is the extrapolation from studies that are performed by infusing nitrite at 
elevated doses to nitrite as a circulating store o f  nitric oxide under basal physiological 
conditions (200-400 nM nitrite). It must be recognised, therefore, that the component 
mechanisms o f nitrite-induced relaxation at higher doses may not be operational at 
normal levels, and this is difficult to confirm in vitro and in vivo largely because o f 
assay limitations. Given the interest in nitrite as a therapeutic agent, the mechanistic 
findings o f this chapter are o f importance. The experimental model utilised is 
haemoglobin independent and demonstrates that nitrite alone directly induces vessel 
relaxation. However, these results cannot discount a role for deoxyhaemoglobin in vivo; 
indeed, it is possible that blood-borne nitric oxide species derived from nitrite during an 
infusion could contribute to the modulation o f long-term vessel tone [310].
Although a relatively weak vasodilator compared to pharmacological 
nitrodilators, the fact that nitrite clearly dilates hypoxic vessels preferentially implies it 
could act as a targeted vasodilator without causing global changes in haemodynamics 
(e.g. the fall in blood pressure seen with nitrodilators). The results o f this chapter 
provide novel findings regarding the vasodilator mechanisms o f nitrite that now need to
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be confirmed in vivo following nitrite infusion. It is clear that nitrite has the potential to 
alter vessel tone, however the fact that it can also alter signalling at a genetic level after 
an acute exposure suggests it may have the potential to impact on the overall health o f 
the vessel in addition to affecting vascular tone.
- 168-
Chapter Four Nitrite Induced Vasorelaxation
4.5 Summary and Conclusions
The results o f this chapter demonstrate that nitrite has a varied and complex 
pharmacology, with the ability to influence vascular physiology via different 
mechanisms and within different time frames. The effects o f nitrite are clearly oxygen 
dependent, hypoxia appears to increase both the activation o f nitrite but also the 
sensitivity o f vascular tissue to the nitrite derived products that are formed. Specifically 
this chapter has demonstrated that:
•  The vasodilatory properties o f nitrite are enhanced in hypoxic vascular tissue
• Nitrite-mediated relaxation proceeds via different mechanisms depending upon 
the presence or absence of endothelium. In denuded vessels, a soluble guanylate 
cyclase-mediated mechanism prevails, while in intact vessels this mechanism is 
complemented by an alternative mechanism operating via cyclooxygenase.
•  The actions o f nitrite are in part mediated via a nitric oxide intermediate. To 
form nitric oxide, nitrite must be reduced and the current model would suggest 
that the enzyme, aldehyde oxidase is primarily responsible.
•  An acute exposure to hypoxia is capable of altering gene expression. 
Specifically, nitrite has the potential to able to inhibit the hypoxia induced 
increase in COX-2 expression but requires further investigation.
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5 Erythrocyte Induced Vasorelaxation: the Influence of 
Oxygen
5.1 Introduction
The phenomenon of whole erythrocytes producing vasorelaxation under hypoxic 
conditions represents an interesting field o f research that has been investigated for a 
number o f years, but the vasorelaxant species and mechanism behind its actions are yet 
to be confirmed. Over this time, a number o f different mechanistic theories to explain 
this phenomenon have been published and the area still represents a matter o f 
contention. A background to the three most prominent suggestions and current 
understanding will be covered below.
5.1.1 The HbSNO Theory
The Stamler group had previously demonstrated the vasoactive properties o f 
nitric oxide groups attached to proteins via cysteine residues e.g. albumin-SNO [266, 
324]. The freely reactive nature o f the cysteine residue in the 93 position o f the 13- 
haemoglobin chain (not compromised by steric hindrance) and the fact that its reactivity 
was modulated by haemoglobin allostery had been known for nearly 5 decades [330, 
419]. However, it was not until 1996 that the Stamler laboratory suggested that nitric 
oxide bound to the p93 cysteine residue of haemoglobin may act as a functional 
regulator of vessel tone and oxygen delivery [325]. The finding that arterial to venous 
gradients in HbSNO and HbNO levels existed, gave rise to a novel mechanism for 
HbSNO cycling [332]. Stamler et al proposed that nitric oxide that reacted with partially 
oxygenated haemoglobin (forming HbNO) in the venous circuit was displaced upon re­
oxygenation in the lung where it was likely to react with proximity thiols, forming 
HbSNO. In the tissue, the reverse process is thought to occur, as haemoglobin is 
deoxygenated, nitric oxide from HbSNO (thought to be less stable on T-state 
haemoglobin [420]) is released. The released nitric oxide is believed to leave the
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erythrocyte through a series o f transnitrosation reactions, passing from one protein to 
another, AE1 is thought to represent the principal protein involved [331]. AE1 contains 
available cysteine residues and is located perfectly in the membrane to interact with 
extracellular proteins and with haemoglobin through an intracellular binding site. Given 
that deoxyhaemoglobin is know to preferentially bind AE1 [387] it suggests that nitric 
oxide from HbSNO could transnitrosate residues o f AE1 upon deoxygenation. This 
transfer method would protect nitric oxide from being re-captured by haemoglobin, 
allowing it to not only leave that individual erythrocyte but to also preserve nitric oxide 
bioactivity in blood. In support o f  this mechanism, a number o f publications have shown 
extracellular thiols to potentiate erythrocyte induced relaxation [325, 421]. In addition, 
the Doctor laboratory have also demonstrated that when isolated erythrocytes are 
deoxygenated in the presence o f extracellular N-acetylcysteine (NAC), NAC-SNO 
levels increase in proportion to desaturation [422].
In contrast, there is also evidence which disputes a role for HbSNO in 
erythrocyte-mediated vasorelaxation. The first publication relates to the formation of 
HbSNO, suggesting that oxygenation o f partially nitrosylated haemoglobin (HbNO) 
does not alter HbNO levels and so cannot be forming HbSNO [423]. However, this data 
only disagrees with the HbSNO cycle theory and does not exclude a role for HbSNO in 
the regulation o f vascular tone. Perhaps the most significant evidence to date was that 
published by the Patel laboratory using a p-cysteine 93 amino acid substituted mouse 
model [424]. The data demonstrate that erythrocytes from mice producing human 
haemoglobin with the P-cysteine 93 substituted for an alanine residue can still induce a 
hypoxic vasodilatation. This publication also shows that the vasorelaxant response to 
erythrocytes, both native and alanine mutants, can be inhibited with L-NMMA (eNOS 
inhibitor). However, there are a number o f caveats to this work. Despite substitution of 
the P-cysteine 93 residue, the overall erythrocyte SNO content remained unchanged, 
suggesting that other nitrosothiols (e.g. GSNO or membrane RSNOs) could still be 
responsible for the observed vasoactivity. The investigators also utilise an exercise stress 
test to investigate their mouse model. In this respect it should be appreciated that 
exercise per se is not a model o f hypoxia, in exercise the increased oxygen demand of
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Although, the relationship between HbSNO content and haemoglob 
conformation [363] and the necessity o f low tissue oxygenation for erythrocy 
vasodilatation [331] have been shown, the role o f haemoglobin conformation in tl 
release o f a vasoactive moiety has not been fully explored.
5.1.2 The Haemoglobin Nitrite Reduction Theory
The second proposed mechanism involves the reduction of nitrite b 
haemoglobin under hypoxic conditions. There have been a number of publications 
this area, largely from the Gladwin and Patel laboratories [337, 342, 426], all of whic 
essentially propose the same mechanism. Early publications demonstrate that tl 
relaxant properties o f nitrite are enhanced in the presence of erythrocytes < 
haemoglobin and that deoxygenation o f haemoglobin enhances its ability to reduc 
nitrite to free nitric oxide [337]. However, the demonstration o f enhanced relaxation b 
erythrocytes and nitrite in combination, reported in the original work by Cosby et al, 
yet to be repeated. As time has passed, more recent research papers from this grou 
paint a slightly different picture. Firstly, published results do not show an enhancemei 
by haemoglobin but rather a lack o f inhibition (haemoglobin usually scavenging nitri 
oxide to inhibit relaxation rather than augmenting it), with relaxation identical und< 
hypoxia regardless o f the presence o f haemoglobin [426]. Secondly, later publicatior 
have completely shifted the focus away from in vitro vessel work and have been largel 
based around speculative in vivo mechanisms, where haemoglobin is thought to a< 
maximally as a nitrite reductase around the p50 of haemoglobin, see section 1.10. 
(page 68). As a suggested mechanism o f erythrocyte-induced hypoxic relaxation, th 
nitrite reduction theory remains heavily questioned, especially given that nitrite-derive
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relaxations occur over a much longer time frame than the transient relaxation observed 
from native erythrocytes (minutes vs. seconds) and th a t  free nitric oxide is unlikely to 
escape re-capture by haemoglobin [343]. Several m echanism s for the escape of free 
nitric oxide (produced from haemoglobin nitrite reduction) from the erythrocyte have 
been put forward, including the suggestion that intermediates such as dinitrogen trioxide 
(N2O3) could form SNO compounds [424, 427] or as a  result o f changes in haemoglobin 
reactivity/membrane association [428].
One idea that has linked elements o f this hypothesis to the HbSNO hypothesis is 
the observation that haemoglobin can act as an H bSN O  synthase, utilising nitrite as a 
substrate [310]. However, although it is feasible that th is  may occur in the circulation 
where haemoglobin allostery is constantly changing, it is  unlikely to work in an isolated 
system and still ultimately suggests that an SNO is responsible.
5.1.3 The Adenosine Triphosphate Theory
The final mechanism is one that involves adenosine triphosphate (ATP) and, 
despite receiving less attention than the previously described mechanisms, is the longest 
standing of the three. It was initially shown by B ergfeld  and Forrester that, under 
hypoxia/hypercapnia, erythrocytes would release A TP [429]. Dietrich et al developed 
this observation into a mechanism in which erythrocytes are thought to act as oxygen 
sensors and affect vessel tone to meet oxygen dem and [430]. It is believed that when 
erythrocytes encounter an area o f low oxygen, they o f f  load both oxygen and ATP. The 
ATP is then thought to stimulate P2Y receptors on th e  endothelium and stimulate the 
production o f nitric oxide and prostacyclin [431]. The theory  has been tested in isolated 
vessel perfusion models, where it was found that w h en  erythrocytes were introduced 
into hypoxic vessels, both changes in vessel d iam eter and increases in ATP were 
observed [432, 433].
While it is plausible that this mechanism co u ld  play a role in vivo, there is 
evidence that does not support it as a mechanism o f  erythrocyte-induced hypoxic
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vasodilatation. Principally, it would seem that this mechanism is reliant upon the 
endothelium to produce vasorelaxant substances and the erythrocyte mediated 
vasodilatation is known to proceed in the absence of endothelium/nitric oxide synthase 
[421].
5.1.4 Current Understanding
Although the exact identity o f the vasorelaxant released from erythrocytes and 
the mechanism by which it is released remain to be elucidated, there are a number of 
known observations (many published from our laboratory) that should be considered 
with respect to the results o f this chapter. They are:
• Low tissue oxygenation appears to be essential for erythrocyte induced 
vasorelaxation [331].
•  Erythrocyte addition to hypoxic tissue produces a transient relaxation that is 
followed by a constriction [91].
• The mechanism o f vasorelaxation is mediated via soluble guanylate cyclase and 
is inhibited by ODQ [91, 421].
• The vasodilatation mechanism is independent of both the endothelium and nitric 
oxide synthases, demonstrated by denudation and the use of L-NMMA/genetic 
elimination [91, 421].
• The vasorelaxant response o f erythrocytes from diabetic patients is impaired, 
most likely due to haemoglobin glycation [91].
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5.1.5 Aims
The true identity o f the vasorelaxant released from erythrocytes remains unknown, 
however, investigating the mechanisms which govern its movement and release could be 
essential in identifying the molecule responsible. The work of this chapter was 
undertaken to perform these investigations and specifically aimed to:
• Assess the haemoglobin allostery dependence of the erythrocyte mediated 
hypoxic vasorelaxation.
• Gain understanding with regard to the transport and consumption of the relaxant 
entity.
• Consider novel vasorelaxant species that may be responsible.
• Provide evidence that may aid in identifying the exact nature of the relaxant 
entity.
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5.2 Specific Protocols
5.2.1 Myography
The myography system was set up daily as per section 2.5 (page 104). All 
erythrocyte experiments were carried out under the hypoxic protocol at ~1% oxygen 
(see section 2.5.2, page 105). To induce relaxation, 20pl of prepared erythrocytes were 
injected into the bath at peak constriction using gel loading pipette tips for efficient 
delivery.
5.2.2 Blood Preparation
For all protocols, fresh blood samples were collected by venepucture of the 
antecubital vein from healthy subjects immediately prior to requirement. Samples were 
centrifuged (1200g, 5mins, 4°C) and the plasma and buffy coat were removed as per 
section 2.1 (page 80).
5.2.3 Erythrocyte Manipulation
Erythrocytes were diluted (approx. 1 in 10 to give 3g/dL haemoglobin) in 
isotonic saline (0.9% w/v, Fresenius Kabi) before loading into the thin film rotating 
tonometer (Section 2.2, page 81). Different gas mixtures were then utilised to obtain 
samples over a range o f haemoglobin oxygen saturations for subsequent testing. A sub 
group of samples were subjected to oxygen cycling to assess the effect o f repeat 
oxygenation on relaxation (protocol shown in Figure 5.1). To identify whether the 
vasorelaxant moiety was simply passed between the erythrocyte and the extracellular 
milieu upon de-oxygenation and re-oxygenation, erythrocyte samples taken to low 
saturation had the extracellular milieu removed prior to re-oxygenation by repeated 
washing with fresh oxygenated saline, saturation and haemoglobin content were then 
reconfirmed (Figure 5.1). All blood gas analysis was carried out using a blood gas
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analyser (OSM 3 Hemoximer, Radiometer, Copenhagen). All samples underwent a final 
centrifugation step to remove saline before addition to the tissue bath.
Gassed with 
95% 0 2
R BC sin
solution
Gassed with 
95% No
Gassed with 
95% 0 2
- 100%
Saturated,
Sample
taken
- 20%
Saturated,
Samples
taken
RBCs washed 
in oxygenated 
saline
-100%  saturated, 
re-oxygenated 
sample
-100%  saturated, 
washed and re­
oxygenated sample
Figure 5.1. A schematic representation o f erythrocyte haemoglobin oxygen saturation cycling and the 
samples generated for vasoactivity assessment.
5.2.4 2,3-DPG
2,3-Diphosphoglycerate (2,3-DPG or 2,3-BPG) is an organic phosphate 
intermediate formed during glycolysis. The intraerythrocytic 2,3-DPG concentration is 
approximately equal to the molar concentration o f  tetrameric haemoglobin (5mM)[83], 
although the amount o f free 2,3-DPG is dependent on haemoglobin saturation and can 
fall as low as 0.5mM in deoxygenated erythrocytes [84]. To assess the effect o f 2,3- 
DPG on the erythrocyte mediated hypoxic dilatation, 2,3-DPG was added to the bath 
(prior to commencing the hypoxic protocol) at a final concentration of 20pM, equimolar 
to the final haemoglobin concentration upon erythrocyte addition to the bath (average 
haemoglobin concentration =32.73g/dl ± 0.79 equivalent to 20.2pM haemoglobin in 
bath concentration), mimicking the in vivo ratio. In contrast to previous experiments, the 
erythrocyte samples were lysed before addition to allow 2,3-DPG to interact with the 
haemoglobin (confirmed by centrifugation). All erythrocyte samples were adjusted to 
-100%  haemoglobin saturation before addition to the bath.
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5.2.5 Carbon Monoxide
An initial assessment o f the vasorelaxant properties o f carbon monoxide (CO) in 
hypoxia and normoxia was made using the carbon monoxide releasing molecule, 
CORM-A1 (Na2[H3BC02], 11/2 = 21 minutes, [434]), a kind gift from Dr Roberto 
Motterlini, Northwick Park Institute for Medical Research, London. CORM-A1 was 
added to the appropriate tissue baths (not in the presence o f erythrocytes) at a final 
concentration o f 1 OOpM, although this concentration appears relatively high, it 
compensates for CORM-A1 being a relatively slow CO releasing molecule. Maximum 
relaxation in this experiment was recorded at the 5 minute time point.
To investigate the role o f carboxyhaemoglobin (HbCO), erythrocytes were 
loaded into the thin film rotation tonometer as previously described (section 2.2, page 
81), deoxygenated to desired level and exposed to a 90% carbon monoxide gas mixture 
to achieve a range o f haemoglobin carbon monoxide saturation levels. Vasoreactivity of 
erythrocyte samples was then evaluated as per section 5.2.1 (page 176).
5.2.6 Oxygen
In addition to nitric oxide and carbon monoxide, oxygen is also a diatomic gas 
that could interact in a similar way with tissue and can also be bound to haemoglobin in 
abundance. To test the actions o f oxygen independently o f haemoglobin upon hypoxic 
vascular rings, aliquots o f saline (0.9% w/v) containing different concentrations of 
oxygen were introduced to pre-constricted hypoxic tissue rings (see section 2.5.2, page 
105). Saline was gassed for 30 minutes with 95% oxygen, 21% oxygen (equivalent to 
atmospheric levels) or nitrogen to produce three different oxygen content samples. 
lOOpl o f each sample was introduced to separate tissue baths, an increased volume was 
used to attempt to adjust the amount o f oxygen added to the bath to within the range of 
to that contained within a 20pl sample o f erythrocytes. To assess potential pathways 
involved, a subsection o f tissue was pre-incubated with ODQ (lOpM final) to inhibit 
soluble guanylate cyclase before the addition o f 1 OOpl saline gassed with 95% oxygen.
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5.2.7 Analysis and Statistical Analysis
Erythrocyte-induced relaxation was calculated by taking the actual maximum 
relaxation and expressing it as a percentage of the maximum phenylephrine induced 
constriction (Figure 5.2). Similarly, erythrocyte induced constriction was calculated by 
taking the actual maximum constriction (with respect to the maximum phenylephrine 
induced constriction) and expressing it as a percentage of the maximum phenylephrine 
induced constriction (Figure 5.2).
Testing between groups was performed using either the student t-test (either 
paired or unpaired where appropriate) or an analysis of variance (ANOVA) with an 
appropriate post hoc test. To assess correlations, the Pearson’s correlation coefficient 
was used. Data are presented as means and error bars represent the standard error of the 
mean (SEM). A P value of less than 0.05 was taken to be significant, individual 
significance levels are indicated within the figure legends. Generally, n=l represents 
data averaged from a matched pair of aortic rings.
Phenylephrine Erythrocyte
Addition Addition
to ­
ot
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Time (minute*)
24 00
Figure 5.2. A representative raw trace of erythrocyte induced vasorelaxation after erythrocyte addition to 
pre-constricted hypoxic tissue. Significant time points and tension changes are appropriately marked.
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5.3 Results
5.3.1 The Effect of Haemoglobin Allostery on Erythrocyte Induced
Vasorelaxation
To establish the dependency of the erythrocyte induced vasorelaxation upon 
haemoglobin allostery, the vasorelaxant properties of a number of erythrocyte samples 
with varying haemoglobin oxygen saturations were tested. Erythrocytes containing 
haemoglobin held in the R-state by oxygen bound to all haem groups (-100% HbC>2 , 
high saturation) elicited significantly more relaxation than partially oxygenated samples 
(a mixture of R and T-state haemoglobin) that were -50%  and -20%  saturated (low 
saturation) (Figure 5.3).
Figure 5.3. Comparison o f erythrocyte induced vasorelaxation produced by highly oxygen saturated 
erythrocytes (average saturation 98.22% ± 0.45, n=13), partially saturated erythrocytes (-50%  saturated) 
(average saturation 51.43% ± 6.16, n=4) and erythrocytes o f low oxygen saturation (average saturation 
20.40% ± 5.28, n=13). Both the -50%  saturated and low saturation erythrocytes elicited a significantly 
lower level o f relaxation than the highly saturated erythrocytes, **(P<0.01) and ***(P<0.001) 
respectively. Groups were compared by one way ANOVA with Bonferroni post hoc test.
14-1
13-
0-
High S atu ration  -5 0 %  Low Saturation
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When a range o f maximum erythrocyte induced relaxation data is correlated 
against the corresponding haemoglobin oxygen saturation, a positive linear relationship 
is observed (Figure 5.4). This observation directly links haemoglobin allostery 
(controlled by oxygen saturation in this case) to the maximum erythrocyte induced 
relaxation.
17. 5*1
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% Haemoglobin Oxygen Saturation
Figure 5.4. Correlation o f erythrocyte induced vasorelaxation vs. % erythrocyte haemoglobin oxygen 
saturation. A significant positive correlation (Pearson’s correlation coefficient r=0.82, p<0.0001) exists 
between the two variables. (n=30, R2= 0.66).
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5.3.2 The Effect of Haemoglobin Oxygen Saturation Cycling on the 
Erythrocyte Induced Relaxation
To ascertain whether or not the same erythrocyte sample could achieve repeat 
relaxations a preliminary experiment utilising fully oxygenated erythrocytes was 
performed (Figure 5.5). Erythrocytes were first added to one hypoxic bath to induce 
relaxation (oxygenated erythrocytes) then, because of the isotonic nature of the Krebs’ 
buffer these cells remained whole and so were recovered, re-oxygenated and introduced 
into a second bath to asses repeatability o f relaxation (repeat oxygenated erythrocytes). 
Although this preliminary work demonstrated that the same erythrocyte sample could 
perform repeat relaxations it was technically difficult to control so a tonometer based 
cycling protocol was developed to essentially achieve the conditions.
10.0-1
Figure 5.5. Preliminary experiment where erythrocytes were utilised to induce relaxation (oxygenated 
erythrocytes) before being recovered, re-oxygenated and used to perform a repeat relaxation (repeat 
oxygenated erythrocytes). n=2.
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The cycling of haemoglobin oxygenation (oxy to deoxy, thought to enhance 
vasorelaxant offloading, followed by a further deoxy to oxy cycle before addition to 
bath) using the tonometer protocol did alter the maximum relaxation (a mean relaxation 
of 12.00% ± 3.6 vs. 8.28% ± 2.3) induced by erythrocytes (Figure 5.6).
17.5-
15.0-
12.5-
10.0-6
£ 7.5-
5.0-
2.5-
0 .0-
Figure 5.6. The effect o f haemoglobin oxygenation cycling. Erythrocyte induced vasorelaxation produced 
by highly oxygen saturated red cells (average saturation 98.22% ± 0.45, n=15) compared to highly 
saturated red cells which were previously taken down to a deoxygenated saturation o f -  20% (20.68% ± 
1.66) before being re-oxygenated (average saturation 97.70% ± 0.39, n=5). No significant difference 
exists between the two groups.
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5.3.3 Potential Cross-Membrane Transfer of the Vasorelaxant
The ability o f the erythrocyte to produce repeated relaxation prompted the 
investigation of the movement or recycling of the vasorelaxant in and out of the cell. 
Deoxygenation could simply release the vasorelaxant out of the cell, which is 
subsequently taken back up upon re-oxygenation. To explore this potential mechanism, 
erythrocytes were deoxygenated to a low saturation upon which the extracellular milieu 
was removed before re-oxygenation in fresh saline. Erythrocytes that were 
deoxygenated, followed by removal of the extracellular milieu and re-oxygenation 
induced a mean relaxation o f 13.0% ± 1 . 9  compared to erythrocytes taken immediately 
at high saturation 12.0% ± 3 . 6  (Figure 5.7). The removal of the initial extracellular 
milieu and replenishment with fresh saline had no statistically significant effect on 
erythrocyte-induced vasorelaxation.
10.0-
Figure 5.7. Potential movement o f the vasorelaxant. Erythrocyte induced vasorelaxations produced by 
highly saturated red cells (average saturation 98.2% ± 0.5, n=13) compared to highly saturated red cells 
which were previously taken down to a deoxygenated saturation o f -  20% (22.4% ± 1.7) then centrifuged 
at 1200g before the extracellular solution was removed, erythrocytes were then washed 3 times in 
oxygenated saline to increase the haemoglobin oxygen saturation up to —100% (average saturation 
98.05% ± 0.65, n=4). No significant difference exists between the two groups.
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5.3.4 The Effect of 2,3-DPG
To further investigate the role of haemoglobin allostery in the erythrocyte 
induced vasorelaxation, the effect that the allosteric modulator 2,3-DPG had (see section 
1.4.2.4, page 18) upon maximum relaxation was considered. Because the access of 2,3- 
DPG to whole cells is limited, lysed erythrocyte samples had to be utilised. However, 
this did not appear to alter the ability of the sample to induce vasorelaxation. The 
addition of 2,3-DPG to the bath before erythrocyte addition significantly increased the 
maximum relaxation achieved when compared to the respective control group (Figure 
5.8).
2,3-DPG Control
Figure 5.8. The effect o f 2,3-DPG on the erythrocyte induced vasorelaxation. Lysed erythrocytes were 
added to either control baths or baths containing 20pM 2,3-DPG. The maximum vasorelaxation generated 
by erythrocytes in the presence o f 2,3-DPG was significantly *(P= 0.03) higher than the control group. 
Average haemoglobin saturation (96.9% ± 0.9). n=4.
One aspect o f the erythrocyte vasorelaxant response that has received less 
attention is the vasoconstriction that is observed post relaxation. The magnitude of this 
post relaxation vasoconstriction was assessed in the 2,3-DPG treat group vs. the control 
group and was found to be higher in the 2,3-DPG group although the difference was not 
statistically significant (Figure 5.9).
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Figure 5.9. The effect o f 2,3-DPG on the erythrocyte induced vasoconstriction. Lysed erythrocytes were 
added to either control baths or baths containing 20pM 2,3-DPG. The maximum vasoconstriction 
generated (post relaxation) by erythrocytes in the presence of 2,3-DPG was higher than the control group, 
although this difference was not found to be statistically significant. Average haemoglobin saturation 
(96.28% ± 0.933). n=4.
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5.3.5 Carbon Monoxide
The identity o f the vasorelaxant released from erythrocytes that is responsible for 
inducing the vascular activity, despite several proposed candidates, remains to be 
confirmed. In this respect it is important to consider other possible candidates, in the 
case o f this chapter, carbon monoxide. Carbon monoxide, released from the carbon 
monoxide releasing compound, CORM-A1 was capable o f inducing a significant 
relaxation in hypoxic tissue compared to both the hypoxic control and the normoxic 
CORM-A1 treated counterpart (Figure 5.10).
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Figure 5.10. Carbon monoxide induced vasorelaxation in hypoxia and normoxia after 5 minutes exposure 
to lOOpM carbon monoxide releasing molecule, CORM-A1. CORM-A1 induced significantly more 
relaxation in hypoxia compared to normoxia ** (P=0.001) and compared to the relevant hypoxia control 
*(P=0.012). n=4.
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In preliminary experiments, a stream o f high concentration carbon monoxide gas 
was utilised to generate erythrocytes containing 100% HbCO to assess the vasorelaxant 
properties o f  HbCO. 100% HbCO was found to completely inhibit the ability o f the 
erythrocyte to vasodilate hypoxic tissue (data not shown). Given the observed allosteric 
control o f this phenomenon, erythrocytes partially saturated with HbCO (-22%  HbCO) 
were generated and assessed. The partial saturation o f erythrocytes with carbon 
monoxide reduced the maximum vasorelaxation achieved, however, due to the power of 
the study the result was not found to be statistically significant (Figure 5.11).
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Figure 5.11. The effect o f partial carbon monoxide saturation upon the erythrocyte induced 
vasorelaxation. Partially saturating the haemoglobin of erythrocytes with carbon monoxide (22.00% 
HbCO, 78% H b02) reduced vasorelaxation when compared to erythrocytes with fully oxygenated 
haemoglobin (97.75%), however the study was not powered to show this difference statistically. Post 
relaxation erythrocytes partially saturated with carbon monoxide where recovered and re-tested for HbCO 
levels and still exhibited 22.0% saturation. n=4.
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5.3.6 Oxygen
As a potential candidate for the vasorelaxant released from erythrocytes, the 
vasorelaxant properties o f oxygen was assessed on hypoxic tissue, independently o f 
haemoglobin. The addition o f oxygenated saline (gassed with 95% oxygen) was capable 
o f inducing a significant relaxation (figure 5.12A, PO.OOl) that is comparable to the 
relaxation induced by oxygenated, native erythrocytes (Figure 5.13). The degree o f 
relaxation observed from saline addition was directly proportional to the oxygen content 
of sample (Figure 5.12B). Pre-incubation o f the vascular tissue with ODQ completely 
inhibited the relaxation response to oxygenated saline (gassed with 95% oxygen) but 
was unable to inhibit the post-vasorelaxation vasoconstriction as seen with native 
erythrocyte samples.
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Figure 5.12. % relaxation induced by saline samples with varying oxygen content. A) 95% oxygen 
saturated saline induced significantly more relaxation than samples gassed with 21% or 0% oxygen 
(PO.01 and PO.OOl, respectively). n=4 B) A correlation of relaxation against % oxygenation o f saline 
samples added. The two variables correlate significantly and positively (P0 .0001, Pearson’s r 
value=0.91, n= 12 pairs).
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Figure 5.13. example traces taken from experiments where either 20pl o f ~100% oxygen saturated 
erythrocytes or lOOpl o f saline gassed with 95% oxygen were added to pre-constricted hypoxic vascular 
rings.
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5.3.7 Vasorelaxation vs. Vasoconstriction
The addition o f erythrocytes to the hypoxic tissue bath initially induces 
vasorelaxation that is directly followed by vasoconstriction (Figure 5.2). To consider the 
relationship between these two events, the maximum percentage vasorelaxation induced 
by a sample was correlated against the corresponding maximum percentage (post 
vasorelaxation) vasoconstriction (Figure 5.14). A significant, positive correlation exists 
between the two variables that appears to go through the origin (0,0) (Figure 5.14).
30-|
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Figure 5.14. A correlation o f maximum erythrocyte induced relaxation vs. the corresponding erythrocyte 
induced constriction. A positive and significant (Pearson’s r=0.85, ***P<0.0001) relationship exists 
between the two variables. Measurements were taken from a variety o f experiments to cover a range of 
relaxation/constriction levels, (r2 =0.73, n=24).
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5.4 Discussion
The ability o f native human erythrocytes to induce relaxation in the hypoxic 
vessel bioassay is well known [331]. This ex vivo response, demonstrated to be at least 
in part mediated via soluble guanylate cyclase [421], has been attributed to several 
mediators from within the erythrocyte, including SNO-Hb [331], ATP [432] and/or 
nitrite [337]. Regardless o f the mediator involved, it is clear that changes in oxygen 
level play a significant role in the mechanism with respect to both the erythrocyte and 
the tissue.
5.4.1 Allosteric Modulation
A number o f studies have proposed that the mechanism behind the erythrocyte- 
induced vasorelaxation is under the control o f haemoglobin allostery, this suggestion is 
based largely on data collected from erythrocyte relaxations in tissue baths at varying 
oxygen levels [331] and saturation-dependent changes in erythrocyte HbSNO 
content/nitrite reductase activity [337, 363]. This chapter contains the first study to 
present data on the direct relationship between haemoglobin conformational state and 
erythrocyte induced relaxation in a hypoxic tissue environment. The findings 
demonstrate that the erythrocyte induced vasorelaxation is dependent on and directly 
proportional to haemoglobin allosteric state, in this case controlled by oxygen 
saturation. Release o f the vasoactive moiety is therefore reliant on haemoglobin 
‘switching’ conformation from R-state to T-state. The results o f this chapter show that 
the relationship between haemoglobin conformation and relaxation is linear, favouring a 
mechanism by which the vasoactive moiety is offloaded in response to progressive 
deoxygenation. This supports the HbSNO theory where the release o f nitric oxide from 
HbSNO is thought to be linked to haemoglobin allostery, but disagrees with some 
aspects o f the nitrite reduction theory. Although the original investigations into nitrite 
reduction by haemoglobin suggested deoxy (T-state) haemoglobin was responsible for 
generating nitric oxide [337], more recent publications from the field have suggested the 
reduction process to be optimal at the point where haemoglobin is 50% saturated (p50)
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[342]. If this mechanism was in operation one would expect a more Gaussian type 
distribution between haemoglobin oxygen saturation and erythrocyte induced 
vasorelaxation with a maxima at 50% saturation, not the linear relationship observed.
Previous studies have specified the requirement for a lowered tissue oxygen 
level in order to produce a vasorelaxant response from erythrocytes [91, 421]. Although 
the responsiveness o f tissue to the same nitric oxide-based stimulus is known to be 
enhanced in hypoxia [98] it is possible that ‘tissue hypoxia’ per se is not required, but 
rather that an environment (hypoxic or otherwise) to drive the transition of haemoglobin 
from R to T-state. Unfortunately, this scenario would be unlikely to ever arise in vivo 
and would be technically demanding to create ex vivo, restricting the ability to study this 
mechanism. One could speculate that it may be feasible to create a ‘donor and recipient’ 
type set-up, akin to that developed by Loewi [435] in the discovery of acetylcholine, 
where one frog heart was stimulated via the vagus nerve and washed, the washings were 
simultaneously dripped onto the heart o f a second frog to produce an effect. In this 
format, erythrocytes contained in a semi-permeable container could be rapidly 
deoxygenated in buffer contained in the first compartment, the buffer would then be 
directly passed over oxygenated tissue in a second compartment, to assess the presence 
and activity o f a vasorelaxant. This experiment could also address whether or not 
erythrocytes need to be in direct contact with the tissue to induce vasorelaxation and 
determine if tissue hypoxia is a requirement.
To further investigate the haemoglobin conformational control o f the release 
mechanism, the allosteric modulator 2,3-DPG was investigated. 2,3-DPG is known to 
shift the oxygen binding curve to the right i.e. it enhances the offloading o f oxygen and 
helps to prevent oxygen re-binding to deoxygenated haem in the tissue (see section 
1.4.2.4, page 18). The addition o f 2,3-DPG to the bath at a final concentration to match 
final haemoglobin concentration was found to increase the maximum vasorelaxation 
induced by lysed erythrocytes. This increase in maximum vasorelaxation could be 
expected given the positive allosteric actions o f 2,3-DPG on ‘offloading’. In contrast, 
the vasoconstriction that occurred post relaxation was found to be unaffected. The
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vasoconstriction has previously been attributed to haemoglobin scavenging of 
endogenous nitric oxide generated by the endothelium [331]. As in the case of oxygen 
re-binding, one would predict 2,3-DPG to aid in the prevention of nitric oxide binding, 
however no difference was observed (if anything constriction was increased) suggesting 
that scavenging o f nitric oxide is not responsible for the post relaxation vasoconstriction. 
If the erythrocyte induced vasorelaxation was to play a role in the control of vascular 
tone in vivo it is likely that it may be most beneficial in tissue areas suffering from 
vascular disease. In this respect, 2,3-DPG levels have been found to be significantly 
increased in diabetic patients, but only in those showing vascular complications [436]. 
In addition to the obvious oxygen offloading advantages, it is possible that this adaptive 
augmentation o f 2,3-DPG levels in some diabetics could also enhance the release of 
erythrocyte derived vasorelaxant.
In the assessment o f 2,3-DPG, lysed erythrocyte samples were utilised to allow 
2,3-DPG access to the haemoglobin. Erythrocyte lysate was found to still have the 
ability to generate vasorelaxation in the model used in this chapter, which carries a 
number o f implications. Firstly, it suggests that the mechanism controlling the 
vasorelaxation can operate independently o f the erythrocyte membrane or outside the 
whole cell scenario, suggesting that the vasorelaxant is associated with haemoglobin and 
can work in isolation from the cell. Secondly, this evidence does not support a role for 
the ATP release theory as this theory would appear to only function in a whole cell 
situation.
5.4.2 Movement and Recycling
It is apparent that allosteric changes in haemoglobin are essential for 
vasorelaxant release, but it is unclear as to how much is released upon each hypoxic 
exposure or how and if the store can be reloaded. To investigate this, erythrocytes were 
subjected to repeat oxygenation cycles and vasorelaxations. The results presented in this 
chapter demonstrate that erythrocytes are capable o f producing repeat vasorelaxations 
(post deoxygenation) that are not significantly different from initial vasorelaxations.
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This suggests that erythrocytes contain a considerable (potentially replenishable) store 
o f vasorelaxant which is either not released in its entirety during an individual hypoxic 
exposure or is replenished in some way upon re-oxygenation. This raises the question as 
to why only a proportion o f vasorelaxant would be released upon each hypoxic 
exposure? In the case o f the HbSNO theory it is proposed that the haemoglobin 
transition from R-state to T-state that destabilises the thiol bound nitric oxide resulting 
in release [363], it is therefore viable that not all HbSNO groups are destabilised and so 
not released or that nitric oxide released from one thiol subsequently reacts with a 
another thiol (on haemoglobin or in the membrane) and so is also not released from the 
erythrocyte. This could explain the ability of erythrocytes to produce repeated 
relaxations, indicative o f a vasorelaxant ‘store’, however, it is interesting that the repeat 
vasorelaxations are comparable to initial vasorelaxations, suggesting that the store is not 
depleting.
The reproducibility o f erythrocyte vasodilatation, despite repeat hypoxic 
exposure, could suggest release followed by re-uptake. To address this, experiments 
were conducted where erythrocytes were deoxygenated, had the extracellular buffer 
removed and then re-oxygenated in fresh buffer. In theory this should prevent the 
vasorelaxant from being passed out o f the cell and then taken back up upon re­
oxygenation. However the results obtained showed no difference in relaxation between 
control samples and those washed in fresh buffer. The vasorelaxant is therefore not 
simply passed back and forth between the intra and extra cellular compartments. With 
respect to the HbSNO theory, it is possible that nitric oxide could be released from 
haemoglobin and bind to membrane thiols and not leave the erythrocyte, particularly as 
there are no extracellular ‘acceptor’ thiols present.
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5.4.3 Other Possible Mediators
5.4.3.1 Carbon Monoxide
All evidence to date points to the release o f a species that is linked to 
haemoglobin allostery and can bind the haem centre o f sGC to produce activation. The 
most likely candidates are selected diatomic gases, as these both associate with 
haemoglobin and can activate sGC. The potential roles of nitric oxide have already been 
researched in depth and are still in question, essentially leaving oxygen and carbon 
monoxide. The decision to investigate carbon monoxide as a potential erythrocyte 
vasorelaxant was based on a number o f published observations that supported a potential 
function o f carbon monoxide, these observations are summarised below;
• The normal circulating level o f HbCO is -1.5%  but can range up to around 10- 
15% in some cases, particularly in those who smoke [437]. Therefore, based on 
normal in vivo haemoglobin concentrations (~2.5mM) at -1%  HbCO there is a 
considerable circulating concentration o f bound carbon monoxide (-25pM).
•  Carbon monoxide is known to produce vasorelaxation that is in some part 
mediated via a sGC dependent mechanism [438].
• Encapsulation o f haemoglobin by a phospholipid membrane retards the reaction 
o f nitric oxide but not carbon monoxide [385].
• Arteriovenous gradients in HbCO levels have been found in both healthy and 
critically ill patients [439].
• The rate o f dissociation o f carbon monoxide is approximate one order of 
magnitude faster than that o f nitric oxide (-10  3 vs. ~10'4 s ') [440, 441],
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• Extracellular haem groups are capable o f extracting carbon monoxide, but not 
nitric oxide from haemoglobin contained within erythrocytes [442].
• Carbon monoxide inhalation has been demonstrated to be protective in scenarios 
such as ischemia-reperfusion injury caused during organ transplantation [443].
In light o f these previous observations and given the results of this chapter 
showing carbon monoxide to have increased activity in hypoxia (CORM-A1 results), the 
vasorelaxant properties o f erythrocytes containing 100% HbCO were tested. The 
addition o f carbon monoxide to full saturation was found to completely inhibit the 
erythrocyte induced vasorelaxation. The observed inhibition is most likely due to the 
stability o f the fully saturated haemoglobin, holding it in the R-state and not allowing 
transition from R-state to T-state conformation. This finding led to the working 
hypothesis that carbon monoxide could potentially be released from partially carbon 
monoxide saturated haemoglobin (balance oxygen saturated) that may still undergo 
some conformational changes upon deoxygenation. In support o f this hypothesis, it has 
previously been shown that mono-liganded HbCO has a faster dissociation rate than di- 
liganded intermediates and that carbon monoxide dissociates faster from a  haem than p 
haem [444]. In order to investigate this hypothesis, erythrocyte samples containing 
-22%  HbCO were generated and tested for vasorelaxant properties. The partial 
saturation o f haemoglobin with carbon monoxide resulted in a partial inhibition of the 
vasorelaxation induced, however, the study was not powered to demonstrate that the 
result was statictally significant. In accordance with the allosteric data using oxygen to 
control conformation it is likely that even in samples that are only partially saturated 
with carbon monoxide, haemoglobin is held in the R-state, therefore insufficient R to T- 
state transition occurs to release the full amount o f vasorelaxant and produce maximum 
vasorelaxation. It can therefore be concluded from these results that carbon monoxide 
bound to haemoglobin is not the intra-erythrocyte species responsible for vasorelaxation 
of hypoxic tissue and that the use o f agents that hold haemoglobin in the R-state inhibit 
conformation change and similarly inhibit vasorelaxation.
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5.4.3.2 Oxygen
Having concluded that carbon monoxide was not responsible for the 
vasorelaxant properties o f erythrocytes, the role o f oxygen itself was considered. 
Oxygenated saline was capable o f inducing vasorelaxation in hypoxic tissue 
independently o f haemoglobin. The vasorelaxation observed was comparable to that 
seen with oxygenated erythrocytes and also displayed some post-addition 
vasoconstriction, suggesting that oxygen could be the vasorelaxant released from 
erythrocytes. In support o f this notion, the oxygenated saline mediated relaxation was 
also soluble guanylate cyclase dependent as is the case with that mediated by 
erythrocytes. In addition, the degree o f vasorelaxation also directly correlated to the 
oxygen content o f the saline added, which is comparable to the direct correlation 
between erythrocyte induced vasorelaxation and haemoglobin oxygen saturation. In this 
respect, our laboratory has previously shown that the concentration of oxygen in the 
tissue bath increases upon the addition o f oxygenated erythrocytes that coincides with 
changes in vessel tone [91], in agreement with a role for oxygen within the mechanism. 
These results do not discount a role for HbSNO but would suggest that oxygen could be 
the primary vasorelaxant released. It is interesting to note that the presence of HbSNO 
shifts the haemoglobin binding curve to the right, which would result in increased 
oxygen offloading and may explain the link between erythrocyte induced vasorelaxation 
and HbSNO content [421].
During the recording o f maximum vasorelaxation, data concerning the 
corresponding post-relaxation vasoconstriction was also recorded during many 
experiments. These data were subsequently used to create a correlation between the two 
variables, maximum vasorelaxation against matched, maximum vasoconstriction. The 
correlation is highly significant and the relationship observed between the two is a 
positive, linear one, demonstrating that one variable is closely related to the other. Using 
linear regression analysis, the data appears to go through the origin, suggesting that if a 
given sample were to generate no vasorelaxation, then no post relaxation 
vasoconstriction would be observed. This finding cannot be reconciled with the proposal
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that the vasoconstriction is produced by haemoglobin scavenging of endogenous nitric 
oxide [331] as this should occur independently o f vasorelaxation. After the completion 
o f the work contained in this chapter the Stamler group produced new findings and 
proposals with regards to the mechanism o f vasoconstriction that occurs post relaxation 
[421]. The publication demonstrates that a post relaxation vasoconstriction still occurs 
even when the vessel is denuded o f endothelium and that the vasoconstriction is in some 
part inhibited by ODQ [421]. It is proposed that the vasoconstriction could therefore be 
mediated to some extent by the vasorelaxant entity through a cGMP mediated 
mechanism or in the case o f HbSNO, an SNO mediated contractile mechanism [421]. A 
dual vasorelaxant/vasoconstrictor mechanism would agree with the correlation between 
vasorelaxation and constriction presented in this chapter.
In light o f the fact that oxygen could be the vasorelaxant moiety released by 
erythrocytes, can the direct relationship between vasorelaxation and vasoconstriction be 
explained by oxygen dependent mechanisms? In terms o f the vasorelaxation there are 
two potential mechanistic roles for oxygen: firstly, in hypoxia it is feasible that soluble 
guanylate cyclase is more sensitive to binding agonists (such as diatomic gases) so 
although less potent than nitric oxide, oxygen could activate soluble guanylate cyclase. 
Secondly, the relaxation mechanism could involve endothelial nitric oxide synthase, in 
hypoxia the enzyme will not efficiently produce nitric oxide, but a transient burst of 
oxygen to the tissue may be sufficient for the enzyme to briefly produce some nitric 
oxide to produce a brief relaxation. Although it is possible that nitric oxide synthase 
could play some role, the fact that erythrocytes can induce relaxation in endothelium 
denuded hypoxic vessels [421] would suggest it not to be the primary pathway involved. 
It is clear from the results o f this chapter that hypoxic tissue will not vasoconstrict to the 
same extent as normoxic tissue given the same phenylephrine stimulus, suggesting that 
contractile mechanisms are limited by hypoxia. It is possible that a burst o f oxygen 
could allow mitochondria to aerobically produce ATP, providing the energy required to 
generate further constriction to the phenylephrine still present in the bath. This 
suggestion could be fitting in a temporal sense as the process o f ATP generation could 
take longer than say the direct stimulation o f soluble guanylate cyclase, lending support
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to a mechanism where transient vasorelaxation precedes a vasoconstriction that is 
related in magnitude.
As the post vasoconstriction is obviously a key element of the erythrocyte- 
induced vasorelaxation it is important to consider the net change in vessel tone that is 
induced by erythrocytes. In the ex vivo experiments o f this chapter, the percentage 
maximum vasoconstriction was comparable, if not higher than the percentage maximum 
vasorelaxation. However, this is only maximum vasorelaxation/constriction and 
therefore doesn’t describe the change in vessel tone with respect to time. Nevertheless, it 
does in some part suggest that within this model there is no overall change in vessel 
tone. The idea o f a ‘stalemate’ situation becomes more complex if one assesses it within 
the in vivo type setting where there is blood flow. If the vasoconstriction mechanism is a 
secondary result o f the vasorelaxant released it will generate both vasorelaxation and 
constriction within the same specific tissue area, conversely, if it is caused by the 
presence of erythrocytes/haemoglobin in a specific state then in a situation o f flow the 
vasoconstriction could effect tissue distal to the site o f relaxation. The distinction 
between these mechanisms is an important one because if the latter were true, then due 
to the rapid transit o f erythrocytes through the circulation it could be possible to induce 
vasorelaxation in the arterioles/capillaries with the vasoconstrictor mechanism acting 
further down the vascular tree e.g. in the veins, where it may not be so influential.
Overall, it is plausible that this mechanism, in addition to many others, could 
serve to adjust basal tone with respect to oxygen demand. However, it should be noted 
that the majority o f erythrocyte-induced vasorelaxations presented in this chapter were 
produced by erythrocytes deoxygenated from 100% oxygen saturation down to below 
-10% . This dramatic change in oxygen saturation does not usually occur in vivo with 
normal arterial to venous transitions being -100%  to -75%  saturation. Therefore 
offloading o f vasorelaxant under normal conditions would be minimal and would occur 
in smaller vessels that are unlikely to be capable o f influencing flow to any great extent. 
Dramatic differences in saturation are more likely to occur in hypoxic tissue, usually 
caused by a restriction in blood flow. In this situation offloading o f vasorelaxant to
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increase blood supply to the area would be ideal. However, for the mechanism to work 
some blood flow is required to continually deliver ‘fresh’ erythrocytes with R-state 
haemoglobin that are capable o f changing conformation and thus inducing the required 
vasorelaxation.
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5.5 Summary and Conclusions
The results o f this chapter have not conclusively elucidated the identity o f the 
vasorelaxant released from erythrocytes but do provide significant and persuasive 
evidence that oxygen is the primary vasorelaxant involved. The findings do not support 
significant roles for either the nitrite or ATP based theories and cannot discount a role 
for HbSNO at some level. The results presented in this chapter do reveal some 
interesting characteristics with regard to the mechanism of erythrocyte induced 
vasorelaxation and provide supporting evidence to suggest that oxygen is the principal 
vasorelaxant involved, these are summarised below.
• The conformational shift in haemoglobin protein structure from R-state to T- 
state (that is controlled by oxygen saturation both in the reported experiments 
and in vivo) appears to be necessary for the induction of vasorelaxation. 
Modulators o f haemoglobin allostery, such as 2,3-DPG, are capable of altering 
this mechanism.
• The relaxant species released from the erythrocyte must be capable of avoiding 
re-capture by or reaction with haemoglobin in the local region of release.
• The vasorelaxant is not simply passed in and out o f the erythrocyte during 
oxygenation cycles.
• Erythrocytes contain a store o f vasorelaxant that is either not released in its 
entirety upon a single deoxygenation event or is potentially replenishable and 
provided the cells are re-oxygenated are capable o f repeat relaxations.
•  Vasorelaxation induced by erythrocytes in a hypoxic environment is 
accompanied by a post relaxation vasoconstriction. The magnitude of this 
vasoconstriction is directly proportional to the preceding vasorelaxation.
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Therefore, overall change in vessel tone should be considered in terms of net 
vasorelaxation and constriction.
• The vasorelaxant is associated with haemoglobin and can induce vasorelaxation 
independently o f a whole cell scenario.
•  Despite its apparent suitability as an erythrocyte vasorelaxant candidate, carbon 
monoxide or HbCO do not appear to be responsible for the vasorelaxation 
assessed in the current model.
• A burst o f oxygen delivered to hypoxic tissue is capable of inducing a transient 
relaxation. The relaxation is soluble guanylate cyclase dependent and is 
comparable to that induced by oxygenated erythrocytes. Oxygen addition also 
produces a post-vasorelaxation vasoconstriction, suggesting that both 
vasoconstriction and vasorelaxation could be oxygen derived.
• Oxygen is likely to represent the primary vasorelaxant released from 
erythrocytes upon an allosteric change stimulated by hypoxia.
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6 The Vasodilator Properties of the Nitrite Anion in the Human 
Circulatory System: the Influence of Oxygen
6.1 Introduction
The vascular actions o f nitrite have been known for more than a century [395], 
however the development o f more potent organic nitrates (e.g. glyceryl trinitrate, GTN), 
rendered nitrite clinically ‘redundant’. Interest in nitrite as a vasodilator has resurged in 
recent times because o f two principal reasons. Firstly, some research suggests that it may 
at basal plasma levels, represent a circulating, bioactive nitric oxide metabolite as 
apposed to a simple waste product (see section 1.10.2, page 68). Secondly, it has been 
proposed that nitrite, although less potent than other agents, may have some clinical 
potential in certain, niche settings, because it has targeted actions such as enhanced 
activity in hypoxic tissue beds for example [98].
At this point it is imperative to make the distinction between sources, potential 
mechanisms and the vascular activity o f endogenous nitrite at basal plasma levels 
(~200nM) and at levels elevated by pharmacological nitrite administration.
Basal plasma nitrite levels are a balance between sources/production and 
excretion/metabolism. Although vascular nitric oxide is thought to be one o f the principal 
sources of plasma nitrite [445], dietary influences can also play a role. In this respect, it 
has been demonstrated that the ingestion o f high nitrate foods results in a subsequent 
increase in plasma nitrite level which coincides with a reduction in blood pressure and 
platelet inhibition, and appears to afford some protection against the damaging effects o f 
vascular ischemia [417]. Nitrate administered orally is thought to be converted to nitrite 
via bacterial anaerobes in the gastrointestinal tract and it is the generated nitrite absorbed 
into the blood stream that is believed to be responsible for the vascular benefits observed 
[417]. However, it should be noted that this study is still artificially increasing plasma 
nitrite levels considerably above baseline. At basal plasma levels, the ability o f nitrite to
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alter vascular tone in vivo and the potential mechanism behind this action are largely 
theoretical. To date, the contributions o f basal plasma nitrite on vascular tone have not 
been demonstrated in vivo and its biological role is inferred from observations such as 
arteriovenous plasma nitrite gradients [327]. Although basal plasma nitrite levels 
generally lie within a relatively narrow range, changes in level are thought to largely 
reflect endothelial function and nitric oxide production. Plasma nitrite levels have been 
shown to negatively correlate with the number o f cardiovascular risk factors that a patient 
exhibits due to defective production or increased oxidative metabolism of nitric oxide 
[380].
A range o f different pharmacological nitrite supplementation studies in animals 
have now been published and demonstrate numerous beneficial effects o f nitrite including 
protection against ischemia reperfusion in a number o f organs [352, 446] and positive 
effects in models o f hypertension [447]. From a clinical perspective, one publication has 
also considered blood pressure and nitrite tachyphylaxis in primates, in reference to the 
tolerance that is observed clinically with organic nitrates [379]. The study found that, 
unlike organic nitrates, nitrite did not cause tachyphylaxis in primates that were 
administered a continuous nitrite infusion and daily boluses over two weeks.
Though there is a wealth o f literature on the applications of nitrite in animal 
studies, this thesis is primarily concerned with studying the vasoactive properties of 
nitrite and its mechanisms o f action with the aim o f assessment in human subjects. In 
addition to very early work with nitrite in humans, five modem publications have 
assessed infusions o f sodium nitrite in man ([98, 337, 379, 403, 445] summarised in table 
6.1). The approach that has been taken in each o f these studies is quite different making 
comparison between them difficult. However, there are some common findings and 
questions that arise from these studies collectively, including:
• Infusion o f nitrite into the brachial artery, particularly at high doses (above 
1 pmole per minute) is capable o f producing vasodilatation in the vascular 
bed to which it is infused.
- 2 0 5 -
• Increasing plasma nitrite levels with high dose nitrite significan
increases levels o f haemoglobin-bound nitric oxide (HbNO) in venc
blood.
• Nitrite infusion has a marked effect on vein diameter in addition to 
effects in arteries.
• The vasodilator properties o f nitrite are enhanced in hypoxic tissue beds.
• What is the mechanism o f action of nitrite reduction in vivo? Be
haemoglobin and oxidoreductase enzymes have been suggested to redu 
nitrite back to nitric oxide, however, in vivo evidence is lacking. O 
publication also failed to show a role for xanthine oxidase (XO) as 
potential vascular nitrite reductase.
The mechanism by which nitrite produces vasodilatation in vivo has not yet be 
demonstrated. However, some mechanisms have been suggested and broadly fall into t\ 
schools o f thought. The first suggests that erythrocytes are responsible for nitri 
activation via the reduction of nitrite to nitric oxide by haemoglobin (see section 1.10. 
page 68). The second suggests that nitrite is activated at a tissue level, independently 
blood, via reduction to nitric oxide by oxidoreductase enzymes, a hypothesis which 
supported by the findings presented in this thesis in chapter 4. Aldehyde oxidase (A( 
has been suggested to be the principle enzyme involved [397] although xanthine oxida 
(XO), nitric oxide synthase and mitochondrial enzymes have also been implicated [39 
399]. These enzymes are also known to more actively reduce nitrite to nitric oxide und 
conditions of hypoxia [413].
- 206 -
Table 6 .1. Summary of human nitrite infusion studies
too
Publication
Lauer ctu l. 
2001.
Subjects
3 subjects
Cosby el ul. 
2006.
Dejam e ta l. 
2007.
9 male and 9 
female. 10 
subjects 
recalled for 
low-dose 
studv.
20 subjects. 
Average 
weight 7 1 ±7 
kg-
Dose reylmen
Imraancrial sodium nitrite was given at 
doses from 0.01 to 36 pm ol/m in.
2 x 3 6 ^m ol/m l infused 'a Iml/min for 
5mins via the brachial artery o f  the 
study arm . Infusion I before exercise, 
infusion 2 before exercise with I, - 
NM M A co-adm inistration. Infusion I 
and 2 were separated by a 30tnin saline 
infusion. Total dose received 
1,08mmoles, low dose studies were 
identical but infusions o f  0.36 pm ol/m l 
were used.
Part A, n=5. Sodium nitrite in saline 
was infused '<7; 2 m 1/m in for 5 minutes 
intrabrachial. at escalating doses from 
0. 7, 14,28 and 55 to 110 pg/kg/m in. 
For reference, a dose o f  28 pg/kg/m in 
for 5 minutes at the average body 
weight would be equivalent to -1 4 4  
pm oles o f  nitrite. After dose escalation 
a rest period o f  180 m inutes was given 
before a dose o f 28 pg/kg/m in for 5 
minutes.
Part B. n*15. Sodium nitrite in saline 
was infused i%2ml/min for 5 minutes, 
at escalating doses from 0 .07 ,0 .14 , 
0 .35 ,0 .7 . 1.4. 3 .5 ,14  and 28 
pg/kg/m in, 10 subjects received a 
coinfusion o f  either oxypurinol 
(600pg/m in) or ascorbic acid 
(24mg/min).
Measurements
Forearm blood flow o f  the 
infusion arm was measured 
by strain gauge 
plethysmography. Venous 
blood samples were also 
taken from the same arm.
Forearm hlood flow o f  the 
infusion arm was measured 
by strain gauge 
plethysmography. Arterial 
and venous blood samples 
were also taken from the 
infusion arm for blood gas 
and nitric oxide m etabolite 
analysis.
Part A. During dose 
escalation blood flow 
m easurem ents (by strain 
gauge plethysmography) and 
blood samples were taken 
from the infusion arm 
(ipsilateral). After the rest 
period o f  180 minutes a 
further infusion was given 
however m easurem ents were 
m ade in the contralateral 
arm.
Part B. Both blood flow 
m easurem ents and blood 
samples were taken.
Interventions
Hand grip 
exercise in the 
infusion arm
Findings
liven at the highest dose nitrite did not 
alter forearm blood flow. Using 
estimations, the authors believe to 
recover 92 -97% o f  nitrite infused into 
the artery from blood taken from the 
corresponding vein.
Both doses administered produced 
increases in plasma nitrite (venous 
levels rose to -2 2 0  p M ) and forearm 
blood flow. The findings were 
unaffected by L -NM M A 
administration. Nitrite infusion 
increased haemoglobin bound nitric 
oxide species and formation was 
inversely proportional to haemoglobin 
oxygen saturation.
Part A. Escalating doses o f  nitrite were 
capable o f  increasing fore arm blood 
flow in the ipsilateral arm. Forearm 
blood flow in the ipsilateral arm was 
altered within seconds o f  comm encing 
arterial nitrite infusion. An infusion o f  
28 pg/kg/m in was capable o f  producing 
increases in forearm blood flow in the 
contralateral arm after a short time 
delay (nitrite concentration in 
contralateral arm ~ I p M ).
Part B. The lowest infusion dose (0.07 
pg/kg/m in ) increased venous plasma 
nitrite to 350nM  and was capable o f  
significantly increasing arterial flow in 
the ipsilateral arm from 3 ± 0.3 
ml/l 00m I/m in to 3.4 ±0.3 
ml/IOOml/min ( n - 15). Neither ascorbic 
acid or oxypurinol altered blood flow 
responses.
Confounding
Factors
Very low subject 
num bers and 
publication lacks 
detail with respect 
to  protocol.
High doses 
administered. 
Exercise was 
utilised as a 
hypoxic stimulus. 
The latter 9 subjects 
received a nitrite 
infusion that 
contained sodium 
bicarbonate to 
titrate the pH to 
above pH 7.0, 
raising questions 
over the pH o f  the 
initial infusion.
Escalating doses 
were utilised with 
no tim e to plateaux 
between each dose. 
Doses used are also 
high, escalating up 
to levels
significantly higher 
than the
physiological range.
O
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Publication Subjects Dose regimen M easurements Interventions Findings Confounding Factors
M a h e r  et 40 P ro to co l A, n o rm o x ia . n“ 26 . F o rearm  v e n o u s H y p o x ia  w as N itrite  w as cap ab le  o f  in d u cin g H y p o x ia  w as *1rf)
a t, 2 0 0 7 . S u b jec ts . S o d iu m  n itrite  w as in fused v o lu m e  w as m easu red ind u ced  by v e n o d ila ta tio n . w h ich  a p p e ar to be ad m in iste red  via  a v
in tra b ra c h ia l a t the fo llo w in g by  rad io n u c le o tid e ad m in istra tio u n c h a n g ed  by  the h y p o x ic m ask  w h ich  co u ld
rS
e sca la tin g  d o se s  4 0 . 100, 314 , 784 , p le th y sm o g ra p h y . n o f  12% in terv en tio n . In co n tra s t, n itrite in tro d u ce  v a riab ility .
n m o l/m in  an d  3 .14  an d  7.84 F o rearm  a rte ria l b lo o d o x y g e n  via a in d u ced  m u ch  g rea te r  c h a n g es  in H y p o x ia  i tse lf  cau ses
p m o l/m in  e a ch  fo r 3 0  m in u tes. How w as m easu red  by 
stra in  g au g e
face m ask 
c o n ta in in g  a
arteria l flow  in h y p o x ia  c o m p a re d  to  
n o rm o x ia .
v a scu la r  c h a n g es  
w hich  o c c u r  o v e r
P ro to c o l B, h y p o x ia . n ~ 1 4 . 7 
su b je c ts  rece iv ed  in trab rach ia l 
n itrite  (7 .8 4  p m o l/m in  fo r 2 0 m in s) 
in h y p o x ia  fo llo w ed  by the  sam e 
in fusion  in n o rm o x ia  w ith a 60m in  
sa lin e  in fu sio n  in be tw een . A fu rth e r 
7 su b je c t u n d e rw en t p ro to c o l B with 
a 3 l4 n m o l/m in  in fusion .
p le th y sm o g ra p h y  in 
b o th  arm s, c h a n g e  in 
flow  in the s tu d y  arm  
w as c o rrec ted  for flow  
in the co n tra la te ra l arm  
an d  e x p re sse d  as a 
ratio . B lo o d  sam p les  
w ere a lso  tak en  for 
n itr ic  o x id e  m etab o lite  
a ssessm en t.
tw o -w a y
v alv e .
h o u rs, in th is  s tudy  
su b je c ts  w ere 
co n s id e red  ‘h y p o x ic ' 
w hen  a rteria l 
s a tu ra tio n  had  d ro p p ed  
to  a stead y  83 -8 8 % .
M ack  et al. 14 S ick le In tra -b ra c h ia l in fusion  o f  sodium F o rearm  b lo o d  flow  o f N itrite  in d u ced  an in crease  in fo rearm N o true co n tro l
2 0 0 8 . cell n itrite  a t the fo llo w in g  esca la tin g the  in fusion  arm  w as b lo o d  flow  in the  s tu d y  arm . su b jec ts, co n tro l d a ta
p a tie n ts  (9 d o se s  0 .4 .4  and  40  p m o l/m l a t m easu red  by strain R esp o n ses  to n itrite  in s ick le  cell w as taken  form
I m ale , S 1 m l/m in  fo r  5 m in u tes. gau g e p atien ts  w ere b lu n ted  c o m p ared  to p rev io u s  s tud ies  w here
to fem ale). p le th y sm o g ra p h y . co n tro ls. S od ium  n itrite  in fu sio n  w as n itrite  d o seo well to le rated  an d  d id  n o t cau se a d m in iste red  w as
0 0
i B lood  sam p le  taken  
form  v e n o u s  ca th e te rs  
o f  b o th  the in fusion  
and  co n tra la te ra l arm .
h y p o ten s io n  o r  
m eth a e m o g lo b in a e m ia .
d iffe ren t.
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Chapter Six Properties of the Nitrite Anion in vivo
6.1.1 Aims
Studying nitrite at basal level in vivo presents many complications, as with any 
system it is often necessary to provoke it in some way in order to gain understanding 
about the way it operates. The work o f chapter three presented in this thesis demonstrates 
that the movement and levels o f circulating nitric oxide metabolites represents a dynamic 
equilibrium in vivo, this chapter aims to investigate this dynamic and its physiological 
consequences through increasing the circulating nitrite pool by way of a low dose 
infusion. Specifically this chapter aims to:
•  Assess the interaction between nitrite and erythrocytes with particular 
respect to the mechanism o f nitrite induced vasoactivity in vivo.
•  Investigate the relationship between plasma nitrite levels and 
biochemical/physiological changes in the physiological concentration range.
• Consider the systemic properties and interactions o f nitrite.
• Examine the influence o f oxygen upon the metabolism and vasoactive
properties o f nitrite in the physiological concentration range.
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6.2 Specific Methods and Protocols
This body o f work was carried out in collaboration with Dr. Thomas Ingram. Dr 
Ingram was responsible for securing ethical approval, aiding in the measurement of some 
nitric oxide metabolites and analysing the forearm blood flow data that had been 
collected.
6.2.1 Subjects
18 healthy male volunteers were recruited locally and all gave informed written 
consent to participate. Female subjects were not included in the study because levels of 
nitric oxide metabolites are known to be altered by circulating estrogens [448], leading to 
cyclical variability which could be confounding. Other exclusion criteria included: 
hypertension, hypercholesterolemia, diabetes mellitus, being a current smoker, taking 
regular prescription drugs or having a family history o f premature coronary artery 
disease. The experimental protocol and recruitment procedure were both approved by the 
local research ethics committee.
All subjects were requested to refrain from consuming alcohol, caffeine and foods 
with high nitrite/nitrate content (e.g. certain vegetables and red meat, which is often 
preserved with high concentration nitrite [449]) for the 12 hours preceding experimental 
testing. Detailed subject characteristics will be covered in the results section o f this 
chapter.
6.2.2 The Environmental Chamber
To ensure accurate and consistent exposure to hypoxia all hypoxic studies were 
carried out in a bespoke environmental chamber (Design Environmental, Ebbw Vale, 
UK). The chamber is - I2 0 M 3 and is purged with a high flow o f nitrogen gas mix (via a 
number of diffusers that create homogenous mixing) to achieve the desired hypoxic 
environment (12% 0 2). The high flow o f gas ensures minimal changes in carbon dioxide
- 2 1 0 -
Chapter Six Properties o f the Nitrite Anion in vivo
level (within the atmospheric range expected at sea level) and that the chamber operates 
at normobaric pressure. Because the chamber operates at normobaric pressure, it allows 
investigators to enter and exit the chamber without causing significant changes in 
chamber oxygen level. The chamber employs a number of highly sensitive, carefully 
positioned sensors to constantly monitor and affect changes in temperature, oxygen level 
and humidity within the chamber environment. For safety reasons, all parameters were 
remotely controlled via an external computer running a custom program (Contour 
program, Design Environmental, Ebbw Vale, UK) for control. The chamber was always 
run at a constant temperature (see results section) and humidity. Corresponding normoxic 
studies were carried out in a similar sized, temperature controlled room at normal 
atmospheric oxygen level (21% O2).
6.2.3 Blood Collection and Measurement
Blood samples were collected from a catheter placed in the antecubital vein o f the 
non-dominant arm. The same arm was also utilised for the measurement of blood flow, 
this procedure involved the inflation o f cuffs around the arm to restrict blood flow, 
therefore blood samples taken at specific time points were always collected before the 
corresponding flow measurements were made, as cuff inflation will alter 
flow/haemoglobin saturation and influence nitric oxide metabolite levels. Samples were 
immediately analysed for blood gas readings, processed as per section 2.1.2 (page 80) and 
snap frozen for future analysis.
Plasma and erythrocyte samples were rapid thawed for the measurement of 
plasma nitrite, nitrate, RSNO/RNNO and haemoglobin bound species (HbNO and 
HbSNO) respectively, utilising the ozone based chemiluminescence measurement 
protocols detailed in section 2.3.4 (page 95). All samples were tested within one week of 
collection.
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6.2.4 Strain Gauge Plethysmography
After an initial assessment o f potential methodologies for the non-invasive 
measurement o f forearm arterial blood flow, it became clear that strain gauge 
plethysmography (SGP) not only represented the most repeatable method, but was well 
suited to our study design.
During testing, the subject was in the seated position with the forearm resting 
horizontally in a support to reduce unwanted movement. To quantify arterial inflow, a 
cuff was first placed around the wrist and inflated to supra-systolic pressure (300mmHg), 
a second proximal cuff was placed around the upper arm; this cuff can be rapidly inflated 
using a rapid cuff inflator (E20, Hokanson) and air source (AG101, Hokanson). The 
proximal cuff is inflated to above venous pressure, but below arterial pressure (50mmHg), 
this abruptly stops venous outflow causing the volume o f the limb to increase due to 
arterial inflow. A mercury strain gauge plethysmograph is placed between the cuffs, 
around the forearm at the point o f largest circumference. The plethysmograph is used to 
measure the volume change in the limb, the rate o f volume change being proportional to 
arterial flow rate at the moment o f  venous occlusion (Figure 6.1). A mercury 
plethysmograph is chosen that is 2cm smaller than circumference of the largest part of the 
forearm. The plethysmograph is connected to a EC6 interface (Hokanson, WA, USA), 
which is routed through an analogue to digital converter (Powerlab, AD instruments) to a 
laptop operating the data acquisition program, chart for windows (AD instruments). 
Repeat measures were taken a minimum o f 6 times and the average of the 5 most 
repeatable measurements was taken as a final reading, expressed as ml o f blood flow per 
100ml of tissue, per minute (ml/lOOml/min).
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1:20 1:401:00
Figure 6 .1. Example strain gauge plethysmography trace. The blue line indicates the section o f the trace 
used to assess gradient which is proportional to arterial in-flow. The x-axis represents time and the y-axis, 
arbitrary un its.
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6.2.5 Specific Protocols
The study was subdivided into three distinct protocols: the primary study, in which a 
sodium nitrite infusion was administered in hypoxia and two control studies in which 
saline was administered in hypoxia and sodium nitrite was administered in normoxia. 
Details of the individual protocols are outlined below.
6.2.5.1 Hypoxia/Nitrite
12 subjects had all baseline measurements made in the chamber under normoxic (21% 
FiCh) conditions before the chamber was sealed and the descent to hypoxia (12% FiC^) 
was commenced. The chamber required 60 minutes to achieve 12% FiC>2, during which 
time subjects relaxed and acclimatised. A period of 120 minutes at 12% FiC>2 followed, 
this time allowed long term hypoxia induced haemodynamic changes (e.g. systemic 
vasodilatation and tachycardia) to stabilise, achieving -90%  of the maximum anticipated 
[450]. Subjects then received a low dose nitrite infusion (Martindale Pharmaceuticals, 
Brentwood, UK) (lpmol/mL @ lmL per min for 30 minutes) to raise systemic plasma 
nitrite levels by approx. 100% (at peak). Blood samples and measurement of forearm 
blood flow were taken throughout (summarised in Figure 6.2).
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Figure 6.2. Schematic o f study protocols. Upper panel shows hypoxia/nitrite and hypoxia/saline protocols, 
lower panel shows normoxia/nitrite protocol where the initial 3 hours o f equilibration (necessary in the 
hypoxic protocol) is omitted. Red and blue arrows indicate time points at which blood samples and blood 
flow measurement were taken respectively. Grey infill denotes period o f nitrite/saline infusion.
6.2.5.2 Hypoxia/Saline
An additional 6 subjects underwent the full hypoxia protocol as per 6.2.5.1 but received 
an equivalent volume of medical grade saline 0.9% w/v (Figure 6.2, upper panel).
6.2.5.3 Normoxia/Nitrite
6 of the subjects recruited for the hypoxia/nitrite protocol were also recruited for a second 
time to participate in a normoxia/nitrite protocol. Subjects essentially underwent the same 
protocol as in 6.2.5.1 (receiving the same dose of sodium nitrite) but the protocol was 
carried out in normoxia with the initial 3 hour equilibration period omitted (Figure 6.2, 
lower panel). Subjects had a 30 minute rest period before the measurement protocol was 
commenced.
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6.2.6 In vitro Nitrite Addition to Erythrocytes
To compare the exposure o f erythrocytes to nitrite via infusion in the in vivo setting, 
parameters of interest were also assessed in an ex vivo experimental model, designed to 
replicate aspects of the conditions found in vivo. Erythrocytes were collected from 
healthy volunteers as previously stated (section 2.1, page 80). Separated erythrocytes 
were reconstituted in PBS to give a final haemoglobin concentration o f lOg/dL, the mix 
was then placed in a thin film rotating tonometer as previously described (section 2.2, 
page 81). A nitrogen purge was utilised to alter the haemoglobin saturation to -50% , 
which was confirmed using a blood gas analyser (OSM3, Radiometer, Copenhagen). The 
mix was then separated into aliquots and nitrite o f varying concentrations (up to 850nM 
final) was added and incubated for 30 minutes at 37°C before centrifugation (10,000g for 
2 minutes). Erythrocyte and supernatant fractions were snap frozen immediately and 
stored for future analysis. Upon rapid thawing erythrocyte and supernatant fractions were 
assessed for nitrite and HbNO levels as per section 2.3.4 (page 95).
6.2.7 Analysis and Statistical Analysis
Testing between groups was performed using either the student t-test (either paired or 
unpaired where appropriate) or an analysis o f variance (ANOVA) (repeat measures 
ANOVA where appropriate) with a Bonferroni post hoc test. To assess correlations the 
Pearson’s correlation coefficient was used. Data are presented as means and error bars 
represent the standard error o f the mean (SEM). Plasma nitrite half-life was calculated 
using all data from peak infusion point to 60 minutes post infusion cessation. A P value of 
less than 0.05 was taken to be significant, individual significance levels are indicated 
within the figure legends. All analysis was performed blinded. ‘No significance’ is 
abbreviated to ‘N S’ in some cases. The grey bar in the background o f all graphs 
represents the 30 minute period of sodium nitrite or saline infusion.
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6.3 Results
6.3.1 Subject Characteristics
General subject characteristics are detailed in table 6.2 below.
Table 6.2. Summary o f  subject characteristics.
Mean Standard Error of Mean
Age (years) 24.2 ± 1.0
Height (cm) 180 ± 1.7
Mass (kg) 78.6 ±2.2
BMI 24.3 ±0.6
Hb (g/dL) 16.4 ±0.3
Participants (n)
Hypoxia/Nitrite 12
Hypoxia/Saline 6
Normoxia/Nitrite 6
(note, paired from 
hypoxia/nitrite 
protocol)
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6.3.2 Cham ber Param eters
The environmental chamber provided a controlled atmosphere, with constant 
temperature throughout the time course o f the experiment (Figure 6.3). The chamber 
required 60 minutes to attain a steady 12% FiC>2 baseline (coming down from 21% O2) 
and remained constant for the duration o f  the experiment, during which time subjects 
‘acclimatised’ to the environment.
25-1 r 28
20 - -26
CM ACo 15-
u_
10 -
-24
-22T—
-205
L 180«
0 240 270
Time (Minutes)
3■o
<D
0)#-*c
o
Fi02
Temperature
 o
Figure 6.3. FiC>2 drops significantly until levels reach 12.0% oxygen after 60 minutes. Over the rest o f the 
protocol, oxygen levels are maintained at 12.05 with no significant change. Time point compared by 
ANOVA and Bonferroni post test, n=18. Temperature level does not change significantly over the course of 
the protocol (mean temperature 21.6 °C ± 0.1), n=18. Shaded area represents period o f nitrite/saline 
infusion.
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6.3.3 Haemodynamic Parameters
Haemodynamic parameters were continually checked throughout all study 
protocols for scientific interest but also for safety i.e. to monitor subject well being. Both 
study protocols that were carried out in hypoxia significantly increased heart rate over the 
initial 3 hours o f the protocol. Once a plateau rate was achieved, no significant changes 
were observed over the rest o f the protocol, including pre-, during and post-nitrite/saline 
infusion (figure 6.4A and C). Heart rate in the normoxic protocol decreased significantly 
over the course o f the entire protocol as subjects relaxed. It should be noted that heart rate 
remained unchanged during the infusion period (Figure 6.4E). Within the accuracy o f the 
equipment used, blood pressure (systolic and diastolic) remained unchanged throughout 
all study protocols (Figure 6.4B, D and F).
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Figure 6.4. Haemodynamics. A) Hypoxia/nitrite heart rate (n=12) B) Hypoxia/nitrite blood pressure (n=12) 
C) Hypoxia/saline heart rate (n=6) D) Hypoxia/saline (n=6) E) Normoxia/nitrite (n=6) F) Normoxia/nitrite 
(n=6). Heart rate drops significantly during the normoxic protocol (P<0.05 0 minutes vs. 75 and 105 
minutes) but does not change significantly during infusion and increases significantly in both hypoxic 
protocols over the first 2 hours (hypoxia/nitrite P<0.05 0 vs. 120 minutes) (hypoxia/saline P<0.01 Ovs. 120 
minutes), no other significant changes in either protocol post 120 minutes. No significant changes in blood 
pressure (systolic or diastolic) during any protocol.
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6.3.4 Blood Parameters
6.3.4.1 Blood pH
Due to the susceptibility of nitrite undergoing acid disproportionation, the effects 
of hypoxia and nitrite/saline infusion upon blood free hydrogen ion concentration (pH) 
were monitored. Blood pH levels did not change significantly during both of the hypoxic 
protocols and remained above pH 7.3 throughout (Figure 6.5). In addition, the infusion of 
saline or nitrite also had no effect on blood pH.
7.60*i
7.50-
7.40*
7.30-
7.20J
0 30 60 90 120 150 180 210 240 270
7.60-I
7.50-
7.40-
7.30-
7.20-J
0 30 60 90 120 150 180 210 240 270
Time (m inutes) Time (m inutes)
Figure 6.5. Changes in blood pH. A) Hypoxia/nitrite protocol (n=10) B) Hypoxia/saline protocol (n=4). No 
significant changes in pH were observed over the course of either protocol.
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6.3.5 Blood Gas Analysis
All blood samples taken underwent blood gas analysis to monitor the result of 
hypoxic exposure. In both hypoxic protocols, venous pC>2 dropped from ~30mmHg to 
~20mmHg after 60 minutes chamber exposure (Figure 6.6A and C). Once p02 levels had 
decreased (within 60 minutes), the level remained unchanged over the remaining period 
o f the protocol. Similarly, capillary haemoglobin oxygen saturation decreased from 97.75 
± 0.2% to 87.67 ± 1.0% (0 vs. 60 minutes, P<0.001, minimum of 82.0 ± 2.4% at 180 
minutes) during the hypoxia/nitrite protocol and from 97.83 ± 0.4% to 87.16 ± 0.6% in 
the hypoxia/saline protocol (Figure 6.6B and D). Venous haemoglobin saturation during 
the normoxia protocol did not significantly change throughout the protocol and had an 
average value o f 69 ± 2.5%.
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Figure 6.6. Changes in blood oxygen levels. A) Hypoxia/nitrite protocol, venous p 0 2 levels (n=10). p 0 2 
level decreases significantly after 120 minutes and remains at this the decreased level over the remaining 
protocol (0 vs. 120-270 minutes P<0.05), B) Hypoxia/nitrite protocol, capillary haemoglobin oxygen 
saturation (n=12). Saturation levels decrease after 60 minutes and remain at a reduced level over the 
remaining protocol (0 vs. 60-270 minutes P<0.05) C) Hypoxia/saline protocol, venous p 0 2 levels (n= 4). 
p 0 2 level decreases significantly after 60 minutes and remains at this the decreased level over the remaining 
protocol (0 vs. 60-270 minutes P<0.05) D) Hypoxia saline protocol, capillary haemoglobin oxygen 
saturation (n=6). Saturation levels decrease after 45 minutes and remain at a reduced level over the 
remaining protocol (0 vs. 45-270 minutes P<0.05). E) Normoxia/nitrite protocol, venous haemoglobin 
oxygen saturation (n=6). No significant changes throughout protocol.
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profile for each of the nitric oxide metabolite species. In this way, the conclusions dra 
were not based on a single measurement and kinetic information was gained regarding 
metabolism of the infused nitrite.
6.3.6.1 Plasma Nitrite
The initial descent to hypoxia over 60 minutes appears to cause an increase 
plasma nitrite concentration in both hypoxia study protocols. However, the increase v 
not found to be statistically different from the baseline, pre-hypoxia level (Figure 6. 
and C) as the study was not powered to investigate such small changes in level, 
investigate the effects of a modest increase in plasma nitrite, a low dose infusion \ 
given over 30 minutes, this elevated plasma nitrite levels in both the normoxia/nitrite < 
hypoxia/nitrite protocols (Figure 6.7A and C). Nitrite infusion in the hypoxia/niti 
protocol significantly increased levels (180 vs. 195 minutes P<0.001, 180 vs.  ^
P<0.001) with plasma nitrite level being doubled at peak compared to pre-infusion lev< 
from 191 ± 12.30nM (180 minutes) to 396 ± 26.38nM (210 minutes), representing a de 
change of ~205nM. Plasma nitrite level then returns to baseline 60 minutes after cessati 
of infusion (180 vs. 270 minutes, NS).
Plasma nitrite level in the normoxia/nitrite protocol is also increased significan 
with infusion (0 vs. 30 P<0.05 and 0 vs. 45 P<0.001) by an amount similar to tl 
observed in the hypoxia/nitrite protocol, a change o f 206.3 ± 36.6nM from baseline 
peak (0 vs. 45 minutes) (Figure 6.7C). As in the hypoxia/nitrite protocol, plasma niti 
levels in the normoxia/nitrite protocol return to baseline within 60 minutes o f infusi 
cessation (0 vs. 105 minutes, NS).
- 2 2 4 -
Chapter Six Properties of the Nitrite Anion in vivo
B
G)
_C
"ro
CO
xoQ.>
X
450- 
S  400- 
S  350- 
2  300- 
2  250- 
Z  200- 
re 150- 
100-  
i  50- 
0-
i-----1-----1-----1-----1-----r
0 30 60 90 120 150 180 210 240 270
Time (m inutes)
i 1-----1-----1-----i-----1-----  r— i
0 30 60 90 120 150 180 210 240 270
Time (m inutes)
<1)
gj
Xo
E
450- 
S  400-
— 350- 
2  300- 
£  250- 
z  200- 
<2 150- 
w 100-
i 0-
3hr
Equilibration
Period
omitted ,
/
0 30 60 90
Time (m inutes)
Figure 6.7. Change in plasma nitrite concentration in all three study protocols A) Hypoxia/nitrite protocol. 
Plasma nitrite increases significantly when infusion is given (180 vs. 195 minutes P 0 .0 0 1 , 180 vs. 210 
minutes P<0.001) and returns to baseline 60 minutes after cessation of infusion (180 vs. 270 minutes, NS). 
Although the initial exposure to hypoxia itself seems to increase plasma nitrite levels the observation is not 
statistically significant (0 vs. 30 minutes and 0 vs. 180 minutes both NS) (n=12) B) Hypoxia/saline 
protocol. No significant changes throughout protocol (n=6). C) Normoxia/nitrite protocol. Plasma nitrite 
increase significantly with infusion (0 vs. 30 minutes P<0.05 and 0 vs. 45 minutes P<0.001) which returns 
to baseline within 60 minutes of infusion cessation (0 vs. 105 minutes, NS) (n=6).
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6.3.6.2 Haemoglobin Bound Species
Infusion of low dose sodium nitrite in the hypoxia/nitrite protocol significantly 
increased HbNO levels, but only after 30 minutes o f infusion (180 vs. 195 minutes NS, 
180 vs. 210 minutes P<0.001) (Figure 6.8A). Overall, HbNO concentrations increased 
from 106 ± 19.2 nM to 237 ± 58.4 (180vs. 210 minutes). Interestingly, the level rapidly 
returned to pre-infusion baseline within 15 minutes post infusion cessation (180 vs. 225 
minutes, NS). HbSNO concentration appeared to be increased by the infusion o f sodium 
nitrite, however the increase was not found to be statistically significant (180 vs. 210 
minutes, NS) (Figure 6.8B).
An identical 30 minute infusion given during the normoxia/nitrite protocol caused 
a moderate increase in HbNO levels, however the increase only became statistically 
significant 15 minutes post infusion cessation (28.9 ± 12.4 nM at time 0 vs. 96.6 ± 22.1 
nM at time 60, P<0.05). No change in HbSNO level was observed during the 
normoxia/nitrite protocol (Figure 6.8F). Both haemoglobin bound species remained 
unchanged throughout the hypoxia/saline protocol (Figure 6.8C and D).
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Figure 6.8. Changes in haemoglobin-bound species in all three protocol groups. A) Hypoxia/nitrite 
protocol, HbNO concentration levels. When nitrite infusion commences, levels increase but do not become 
significant until 30 minutes of infusion have been given (180 vs. 195 minutes NS, 180 vs. 210 minutes 
P<0.001) and then return to pre-infusion baseline within 15 minutes o f infusion cessation (180 vs. 225 
minutes NS) (n=12). B) Hypoxia/nitrite protocol, HbSNO concentration levels. Although they appear to rise 
during infusion, levels do not change significantly during the protocol (n=12). C) and D) Hypoxia/saline 
protocol, HbNO and HbSNO concentration levels. Levels o f both species did not change significantly 
during the protocol (n= 6 in both cases). E) Normoxia/nitrite protocol, HbNO concentration levels. Levels 
do rise moderately but do not become significant until 15 minutes post infusion cessation (0 vs. 60 P<0.05) 
(n=6). F) Normoxia/nitrite protocol, HbSNO concentration levels. Levels do not change over the course of 
the protocol (n=6).
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6.3.6.3 Plasma Nitrate and RSNO/RNNO
Levels of plasma nitrate did not change significantly during either o f the hypoxia 
protocols (Figure 6.9A, C and E). Levels o f plasma RSNO/RNNO did not change 
significantly during any of the three protocols (Figure 6.9B, D and F).
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Figure 6.9. Changes in plasma nitrate and RSNO/RNNO concentration over all 3 protocols. A) 
Hypoxia/nitrite protocol, plasma nitrate concentration (n=12) B) Hypoxia/nitrite protocol, plasma 
RSNO/RNNO level (n=12) C) Hypoxia/saline protocol, plasma nitrate (n=6) D) Hypoxia/saline protocol, 
plasma RSNO/RNNO concentration (n=6) E) Normoxia/nitrite protcol, plasma nitrate concentration (n=6) 
F) Normoxia/nitrite protcol, RSNO/RNNO concentration (n=6). No statistically significant changes in 
nitrate or RSNO/RNNO concentration levels throughout any o f the protocols.
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6.3.7 Forearm Blood Flow
To assess the physiological effect o f nitric oxide metabolite manipulation through 
nitrite infusion, forearm blood flow was measured at specific time points during all three 
study protocols. Infusion o f sodium nitrite in the hypoxia/nitrite protocol increased 
forearm blood flow significantly (180 vs. 195 minutes, p<0.05. 180 vs. 210 minutes, 
p<0.001) (Figure 6.10A). The increased flow returned to baseline 60 minutes after 
cessation o f infusion (180 vs. 270 NS). In both the hypoxia/saline and normoxia/nitrite 
protocols blood flow remained unchanged throughout (Figure 6.10B and C). Forearm 
blood flow was not statically different at the beginning o f the protocol (0 minutes) or at 
the pre-infusion point (180 minutes) between groups.
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Figure 6.10. Changes in forearm arterial blood flow in all three protocols. A) Hypoxia/nitrite protocol. 
Forearm blood flow increased significantly during the infusion period (180 vs. 195 minutes, P<0.05 and 
180 vs. 210 minutes, P<0.001) and returned to baseline 60 minutes after cessation of infusion (180 vs. 270 
NS) (n=12). B) Hypoxia/saline protocol, no significant changes throughout protocol. (n=6) C) 
Normoxia/nitrite protocol. No significant change in forearm blood flow throughout protocol (n=6). No 
significant difference in forearm blood flow starting values (0 minutes) or pre-infusion (180/15 minutes) 
values between all groups.
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6.3.8 Further Interpretation and Comparison
To compare the effect o f sodium nitrite infusion on the dynamics o f plasma nitrite 
level in hypoxia and normoxia, the profile o f metabolites in each protocol was plotted 
(Figure 6.11). The profiles can be seen to be offset, as subjects who participated in the 
hypoxia protocol had a slightly elevated plasma nitrite pre-infusion value compared to 
their pre-hypoxia, normoxic baseline values and the levels exhibited by the normoxic 
controls, however a comparable hypoxia-induced elevation was also observed in those 
who participated in the hypoxia/saline protocol.
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Figure 6.11. The time-corrected change in plasma nitrite level from commencement o f sodium nitrite 
infusion to one hour post cessation o f  infusion in the hypoxia/nitrite and normoxia/nitrite protocols.
Interestingly, the half-life o f plasma nitrite was calculated to be 21.7 ± 2.9 min in 
hypoxia and 21.3 ± 3.4 min in normoxia (Figure 6.12). This parallel can be seen visually 
by comparison o f the profiles o f  plasma nitrite in normoxia and hypoxia that are similar, 
both in terms o f elevation and decay (Figure 6.11).
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F ig u re  6.12. Plasma nitrite half-life post infusion cessation in both hypoxia/nitrite and normoxia/nitrite 
pro tocols. Hypoxia/nitrite average =21.7±2.9 minutes, (n=12). Normoxia/nitrite average T1/2=21.3±3.4 
m inu tes, (n=6).
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To evaluate potential links between nitric oxide metabolites and altered 
physiology within a given protocol, the profile o f change in each parameter was plotted 
together (Figure 6.13). In the hypoxia/nitrite protocol, the change in plasma nitrite 
concentration and change in forearm blood flow appear to follow a similar profile. 
Conversely, HbNO levels in the same protocol appear to rise in response to nitrite 
infusion, but only after a delay and then return to baseline upon cessation of nitrite 
infusion. The relationship between these parameters can be considered by correlating one 
against another (Figure 6.14) Plasma nitrite concentration correlates positively and 
significantly with forearm blood flow in the hypoxic environment (Pearson r= 0.43, 
p<0.0001) (Figure 6.14A) but not in the normoxic environment (Pearson r=0.032) (Figure 
6.14C). In both the hypoxia/nitrite and the normoxia/nitrite protocols, HbNO levels did 
not correlate with forearm blood flow (Pearson r= 0.069, NS and-0.143, NS, respectively) 
(Figure 6.14B and D).
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Figure 6.14. Correlations of nitric oxide metabolites with forearm blood flow in the hypoxia/nitrite and 
normoxia/nitrite protocols. A) Hypoxia/nitrite protocol, plasma nitrite concentration significantly correlates 
against forearm blood flow (Pearson’s r=0.432, PO.OOOl, n=93) B) Hypoxia/nitrite protocol, HbNO 
concentration does not correlate with forearm blood flow (Pearson’s r= 0.069, NS, n=93) C) 
Normoxia/nitrite protocol, plasma nitrite concentration does not correlated with forearm blood flow 
(Pearson’s r=0.032, NS, n=30) D) Normoxia/nitrite protocol, HbNO concentration does not correlated with 
forearm blood flow (Pearson’s r=-0.215, NS, n=30).
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To further consider the interesting observation that HbNO levels only increased 
after an initial lag and then rapidly decreased when the nitrite infusion ended, the 
relationship between HbNO levels and plasma nitrite levels was examined. The 
correlation between HbNO and corresponding sample plasma nitrite (all samples taken 
from the hypoxia/nitrite group over full hypoxic protocol including baseline and infusion) 
although correlate well together (Pearson’s r=0.601), appear to become positive only at 
higher plasma nitrite concentrations (Figure 6.15 A).
To explore this observation in more detail, ex vivo erythrocyte samples were 
subjected to similar, but more controlled conditions in the laboratory. In an aim to mimic 
venous haemoglobin saturation o f the in vivo hypoxic protocols, erythrocytes were 
adjusted to 50% haemoglobin oxygen saturation for experimentation. A correlation 
between HbNO and corresponding extracellular nitrite in this setting also became more 
prominent at higher extracellular nitrite levels (Figure 6.15B) as seen with the samples 
collected from the in vivo study. Indeed, intra erythrocyte HbNO levels appeared 
unchanged despite varying extra-cellular nitrite concentration within a physiological 
range (50-200nM) (Figure 6.15B).
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Figure 6.15. Correlations o f  plasma/extracellular nitrite concentration vs. corresponding HbNO 
concentration. A) Samples generated in vivo during the hypoxia/nitrite protocol (in hypoxia only) 
(Pearson’s r=0.601, P<0.0001, n=137). B) Samples generated ex vivo after adjusting haemoglobin 
concentration to lOg/dL (10.3±0.17) and saturation to 50% (50.3±0.8) followed by incubation with varying 
extracellular nitrite concentrations (up to 850nM) for 30 mins at 37°C (Pearson’s r=0.82, P<0.0001, n=103).
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6.3.9 Forearm Blood Flow Observer Variation
To validate assessment o f the strain gauge plethysmography data used to compare 
forearm arterial blood flow, a comparison o f data analysed by one observer against a 
second observer (Figure 6.16A) and a comparison o f two repeat analyses made by the 
same observer (Figure 6.16B) were made using Bland-Altman plots. The bias in both 
inter and intra observer measurements was minimal, however the inter-observer plot did 
show a trend for over estimation at higher average forearm blood flows by observer 2. All 
data presented in the chapter was therefore taken from observer 1, including the intra 
observer variability on repeat measures (Figure 6.16B), which shows very little bias.
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Figure 6.16. Bland-Altman plots o f  forearm blood flow measurements A) Inter-observer variability, bias 
between observer 1 and observer 2 is minimal but does show a trend at higher average blood flows, 
(n=140). B) Intra-observer variability, repeated measures made by observer 1, (n=30). Solid line from y- 
axis indicates bias level, broken lines indicate upper and lower 95% agreement limits.
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effects o f low dose nitrite supplementation in hypoxic human subjects and to considei 
mechanisms o f nitrite processing at low, near basal plasma nitrite levels.
In comparison to the controlled in vitro experiments of a laboratory, completi 
study in human subjects can introduce considerable variability. The collection of acci 
data for this chapter required the testing protocols to be very controlled. Initially, 
pilot studies were completed to hone the protocols and develop data and sar 
collection. Efforts to accurately control variables of the experimental procedure cer 
on the hypoxic exposure and thus the environmental chamber. Unlike a face mask, 
environmental chamber provided a very effective method of producing contrc 
hypoxia and allowed for a measured equilibration period for hypoxia indi 
physiological changes to take place. The importance o f controlling the hypoxia expo 
with an equilibration period became apparent when the data was analysed. In additic 
the haemodynamic changes expected in hypoxia, nitric oxide metabolite levels 
appeared to be influenced. During the initial 60 minute descent from a FiC>2 of 21' 
12% nitric oxide metabolite levels, plasma nitrite in particular appeared to transie 
increase before dropping to a stable, but elevated baseline prior to the infusion pei 
Although the change did not reach statistical significance, as a result of the study 
being powered to assess these low level changes, a corresponding change in c 
metabolites suggests the result to be genuine. The exact mechanism behind 
observation is unclear, however it is possible that hypoxic exposure may influ 
vascular activity, which could occur at many signalling levels including j 
transcription, as shown in chapter 4. In this respect, nitric oxide metabolite levels 1 
been shown to be increased in groups that inhabit high-altitude areas where atmospf 
oxygen levels are low compared to those living at sea level [451].
- 2 3 9 -
nitrite elevation and decay (half-life) was very similar in both the hypoxia/nitrite 
normoxia/nitrite protocols. This suggests that nitrite was processed at the same ra 
both cases, however, given that physiological effects are observed during 
hypoxia/nitrite protocol only, the route o f processing or metabolism clearly mus 
different in the two settings.
The mechanism of nitrite-induced vasodilatation appears to be dependent on 
key factors: oxygen level and plasma nitrite concentration. Each of these factors wi 
discussed with respect to the current suggested mechanisms of activation and findin: 
this chapter.
The activation o f nitrite in vivo has thus far been attributed to one of two typ 
mechanism, those involving haemoglobin reduction [337] and those involving redu 
by tissue enzymes [397]. Nitrite reduction by haemoglobin in vivo is thought t 
maximal when haemoglobin is 50% saturated with oxygen [338]. Under nonr 
conditions, the haemoglobin o f circulating erythrocytes is unlikely to be de-saturat< 
the 50% level, therefore this route o f metabolism and potential source of nitric c 
generation is improbable. In contrast, when subjects are exposed to hypoxia, the lev 
inspired oxygen could potentially drop sufficiently for a proportion of 50% ox 
saturated haemoglobin to occur at specific points in the circulation. Consequently, 
mechanism of nitrite reduction could be up-rated in hypoxia and thus may pro 
sufficient nitric oxide to alter vessel tone, in apparent agreement with the fine 
presented in this chapter. However, the same is true of the oxidoreductase en2 
mechanism. In situations where oxygen is plentiful, oxidoreductase enzymes, sue 
aldehyde oxidase and xanthine oxidase will catalyse reactions between their no 
substrates, conversely, in hypoxic conditions these enzymes will more readily catalysi
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work carried out with very high dose nitrite infusion and is based on the assumption 
increases in HbNO levels are a marker o f nitrite interaction with haemoglobin and 
potential reduction of nitrite to nitric oxide [337, 379]. The findings of these publicat 
show that plasma nitrite, HbNO and changes in blood flow all correlate well with 
another after high, incremental nitrite dosing.
A potential role for erythrocytes has previously been implicated from 
observation that plasma nitrite and HbNO correlate with one another during infu: 
rather than from a measure o f erythrocyte produced nitric oxide. The findings of 
chapter using low dose nitrite infusion show a clear correlation between plasma ni 
and forearm blood flow, but fail to find the same association with HbNO levels. In 
although HbNO levels did increase during infusion after a delay, levels retume 
baseline within 15 minutes o f infusion cessation while elevated plasma nitrite levels 
increased forearm blood flow persisted. This is surprising, given that haemogl 
saturation remained low, plasma nitrite levels remained high and the results of chapi 
show nitrite entry to erythrocytes to be enhanced at high extracellular nitrite levels 
low oxygen saturation. Taken together, this suggests that haemoglobin reduc 
mechanisms involved with high dose nitrite may not be mirrored at low dose and imj 
that HbNO is not a good surrogate for haemoglobin nitrite reduction at low ni 
concentrations.
In support o f a role for haemoglobin nitrite reduction, the same research group 1 
suggested that erythrocytes act as circulating stores o f nitrite, reporting that i 
erythrocyte nitrite to represent two thirds o f whole blood nitrite [364]. Despite sin 
measured plasma nitrite levels and the use of similar methodology, our laboratory 
previously demonstrated a plasma nitrite to erythrocyte associated nitrite signal ratio
ferricyanide/hexacyanoferrate, commonly a potassium salt) to erythrocyte samples. T 
is thought to bind haemoglobin and stabilise nitric oxide metabolite species, prevent 
inter-conversion, so samples can be processed and stored for future analysis. Howe> 
ferricyanide is known to cleave nitric oxide from HbNO and has been used in 1 
capacity for quantitative HbNO assays [452]. In addition, it has previously been sho 
that nitric oxide cleaved from HbNO subsequently forms nitrite [367]. It therefore folic 
that in erythrocyte samples incubated with ‘stabilisation solution’, HbNO would 
converted to nitrite and therefore account for the exaggerated intra-erythrocyte nit 
levels observed by these investigators, together with expected plasma nitrite levels.
The results o f Chapter 3 demonstrate that nitrite entry at physiological extracelli 
nitrite levels (~200nM) is a relatively slow process, particularly at high haemoglo 
oxygen saturation. This chapter finds both in vivo and in vitro in deoxygenated conl 
blood samples that HbNO formation (thought of as a marker of nitrite haemoglo 
interaction), does not occur appreciably when extracellular/plasma nitrite levels are k 
However, as extracellular nitrite levels are augmented, the amount of HbNO does tl 
increase in a uniform fashion. In the in vivo study, HbNO levels did increase dur 
nitrite infusion but only after a delay and returned to baseline within 15 minutes 
infusion cessation. The delay in formation agrees with the slow entry rate of nitrite £ 
the rapid decrease post infusion cessation is most likely due to metabolism of HbNO 
haemoglobin is oxygenated across the lung [332]. It should be noted that this delaj 
increase is not simply a methodological issue. Pre-infusion HbNO levels in 
hypoxia/nitrite protocol were ~100nM and chapter 3 of this thesis demonstrates that i 
methodology utilised is capable o f distinguishing changes in HbNO at a le1 
considerably below this.
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The fact that nitrite entry into erythrocytes is slow and that HbNO levels do not 
appear to correlate with changes in physiology, suggests that the haemoglobin nitrite 
reduction mechanism does not play a significant role in the vascular effects o f nitrite at 
low, near-basal plasma nitrite levels. It is therefore more likely that the vasoactive 
properties o f nitrite at low dose are mediated via reduction in the tissue. This agrees with 
the work o f chapter 4 in a isolated vessel model, where vasorelaxation was independent 
o f haemoglobin and appeared to be considerably mediated by aldehyde oxidase. The 
extrapolation o f findings, generated under non-physiological conditions with high dose 
infusion, to the physiological setting is a problem that is prominent within the nitric oxide 
field. The data presented in this chapter suggests this extrapolation not to be valid and, 
even if haemoglobin was capable o f reducing nitrite to nitric oxide, its ability to escape 
recapture by haemoglobin to affect vessel tone is still questionable.
It is clear that circulating plasma nitrite is involved in the flux o f nitric oxide 
moiety, whether basal levels o f plasma nitrite play a role in controlling vessel tone in vivo 
remains to be demonstrated. However, the findings o f this chapter would suggest that 
activation o f nitrite in the circulation by haemoglobin is unlikely to play a significant role 
at these lower plasma nitrite levels. Importantly, it seems that nitrite even at lower doses 
does appear to be capable o f altering vascular tone given a provoking environment (e.g. 
hypoxia). Its potential as a therapeutic agent relies upon its ability to only act in tissues 
where it is required. This targeted action could be o f great benefit in pathologies where 
there are specific sites o f poor blood flow or hypoxia in which nitrite could improve 
regional blood flow without causing dramatic changes in global haemodynamics i.e. 
cause hypotension.
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6.5 Summary and Conclusions
The work o f this chapter does not discount that circulating nitrite may interact 
slowly with blood and vascular tissue, contributing to the overall flux of nitric oxide 
metabolites. However, it does question the mechanisms by which nitrite can change 
vascular tone, particularly in the physiological plasma nitrite concentration range. Some 
interesting and perhaps unexpected findings have also been revealed through this work 
and specific points are summarised below.
•  The infusion o f low dose sodium nitrite is capable o f altering arterial 
forearm blood flow in hypoxia but not normoxia suggesting an enhancement 
o f nitrite vasoactivity under hypoxic conditions.
• The elevation and decay profiles o f infused nitrite are similar in normoxia 
and hypoxia. This is unexpected, given that nitrite uptake by erythrocytes 
was enhanced under deoxygenated conditions (chapter 3), suggesting that 
metabolism o f low dose nitrite by erythrocytes plays a very minor role in 
overall nitrite metabolism.
• In hypoxia, forearm blood flow correlates with plasma nitrite level but not 
with HbNO levels advocating a minimal role for erythrocytes in nitrite 
activation.
• Both in vivo and vitro in deoxygenated blood, intra-erythrocyte HbNO does 
not appear to be formed to any great extent at basal plasma nitrite levels.
•  The haemoglobin-dependent mechanisms o f nitrite-induced vasodilatation 
thought to be involved at high dose do not appear to be involved at low or 
basal plasma nitrite levels.
1 '
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The vasoactive properties o f nitrite at low plasma nitrite levels are most 
likely mediated via tissue enzymes.
Therapeutically, high dose nitrite is not required to produce a vasodilatory 
effect in hypoxic vasculature.
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7 Overall Conclusions & Insights
The aims o f this thesis were to consider nitric oxide metabolites in terms of their 
biochemistry and physiological actions with particular reference to the effect o f oxygen 
upon these biological aspects. The thesis also aimed to challenge the current 
understanding with respect to the related mechanistic pathways involved. The results 
presented herein provide insight into a number o f mechanisms that relate to nitric oxide 
metabolite bioactivity and have discovered novel aspects o f signalling pathways and the 
molecules that control them.
It is apparent that nitric oxide metabolites represent a dynamic group o f molecules 
that are, at some level, bioactive. Despite the vast amounts o f research in the field, this 
work has shown me that a number o f common misconceptions and extrapolations 
regarding the chemistry and biological activity o f these metabolites exist within the 
literature, particularly with respect to mechanisms o f action. The field has run away with 
some suggested mechanisms that are in essence theoretical with very little basic science 
foundation. The repeated publication o f these suggested modes o f operation has occurred 
so extensively and over such a lengthy period o f time that one could be mistaken in 
thinking that they had been confirmed and are thus fact. It is therefore imperative that 
findings regarding any aspect o f nitric oxide metabolite behaviour be considered in the 
context o f the experimental setting utilised. In this respect, one can essentially divide the 
study of nitric oxide metabolites into two groups based upon the concentration of 
metabolites in question, i.e. assessing the biological aspects o f nitric oxide metabolites at 
a basal level or in scenarios where levels have been artificially increased. Obviously the 
in vivo mechanisms involved in the metabolism and biological activity o f metabolites do 
not obey this divide and most likely operate in a continuum, however, it is these settings 
in which the metabolite field pursues answers and therefore the context in which results 
must be contemplated.
At basal levels, it is unclear as to whether or not nitric oxide metabolites possess 
any functional roles. A huge literature exists surrounding the actions of plasma nitrite at a
u i i a  m a i  u i c  n i u i v ;  u a i u c  meiaDome pool is in a continual state ot tlux, with leve 
any one metabolite heavily influenced by both the local level of other metabolites 
local changes in oxygenation. These findings are in close agreement with previous v 
from our laboratory showing that although individual metabolite species change ac 
the coronary circulation, there is no global change in metabolites, just oxygen depent 
reapportionment. Under basal conditions, the circulating level of nitrite appears tc 
stable and controlled, with the plasma nitrite level o f subjects studied in chapto 
showing very little variance at baseline, for example. In relation, when erythrocytes v 
exposed to extracellular nitrite in the physiological range very little nitrite entered 
cells, however the rate o f entry was found to be oxygen dependent. Nitrite does have 
potential to cause a number o f additional side effects at a cellular level, particularl 
high concentration, via disruption o f ionic balance or in the case o f the erythroc 
methaemoglobinaemia. Therefore, it is perhaps not surprising that plasma levels are 1 
within a tight range and specific cell types are resistant to extreme nitrite influx. In 
opinion, the field to date has focused too heavily upon the direct actions of nitric o? 
and its metabolites rather than the molecules, such as oxygen, that influence so m 
aspects o f their biology.
The involvement o f the erythrocyte in nitric oxide metabolite biochemistry still repres< 
a contentious element o f the nitric oxide field, particularly in regard to the functior 
haemoglobin. Haemoglobin has been implicated in two distinct ways, firstly as a nil 
reductase and secondly as a form o f stored/bioactive nitric oxide, HbSNO. Both of tf 
proposed mechanisms are dependent upon oxygenation or haemoglobin allostery 
generate a species that can alter vessel tone, thereby theoretically matching respirat 
demand with blood flow at regional level. As with many systems of nature, it ma 
perfect sense to link these two factors that are ultimately dependent upon one another, 
is the case with most good theories, these are particularly difficult to question or oppc
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erythrocytes is limited, it would suggest that although nitrite reduction by haemo; 
may be energetically possible, a functional role for this mechanism seems improba 
should be noted, however, that these observations were gained through manipii 
nitrite concentration level, although in the case o f the in vivo study, very modestl 
within the physiological range.
To date, the erythrocyte induced hypoxic vasodilatation has been largely ascribed 
actions o f HbSNO. However, conclusive evidence demonstrating HbSNO to t 
mediator involved has thus far not been published. There is no doubt that HbSNO, 1 
SNO compounds, does have vasoactive properties. Nonetheless, a number of aspe 
the erythrocyte induced vasorelaxation do not support a role for HbSNO. This th< 
the first to document significant and persuasive evidence to suggest that the media 
the erythrocyte induced vasorelaxation is in fact oxygen. A role for oxygen as the pr 
mediator o f this phenomenon can be reconciled with the majority of current literatui 
will hopefully form the basis o f another ‘good theory’ that researchers will contir 
question. These findings do not discount a role for HbSNO, but do suggest that it 
the principal mediator involved. There are, however, many potential roles for thiol 1 
nitric oxide in vivo, not only from a vasodilatory point of view but from a signalling 
As with many protein modifications, such as phosphorylation, the significance of 
oxide thiol modification is coming to fruition. With thousands of potential target thi< 
a vast range o f proteins from membrane receptors to transcription factors, it is clea 
the potential signalling and regulatory roles of SNOs are huge and not just limited a< 
in the vascular setting.
Certain aspects o f work piloted during the compilation of this thesis unfortunately < 
not be fully developed. One particular subsection of work that I believe warrants fi
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investigation surrounds the application o f the models developed and novel findings of this 
thesis to research the disease, diabetes mellitus. Diabetes mellitus represents a very 
interesting setting in which to study nitric oxide metabolites and erythrocytes as the 
disease progression is known to dramatically affect the cardiovascular system and to 
modify haemoglobin through glycosylation. Some initial findings are summarised below;
• Preliminary findings from the real time nitric oxide reaction model show that the 
haemoglobin o f diabetic patients reacts with and processes nitric oxide differently, 
depending upon the level o f haemoglobin glycosylation (HbAlc).
•  Chapter 5 demonstrated that the erythrocyte induced hypoxic vasodilatation was 
dependent upon haemoglobin allostery. As haemoglobin oxygen binding is altered 
in diabetics, erythrocyte induced vasorelaxation was assessed with a range of 
diabetic blood samples. When tested, it appears that diabetic erythrocytes may 
give a reduced response in the hypoxic myography model that correlates with the 
degree o f haemoglobin glycosylation (HbAlc). It is not clear if this is a direct 
haemoglobin oxygen offloading effect or if  H bA lc is purely a marker of other 
diabetes induced changes within the erythrocyte.
• Another key aspect o f this thesis has focused on the processing of nitrite by 
erythrocytes. Using some simple experiments where whole blood was doped with 
nitrite before centrifugation over a range o f speeds it appears that nitrite does not 
partition uniformly between plasma and erythrocyte fraction when comparing 
control blood against blood form a diabetic patient. This could be due to 
differences in membrane oxidation between diabetics and controls but could have 
implications with regard to nitrite bioactivity. In a separate experiment using 
nitrite and erythrocyte ghosts, it appears that there is also a source o f nitrite 
reduction within the erythrocyte membrane. If nitrite is more likely to associate 
with the erythrocyte in some cases this could provide an enhanced route for the 
conversion o f nitrite to more biologically active species.
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A direct role for nitric oxide metabolites as clinical therapeutics seems quite 
limited. Nitrite carries the most potential but may only show real benefit above and 
beyond existing treatments in very niche settings where tissue hypoxia is a key element. 
The true value o f nitric oxide metabolites or the erythrocyte-induced hypoxic 
vasodilatation may ultimately come from more indirect manipulative processes. To 
achieve this and exploit these systems in full, it is essential that mechanisms of both 
molecular bioactivity and system dysfunction in disease states are fully explored. The 
results o f this thesis contribute to the understanding with regards to mechanism, however 
the next step is to find a way o f exploiting this novel information in the disease setting.
Overall, it is clear that the diatomic gases are not only important signalling 
molecules but can also dictate the responsiveness o f many enzymes and tissue systems. 
However, it is oxygen that governs the formation, metabolism and biological activity o f 
nitric oxide metabolites, is responsible for erythrocyte induced hypoxic vasodilatation and 
which ultimately dictates the health o f all tissues, including those of the cardiovascular 
system. In this sense, it is not surprising that haemoglobin can also play an important role, 
but the results o f this thesis would point to that being one o f transportation and storage of 
gaseous diatoms, rather than an enzymatic converter or reductase. Nitric oxide is a very 
important signalling molecule that has duly received a significant amount o f attention, 
however I conclude that it is the somewhat neglected grandparent of the family, oxygen, 
which provides fundamental control and is a prerequisite of signalling in this setting.
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